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General introduction 
 
1 General introduction 
 
 
 
 
 
2 Chapter 1  
1.1 Primary malignant brain tumors 
 
Brain tumors represent a heterogeneous group of central nervous system (CNS) neoplasms. 
The World Health Organization (WHO) recognizes approximately 100 different types of brain 
tumors classified according to pathological diagnosis. In general, these tumors can be 
classified into either primary or secondary tumors, depending on whether they originate from 
the brain or spread to the CNS from elsewhere. Primary tumors often spread into other sites in 
the central nervous system, such as the spinal cord, but rarely metastasize to other parts of the 
body. These tumors show a high biological diversity, and can be named and classified 
according to the normal brain tissue from which they have derived. A major part of all 
primary brain tumors are collectively known as gliomas. The term “glioma” specifies a group 
of cancers that includes astrocytomas, oligodendrogliomas, ependymomas and 
oligoastrocytomas. They are malignant forms of glial cells, which primarily constitute the 
connective and supportive tissue in the central nervous system. Several glial cell types are 
known from which gliomas can derive: 
 
− Astrocytomas are primary brain tumors derived from astrocytes, which serve 
supportive functions for nerve cells, and their foot processes encapsulate the brain 
capillaries. 
− Oligodendrogliomas originate from oligodendrocytes, which surround nerve cells and 
thereby provide a protective coating. Pure oligodendrogliomas however are rare, and 
in most cases malignant oligodendroglioma cells occur in mixed gliomas. 
− Ependymomas are derived from ependymal cells. These cells line the brain ventricles 
and the central canal of the spinal cord. 
− Mixed gliomas consist of a mixture of different malignant glioma cells, mostly 
malignant oligodendrocytes and astrocytes. 
 
Of these gliomas, the astrocytomas have the highest incidence of 5 to 10 per 100,000 persons 
(Legler, 1999; Wrensch, 2002). In adults astrocytomas amount to about 75% of all primary 
malignant brain tumors. 
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1.1.1 Classification 
 
Approximately half of all primary brain tumors are glial cell neoplasms, and more than three 
quarters of all glial tumors are astrocytomas. Astrocytomas differ in their pathological 
behavior: some astrocytomas are classified as low-grade tumors, meaning they are growing 
slowly, whereas glioblastoma multiforme represent the most aggressive type. Based on their 
histological appearance the World Health Organization classifies astrocytomas into four 
grades. Pilocytic astrocytomas (WHO grade I) are relatively benign tumors that generally 
occur in children and young adults. Low-grade or diffuse astrocytomas (WHO grade II) are 
tumors of well-differentiated cells that grow slowly, but diffusely infiltrate normal brain 
structures. Malignant or high-grade gliomas include anaplastic astrocytomas or anaplastic 
oligodendrogliomas (WHO grade III) and glioblastomas (WHO grade IV). The characteristic 
histopathology of these gliomas is defined by the presence of mitosis, cellular and nuclear 
atopia, and in glioblastomas by microvascular proliferation, necrosis and pseudopallisading 
(Burger, 1985).  
 
1.1.2 Prognosis 
 
The prognosis for patients with malignant gliomas remains very dismal: the median survival 
of patients with anaplastic astrocytomas is two to three years, and that of patients with 
glioblastoma multiforme is ten to twelve months. Thus, glioblastoma multiforme is one of the 
most lethal and treatment-resistant human tumors. Among the therapeutic triad of surgery, 
radiation therapy, and chemotherapy, only radiation therapy has been shown to improve 
survival (Salazar, 1979). Despite more than 30 years of intensive efforts to find an effective 
chemotherapy regimen for glioblastoma multiforme, the median survival of 12 to 15 months 
has not changed appreciably since the introduction of radiation therapy. Furthermore, the 
improvements in surgery, radiation and chemotherapy failed to result in long-term survival 
for most patients with malignant gliomas. Malignant gliomas recur most commonly within 2 
cm of the primary tumor location (Wallner et al., 1989), and only a minority of patients 
achieves long-term survival (Senger et al., 2003). However, the results of combined 
temozolomide and radiation in the randomized study by Stupp et al. in patients with 
glioblastoma are encouraging (see Chapter 1.2.4). 
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1.1.3 Diagnosis and characteristics of astrocytomas 
 
Due to the distinct ability of astrocytomas to invade normal brain tissue, extensive resections 
are unlikely to eradicate all malignant cells. The great variability in the geometry, extent, and 
character of the peripheral infiltrating margin of glioblastomas displays a diagnostic problem 
(Burger et al., 1988). The regional histological heterogeneity within each tumor hampers 
tumor sampling. Particularly a small biopsy may result in the incorrect diagnosis of a lower 
grade tumor. In many cases the first diagnosis from the biopsy has to be changed when the 
tumors have been removed by resection (Jackson, 2001). Furthermore, when a low-grade 
glioma is diagnosed, transformation to a higher malignant grade is very probable. This may be 
ascribed to a progressive genetic instability recently linked to the loss of chromosome 10 in 
the tumor cells (Nigro et al., 2005). 
Currently evaluated gene expression arrays allow detailed genetic profiling of tumors with a 
highly specific molecular classification of tumor type and grade (Mischel, 2003). This 
approach may also provide the basis for a more accurate and histology independent 
classification system in the future (Nutt et al., 2003; Freije et al., 2004). Figure 1.1 shows the 
most frequent genetic abnormalities in astocytomas, reviewed by Gonzalez and Gilbert 
(Gonzalez and Gilbert, 2005). The genetic profiling and molecular analysis of tumors is 
suggested to allow optimized individual treatment. Especially the O6-methylguanine-DNA 
methyltransferase (MGMT) represents the most important and clinically relevant resistance 
mechanism. Since temozolomide produces cytotoxicity by methylation of DNA (O6-
methylation of guanine), the activity of DNA repair mechanisms has been suggested to stand 
against temozolomide efficacy, and may cause poor response to temozolomide treatment. 
Friedman et al. found a significant negative correlation between MGMT expression in newly 
diagnosed glioblastoma and the response to temozolomide treatment (Friedman, 1998). 
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Figure 1.1: Pathways from normal precursor cells to gliomas. Several genetic abnormalities 
have been associated with the development of glioblastoma via different WHO grades, or by 
direct transformation into WHO grade IV (Lesniak and Brem, 2004; Gonzalez and Gilbert, 
2005). 
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1.2 Standard therapy 
 
1.2.1 Tumor resection 
 
Surgical resection can achieve rapid symptom control, which is of primary relevancy for 
patients with large tumors, causing life-threatening situations. Moreover, resection provides 
tissue for histological diagnosis. Even though a complete eradication of the tumor is rather 
unlikely, extensive tumor resection has an impact on survival. As reported by Lacroix et al., a 
significant advantage in patients’ survival was associated with the resection of 98 % or more 
of the tumor volume (median survival of 13 months) compared to resections of less than 98 % 
(median survival of 8.8 months) (Lacroix et al., 2002). However, in many cases surgical 
removal to this extent is not possible due to the highly invasive growth of the tumor. 
 
1.2.2 Radiation treatment 
 
Radiation represents one of the most effective forms of treatment for gliomas. Nearly all 
treatment regimens for newly diagnosed tumors include radiation treatment. Several studies 
showed that it is best to use radiotherapy in the post-surgical treatment of malignant glioma, 
e.g. for anaplastic astrocytoma (Walker, 1978) and for glioblastoma multiforme patients 
(Deutsch, 1989). The current standard of the radiation therapy specifies the use of a total dose 
of 60 Gy in 30 fractions. With higher radiation doses no additional benefit was observed 
(Nelson, 1988). Hyper-fractionation of the dose does not improve the outcome significantly, 
as shown in patients suffering from WHO grade III and IV tumors (Ludgate et al., 1988). 
Another technique in radiotherapy involves the use of radiosensitizers, chemotherapeutic 
agents, which are supposed to increase the sensitivity of the tumors against radiation. Several 
compounds have been evaluated for this therapeutic purpose, e.g. misonidazole (Huncharek, 
1998; Prados et al., 1999), carmustin (BCNU), lomustine (CCNU), and vincristine, with or 
without bromdesoxyuridine (Prados et al., 1999). To date, no clear clinical benefit compared 
to the standard radiation regimen has been demonstrated. Stereotactic radiosurgery (SRS) also 
has been considered as a promising treatment approach, but SRS followed by conventional 
radiation therapy in combination with BCNU showed no improved outcome in the treated 
patients with glioblastoma multiforme (Souhami et al., 2004). Finally, the interstitial 
brachytherapy of glioma with stereotactic radiation implants has been evaluated, also with no 
decisive success (Laperriere et al., 1998). 
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1.2.3 Chemotherapy 
 
The combination of radiotherapy and chemotherapy in the treatment of malignant gliomas has 
been studied for several decades, but all trials failed to demonstrate a significant increase in 
survival (Walker et al., 1980). A large individual patient data based meta-analysis including 
over 3000 patients showed that adjuvant (after radiation treatment) chemotherapy may 
improve the 2-year survival by only 5 %, from 15 % to 20 % (Table 1.1) (Glioma Meta-
analysis Trialists (GMT) Group, 2002). Unfortunately, no curative chemotherapy for 
malignant gliomas exists so far. The choice of applicable chemotherapeutic agents for the 
therapy of malignant brain tumors is limited to a few compounds, because of the poor 
penetration from the blood to the brain after systemic administration. Amongst them are the 
alkylating nitrosoureas carmustine (BCNU), lomustine (CCNU) as well as procarbazine, and 
temozolomide (Figure 1.2).  
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Figure 1.2: Structures of carmustine, lamustine, procarbazine and temozolomide. 
 
Most of the present chemotherapy regimens are involved in adjuvant therapy after tumor 
resection or irradiation therapy. Several randomized trials have been conducted on the 
combined radiotherapy and chemotherapy. Some studies failed to demonstrate a significant 
increase in survival when chemotherapy was added to radiation treatment (Walker, 1978; 
Walker et al., 1980; Medical Research Council Brain Tumor Working party, 2001). However, 
meta-analysis of several randomized clinical trials demonstrated some benefit for the adjuvant 
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chemotherapy. Fine et al. used the results from 16 randomized clinical trials and reported on 
an absolute increase in patient survival of 10.1 % at 1 year and 8.6 % at 2 years after 
treatment with combined radiation and chemotherapy (Fine et al., 1993). Another meta-
analysis with the data from 12 randomized controlled trials was performed by Stewart 
(Stewart, 2002). The results showed a significant increase of 6 % in the 1-year survival, and 
an increase of two months in the median survival. Despite the positive results from the meta-
analysis, individual trials failed to provide a significant therapeutic advantage. As mentioned 
in a review on the treatment of astrocytomas by Gonzalez and Gilbert (Gonzalez and Gilbert, 
2005), much of the controversy on the administration of adjuvant chemotherapy was the 
concern about toxic side effects associated with the use of nitrosoureas in classical adjuvant 
chemotherapy. 
 
Table 1.1: Median 1- and 2-year survival of patients with high-grade glioma after various 
postoperative adjuvant treatments (van den Bent et al., 2006). 
 
Reference Treatment Median 
survival 
% 1-year 
survival  
% 2-year 
survival  
Walker et al. 1978 Supportive care 
BCNU 
RT 
RT + BCNU 
3 months 
4 months 
8 months 
8 months 
3 
12 
24 
32 
0 
0 
1 
5 
Glioma Meta-
analysis Trialists 
group 2002 
RT 
RT + CT 
 40 
46 
15 
20 
EORTC 26981 
Stupp et al. 2005 
RT 
RT + temozolomide 
12 months 
15 months 
51 
61 
10 
27 
 
RT: radiotherapy; CT: chemotherapy; BCNU: carmustine 
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1.2.4 Temozolomide 
 
Temozolomide (Temodal®) is an alkylating agent with an almost 100 % oral bioavailability. It 
penetrates into all body tissues including the central nervous system due to its ability to pass 
the blood-brain barrier (BBB). Spontaneous conversion into the active metabolite MTIC is 
postulated as the mechanism of activation (Ostermann et al., 2004). The activity of 
temozolomide was first demonstrated in patients with recurrent high-grade glioma.  Three 
phase II trials were conducted with patients suffering from glioblastoma multiforme and 
anaplastic astrocytoma at first relapse (Yung et al., 1999; Yung et al., 2000; Brada et al., 
2001). Low objective response rates in glioblastoma multiforme of 5 % to 7 % were 
disappointing, but an interesting response rate of 35 % in the anaplastic astrocytoma study 
was observed. These studies suggested an increase in the fraction of patients being 
progression-free at 6 months compared to a historical database. In the study of Yung et al. a 
significantly improved progression-free survival (PFS) rate at 6 months was observed for 
temozolomide (21 % versus 8 % with procarbazine treatment). Moreover the median PFS was 
increased (12.4 versus 8.3 weeks), and a higher 6-month survival rate was observed (60 % 
versus 44 %) (Yung et al., 2000). Temozolomide has largely replaced the nitrosoureas in the 
treatment of primary malignant brain tumors, and is considered as the mainstay of 
chemotherapy of high-grade gliomas. A recent study showed that the combined irradiation 
and temozolomide treatment in newly diagnosed glioblastoma multiforme patients improved 
median survival by 3 months, compared to radiotherapy alone, with acceptable levels of 
severe side effects (Stupp et al., 2005). Recent developments in the use of temozolomide in 
the chemotherapy of brain tumors has been reviewed by van den Bent et al. (van den Bent et 
al., 2006). 
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1.3 New approaches to the treatment of gliomas 
 
Taken together, after more than 30 years of intensive research efforts the median survival of 
12 to 15 months in glioma patients has not markedly changed since the introduction of 
radiation therapy. For glioblastoma multiforme no effective chemotherapy regimen exists so 
far. Only modest therapy improvements were achieved by advances in surgery, irradiation 
treatment, and some advances in chemotherapy. However, no improved long-term survival for 
most patients with malignant glioma was accomplished. Only the combined therapy of 
temozolomide and radiation treatment yielded encouraging results in long term survival of 
patients suffering from malignant glioma. Moreover, genetic profiling provides the specific 
classification of tumor type and grade with a more accurate prognosis. Thus, it may allow the 
development of a more effective and individualized treatment of patients in the future. 
However, there is still a great need to develop new approaches for the treatment of brain 
tumors.  
 
1.3.1 Down-regulation of oncogenes in tumor cells by RNA interference 
 
A modern and promising technology is cancer gene therapy aiming at effective and selective 
killing of malignant cells. This modern treatment option is based on the efforts that have been 
made in identification, cloning, sequencing and functional analysis of oncogenes during the 
last three decades. In the 1980s activated oncogenes in human tumor cells, especially ras 
genes (H-ras, K-ras and N-ras) were identified. With its central role in cell signaling, ras is 
one of the most mutated oncogenes in human malignancies, accounting for about 30 %-50 % 
of human cancers (Bos, 1989). Not only one mutated oncogene but also several genetic 
abnormalities are responsible for the development of tumors. Almost all human cancers have 
accumulated multiple genetic lesions including oncogenes and it is often unknown whether an 
oncogene is continuously required for tumorgenesis. Furthermore, it is very difficult to target 
an essential oncogene with drugs without affecting the corresponding non-mutated 
protooncogene or related factors (Heidenreich, 2004), for example in the case of a sequence-
specific anti-ras therapy. The wild-type ras and its oncogenic form differ very slightly with 
regard to their DNA sequence (one point mutation) but enormously in their biochemical 
consequences. The recent discovery of RNA interference provides now tools to examine the 
role of oncogenes in tumorgenesis and it could be shown that the application of small double-
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stranded RNA molecules (small interfering RNA, siRNA) silenced gene expression in 
mammalian cell culture (Elbashir et al., 2001). Moreover, oncogene specific siRNAs may 
become promising candidates for more cancer-specific therapeutic approaches 
(Brummelkamp et al., 2002). Brummelkamp et al. showed that the expression of mutated K-
rasV12 was inhibited by RNA interference while other ras isoforms were unaffected. 
However, the main challenge to any gene therapy must also be overcome with RNA 
interference: the double-stranded RNA or the expression vector encoding siRNA molecules 
have to reach the tumor cells efficiently, which displays a special problem in the case of brain 
tumors. The neutralization by the immune system may be a barrier for the small interfering 
RNAs to reach their destination. Due to the extreme sequence specificity of RNAi cancer 
cells may circumvent the siRNA-mediated attack, because a single point mutation in the 
targeted region prevents mRNA degradation and may cause RNAi-resistance in tumors 
(Borkhardt, 2002). The available technologies, e.g. the potency of therapeutic genes and 
efficacy of gene delivery systems, are far from optimal to achieve the desired clinical benefits 
in the field of solid tumors (Rubanyi, 2001). A proof for the in vivo efficacy of systemically 
delivered siRNAs is still missing and the investigations of the pharmacokinetics of siRNAs 
are in their beginnings with no therapeutically acceptable delivery method (Heidenreich, 
2004). Therefore, a non-toxic transfection reagent with promising properties for in vivo 
application was examined for its efficacy of siRNA transfection. For details see Chapter 2. 
 
1.3.2 Inhibition of mitotic kinesin Eg5 by specific inhibitors 
 
Another strategy for the therapy of brain tumors is the evaluation of new potential 
pharmacological targets, and new classes of pharmacologically active compounds, capable of 
penetrating into the brain after standard drug administration. The mitotic kinesins are 
potential pharmacological targets in tumor therapy, because they are exclusively involved in 
the formation and function of the mitotic spindle, and some kinesins are only expressed in 
proliferating cells. The mitotic kinesin Eg5 mediates centrosome separation and the formation 
of the bipolar spindle. Inhibition of Eg5 leads to cell cycle arrest during mitosis, giving rise to 
cells with monopolar spindles, so-called monoasters (Blangy et al., 1995). In contrast to 
classical mitotic inhibitors (vinca alcaloids, taxanes), Eg5 inhibitors do not interfere with 
other microtubule-dependent processes (Wood et al., 2001), being the main reason for 
neurotoxicity (Quasthoff and Hartung, 2002). Thus, these compounds are supposed to be less 
neurotoxic anticancer drugs. Monastrol was the first specific small-molecule inhibitor of Eg5 
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(Mayer et al., 1999), however with a low inhibitory potency. As the inhibition of the mitotic 
kinesin Eg5 is an attractive new approach to cancer treatment (Wood et al., 2001), new 
monastrol analogs were synthesized (Gartner et al., 2005; Sarli et al., 2005; Tarby et al., 
2006) and investigated for their antiproliferative activity against human glioblastoma cells. 
For details see Chapter 3. 
 
1.3.3 Overcoming the blood-brain barrier 
 
The brain is one of the least accessible organs for the delivery of pharmacological compounds 
(Scherrmann, 2002). There are two physiological barriers separating the brain from the 
systemic blood circulation. These are the blood-brain barrier (BBB) and the blood-
cerebrospinal fluid barrier (BCSFB) controlling the entry and exit of endogenous and 
exogenous compounds. The regulation of drug concentrations in the brain via the BCSFB is 
considered to be negligibly small (Rautioa and Chikhale, 2004), because the surface area of 
the BBB is estimated to be 5000 times greater than that of the BCSFB (Pardridge, 1995). 
The BBB is defined by the brain capillaries which consist of a monolayer of polarized 
endothelial cells connected by tight junctions (Brightman, 1977). The tight junctions forming 
a continuous lipid layer effectively restrict the influx of molecules from the blood into the 
brain. Consequently, only small, electrically neutral, lipid soluble molecules can penetrate the 
BBB, and most chemotherapeutic agents do not fall in this category (Lesniak and Brem, 
2004). Moreover, drug efflux transporters on the luminal membrane of the cerebral 
endothelium, e.g. the ABCB1 transporter (p-glycoprotein 170) actively remove a broad 
variety of drugs before they can enter the CNS. Thus, the treatment of brain tumors often fails 
due to very low concentrations of drugs within the CNS. By blocking the ABCB1 mediated 
efflux it is possible to increase the concentration of ABCB1 substrates, e. g. paclitaxel, in the 
brain (Scherrmann, 2002; Begley, 2004; Fromm, 2004; Bauer et al., 2005; Loescher and 
Potschka, 2005). The ABCB1 mediated transport is inhibited by certain substances, the so-
called ABCB1 modulators (Fricker and Miller, 2004; Breedveld, 2006). Co-administration of 
paclitaxel and valspodar, a 2nd generation modulator of ABCB1, led to increased paclitaxel 
levels in the brain (Fellner et al., 2002). Hence, modulators of drug efflux transporters are 
very promising drugs for the treatment of primary and secondary brain tumors in combination 
with cytostatic agents. The development of other potent modulators of the ABC transporters is 
of particular interest in order to enlarge the variety of applicable anticancer drugs in the 
treatment of malignant brain tumors. For details see Chapter 4. 
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2.1 Introduction 
 
2.1.1 RNA interference 
During the past decade it has been elucidated how RNA molecules can act as regulators of 
gene expression. Long double-stranded RNAs induce post-transcriptional and gene-specific 
silencing in many different organisms by presenting various short or small interfering RNA 
(siRNA) sequences to the target mRNA. The underlying regulatory pathway is the ancient and 
conserved RNA interference (RNAi) pathway utilizing small duplex RNAs (Carmichael, 
2005).  
 
2.1.1.1 Mechanism of RNAi 
RNAi mediated by the introduction of long dsRNA has been used as a method to investigate 
gene function in various organisms including plants (Baulcombe, 1999), Planaria (Alvarado 
and Newmark, 1999), Hydras (Lohmann et al., 1999), Trypanosomes (Ngô et al., 1998), 
Drosophila (Misquitta and M., 1999), mosquitoes (Caplen et al., 2002) and mouse oocytes 
(Svoboda et al., 2000; Wianny and Zernicka-Goetz, 2000). RNAi is carried out in two steps, 
and several studies have shown that this process is restricted to the cytoplasm (Zeng and 
Cullen, 2002; Kawasaki and Taira, 2003). In the first step, small or short interfering RNAs 
(siRNAs) are generated from the long double-stranded RNA via digestion by the RNase Dicer 
in an ATP-dependent reaction (Novina et al., 2002). SiRNAs are 21−23-nt dsRNA duplexes 
with symmetric 2−3-nt 3´ overhangs and 5´-phosphate and 3´-hydroxyl groups (Elbashir et 
al., 2001b). This structure is characteristic of an RNase III-like enzymatic cleavage pattern, 
which led to the identification of the highly conserved Dicer family of RNase III enzymes as 
the mediators of the dsRNA cleavage (Bernstein et al., 2001; Ketting et al., 2001). 
In the second step, the siRNAs are incorporated into a multi-component nuclease, the RNA-
inducing silencing complex (RISC) that recognizes and destroys target mRNAs. There is a 
strict requirement for the siRNA to be 5´phosphorylated to enter into RISC (Nykänen et al., 
2001; Schwarz et al., 2002), and siRNAs that lack a 5´phosphate are rapidly phosphorylated 
by an endogenous kinase (Schwarz et al., 2002). Recent reports suggest that RISC must be 
activated from a latent form, containing a double-stranded siRNA to an active from, RISC* 
(Nykänen et al., 2001). By the ATP-dependent unwinding of the siRNA the non-
complementary strand is discarded. Then RISC* uses the unwound single-stranded siRNA as 
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a guide to substrate selection by the specific binding of the antisense strand to its 
complementary target mRNA through Watson-Crick base-pairing (Hammond et al., 2000; 
Martinez et al., 2002). The target mRNA is cleaved at a single site in the centre of the duplex 
region between the guide siRNA and the target mRNA, 10 nt from the 5´ end of the siRNA 
(Elbashir et al., 2001b). This endonucleolytic cleavage leads to subsequent degradation of the 
target mRNA by cellular nucleases thereby preventing unwanted protein expression. The 
liberated RISC* complex is catalytic as it can turn over several times and cleave multiple 
targets resulting in very efficient and long-term destruction of unwanted target mRNAs 
(Haley and Zamore, 2004). 
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Figure 2.1: The RNA interference pathway. a) Long double-stranded RNA (dsRNA) is 
cleaved by the RNase III family member, Dicer, into siRNAs in an ATP-dependent reaction. 
b) After the transduction of synthetic siRNAs the siRNAs are phosphorylated by a cellular 
kinase. These siRNAs from step a) or b), respectively, are then incorporated into the RNA-
inducing silencing complex (RISC). Although the uptake of siRNAs by RISC is independent 
of ATP, the unwinding of the siRNA duplex requires ATP. Once unwound, the single-
stranded antisense strand guides RISC to messenger RNA that has a complementary 
sequence, which results in the endonucleolytic cleavage of the target mRNA (modified from 
Dykxhoorn et al., 2003). 
 
2.1.1.2 Silencing by small interfering RNA (siRNA) 
The applicability of long double-stranded RNAs is limited in mammals because the 
introduction of dsRNA longer than 30 nt induces a sequence-nonspecific interferon response 
(Elbashir et al., 2001a). Interferon triggers the degradation of mRNA by inducing 2´-
5´oligoadenylate synthase, which in turn activates RNase L. In addition, interferon activates 
the protein kinase R, which phosphorylates the translation initiation factor eIF2α leading to a 
global inhibition of mRNA translation (Stark et al., 1998). To test, whether siRNAs could 
mediate effective silencing of gene expression without inducing the interferon response, 
Tuschl and colleagues (Elbashir et al., 2001a) introduced chemically synthesized siRNA into 
mammalian cells. They showed that the synthetic siRNAs were functional in vivo and the 
siRNA transfection resulted in the sequence-specific silencing of the targeted protein in 
several cell lines without activating nonspecific effects. These findings led to the widespread 
use of this technology to study gene function, including the targeted disruption of clinically 
relevant genes (Dykxhoorn et al., 2003). Since siRNAs are too short to induce an interferon 
response, and since all other RISC components necessary for genes suppression are present in 
mammals, transfection of mammalian cells with preformed siRNAs may result in a profound 
and sequence-specific inhibition of gene expression (Caplen et al., 2001; Elbashir et al., 
2001a). Consequently, this RNAi-based technology permits not only target validation but is 
also considered as a potential therapeutic application (Heidenreich, 2004). 
 
2.1.1.3 siRNA design 
To promote efficient gene silencing using a siRNA to a single site in the target mRNA, 
consideration of the siRNA sequence is crucial (Dykxhoorn et al., 2003). It is known that 
siRNAs, which target different regions of the same gene, vary markedly in their effectiveness 
(Holen et al., 2002; Miyagishi and Taira, 2002; Hemann et al., 2003; Vickers et al., 2003). As 
the rules that govern efficient siRNA-directed silencing still remain undefined, the selection 
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of the right siRNAs is an empirical process. On the basis of the analysis of a small number of 
target genes, several groups have proposed a set of guidelines that seek to narrow the choices 
of siRNA that could potentially silence gene expression (Elbashir et al., 2002; Paddison and 
Hannon, 2002). There exist many protocols and web-based tools for siRNA design with most 
following the guidelines outlined by Tuschl and colleagues (Tuschl et al., 1999; Elbashir et 
al., 2001a; Elbashir et al., 2001b; Elbashir et al., 2001c). Several siRNA sequences in 
different locations along the gene of interest can be selected and tested. Key parameters to 
consider include the length of 19 to 21 nt, the format AAN19TT is preferable and the GC 
content of 30 to 50 %. To ensure that the chosen siRNA sequence targets a single gene, a 
BLAST search of the selected sequence should be carried out against sequence databases such 
as EST or Unigene libraries using the National Center of Biotechnology Information (NCBI) 
website. A query against the small nucleotide polymorphism database will confirm that there 
are no sequence polymorphisms. A single point mutation in certain locations of the paired 
region of a siRNA duplex is sufficient to abolish target mRNA degradation (Elbashir et al., 
2001a) Helpful web-based tools are for example provided by Qiagen using the GeneGlobe 
web portal (http://www.qiagen.com). 
 
 
2.1.2 Transient transfection of siRNA 
Transient transfection of siRNA duplexes into mammalian cells can be performed by 
conventional liposomal methods using various commercial reagents or through 
electroporation. Recent evidence showed that the effectiveness of siRNAs may depend on the 
method of transfection (Walters and Jelinek, 2002).  
 
2.1.2.1 Electroporation 
Electroporation as a simple physical method of transferring genes into eucaryotic cells was 
first described in 1982 (Wong and Neumann, 1982). Electroporation designates the use of 
short (5-10 µs) high-voltage (5-10 kV/cm) pulses to overcome the barrier of the cell 
membrane. By applying an external electric field, which just surpasses the capacitance of the 
cell membrane, transient and reversible breakdown of the membrane can be induced. This 
transient, permeabilized state can be used to load cells with a variety of different molecules, 
either through simple diffusion in the case of small molecules, or through electrophoretically 
driven processes allowing passage through the destabilized membrane - as is the case for 
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nucleic acid transfer (Shigekawa and Dower, 1988; Tupin et al., 2003). The transfection rates 
depend on the amplitude and the period of the electric pulses as well as the concentration and 
quantity of the nucleic acids. Electroporation has proven useful both in vitro, in vivo and in 
patients, where drug delivery to malignant tumors has been performed (Gehl, 2003). 
Electroporation in vivo is carried out directly after the injection of naked DNA by an 
electrode which is localized in the targeted tissue. Successful transfections in vivo by means 
of electroporation were observed in muscles (Rambabu et al., 2005), brain (Luo and Redies, 
2004), skin (Pavselj and Preat, 2005), liver (Thanaketpaisarn et al., 2005) and tumors (Mitrus 
et al., 2005). 
 
2.1.2.2 Lipofection 
The binding of nucleic acids to lipids results in organized structures like liposomes or 
micelles are formed. Liposomes are vesicles that consist of a phospholipid bilayer 
surrounding an aqueous compartment (Agrawal et al., 1997; Petersen et al., 2002). Liposomes 
have become the vehicles of choice for transfer of nucleic acids such as plasmids and 
oligodeoxynucleotides to cells in culture and in principle in vivo (Dass, 2002). Although 
generally not as efficient as viral vectors, nonviral systems such as lipidic vectors have the 
potential advantages of being less toxic, nonrestrictive in cargo DNA size, potentially 
targetable, and easy to produce in relatively large amounts. More important, lipidic vectors 
generally lack immunogenicity, allowing repeated in vivo transfection using the same vector. 
Different types of lipidic gene transfer vectors are described: 1) DNA/cationic liposome 
complexes, 2) DNA encapsulated in neutral or anionic liposomes, and 3) liposome-entrapped, 
polycation-condensed DNA (Lee and Huang, 1997). In principle, these delivery systems are 
also suitable for the transfection of siRNA. Therefore, several in vitro and in vivo studies 
were carried out to develop optimal liposomal-based siRNA transfection reagents (Hassani et 
al., 2005; Santel et al., 2006a; Santel et al., 2006b; Tagami et al., 2007). Many optimized lipid 
formulations for siRNA are already commercially available, for example Lipofectamine™ 
2000 (Invitrogen Inc., Karlsruhe, Germany), GeneSilencer® (Peqlab), GeneEraser™ 
(Stratagene) and HiPerFect® (Qiagen), but only applicable in vitro so far. 
 
Cationic lipids and helper lipids 
Cationic lipid–DNA complexes, also called lipoplexes, are formed by the interaction of 
anionic nucleic acids binding to the surface of cationic lipids eventually forming 
multilamellar lipid–nucleic acid complexes. The negatively-charged nucleic acids are 
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attracted to the surface of the positively-charged vesicles, initially forming complexes with 
nucleic acid molecules docked onto the surface of the cationic vesicles (Dass, 2002) (Figure 
2.2). In the case of double-stranded DNA, the nucleic acid molecules persist glued to lipidic 
molecules with a lipid bilayer surrounding the compacted nucleolipidic particles in one of 
several different moieties (Choi et al., 2001). 
 
Figure 2.2: Formation of lipoplexes. Anionic nucleic acid molecules are attracted to the 
surface cationic charge of the liposomes (made from a cationic and a neutral lipid mixture) 
forming complexes that eventually form compact nucleolipidic particles of various 
morphologies and sizes (Dass, 2002). 
 
Most of the cationic lipid reagents in use today are formulated as liposomes containing two 
lipid species, a cationic amphiphile and a neutral phospholipid (Felgner et al., 1994; Hofland 
et al., 1996; Godbey and Mikos, 2001). Commonly used cationic lipids are 1,2-dioleyl-3-
trimethyl ammonium propane (DOTAP) (Lasic, 1997), N-[1-(2,3-dioleyloxy)-propyl-N,N,N-
trimethyl ammonium chloride (DOTMA) (Felgner et al., 1987), 2,3-dioleyloxy-N-[2-
(spermincarboxamido)ethyl]-N,N-dimethyl-1-propanaminium (DOSPA) (Lasic, 1997), 
dioctadecylamidoglycylspermine (DOGS, Transfectam®)(Behr et al., 1989) and 3β-[N-[2-
(N,N-dimethylamino)ethyl]carbamoyl]cholesterol (DC-Chol) (Zhdanov et al., 2002). The 
cationic lipids form complexes with the polyanionic nucleic acids leading to DNA 
condensation and the formation of the lipoplexes that protects the DNA form degradation by 
intracellular nucleases. The positively charged lipoplexes adhere onto the negatively charged 
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cellular surface, whereby the internalization is facilitated. The neutral lipids, also called helper 
or fusogenic lipids, support permeation and fusion of the lipoplexes with the cell membrane. 
Dioleyl phosphatidylethanolamine (DOPE) is mostly used as a helper lipid for formation of 
liposomes from cationic lipids (Felgner et al., 1994). In many cases, for example Lipofectin®, 
the equimolar mixture of a cationic lipid and DOPE ensures optimally efficient transfection 
(Felgner et al., 1987). The major disadvantage of cationic liposomes as a gene delivery 
system is their much lower transfection efficiency compared to viral vector systems. The 
limitations of cationic liposome usage for transfection purposes (as a gene therapy tool) are 
closely connected to a short lifetime of the complexes, as well as to their inactivation by 
serum proteins (Zhdanov et al., 2002) and the cytotoxicity of cationic lipids at high 
concentrations in vitro (Lappalainen et al., 1994; Patil et al., 2004) and in vivo (Filion and 
Phillips, 1997; Dokka et al., 2000).  
 
Anionic and neutral lipids 
Anionic and neutral lipids for the construction of synthetic vectors as alternative for cationic 
lipids have also been used (Patil and Rhodesa, 2000; Fillion et al., 2001; Lakkaraju et al., 
2001; Patil et al., 2004). But their transfection efficiency is very low and has to be improved. 
One major problem is the packaging of the negatively charged DNA into the liposomes 
enabled by cations like Na+, K+ (Fillion et al., 2001), Ca2+ (Patil et al., 2005b) and polycations 
(Lee and Huang, 1997; Guo et al., 2002) which saturate the negative charge of the nucleic 
acids. Disadvantages of anionic liposomes as delivery vectors are the poor DNA 
encapsulation (Zelphati and Szoka, 1996) and the lack of toxicity data (Fillion et al., 2001). 
Nevertheless, neutral and anionic liposomes has been developed for gene therapy in vivo 
(Gaucheron et al., 2001). 
 
pH-sensitive liposomes 
They are designed in order to release their contents in response to acidic pH within the 
endosomal system while remaining stable at neutral pH in plasma thus improving the 
cytoplasmic delivery of various polar materials and macromolecules (Venugopalan et al., 
2002). pH-sensitive liposomes have been used to deliver anticancer drugs, antibiotics, 
antisense oligonucleotides, ribozymes, plasmids, proteins and peptides to cells in culture or in 
vivo (Simoes et al., 2004) 
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Immunoliposomes 
Immunoliposomes are generated by the modification of the lipid bilayer membrane 
integrating antibodies or antibody-fragments (Kontermann, 2006). These antibodies are 
targeted at defined receptors on the surface of the targeted cells. Thus, immunoliposomes can 
be designed for specific recognition of a target antigen followed by receptor-mediated 
endocytosis. In principle, the therapeutic index can be increased by targeting liposomes and 
their contents directly into tumor cells, and this may be useful for resistant cancers (Mamot et 
al., 2003). 
 
Stealth liposomes 
Stealth liposomes are sterically stabilized liposomal formulations containing 
polyethylenglycol (PEG) conjugated lipids. PEG prevents the recognition of the liposomes by 
the reticuloendothelial system and thus their degradation. Pegylated liposomes were called 
"stealth liposomes" because of their ability to evade interception by the immune system, by 
analogy as a stealth bomber evades radar. They are characterized by a very long-circulation 
half-life, favorable pharmacokinetic behavior and specific accumulation in tumor tissues 
(Cattel et al., 2003). 
 
2.1.2.3 Polyfection 
One non-viral gene delivery strategy involves the use of polycationic polymers as a DNA 
complexing agent. Generally cationic polymers are preferred due to their ability to form 
positively charged complexes with anionic nucleic acids (Hwang and Davis, 2001). These 
Polymer/DNA complexes, termed polyplexes, interact with the negatively charged cell 
surface and are taken up by a variety of cells via endocytosis (Luo and Saltzman, 2000).  
Polymers display striking advantages as vectors for gene delivery. They can be specifically 
tailored for the proposed application by choosing appropriate molecular weights, coupling of 
cell or tissue specific targeting moieties and/or performing other modifications that confer 
upon them specific physiological or physicochemical properties (Merdan et al., 2002). Among 
the variety of different non-viral vectors, the use of polymers confers several advantages, due 
to their ease of preparation, purification and chemical modification as well as their enormous 
stability (Lungwitz et al., 2005). Commonly used polymers are polyethylenimine (PEI) 
(Lemkine and Demeneix, 2001), poly-L-lysine (PLL) (Lollo et al., 2002), chitosan (Borchard, 
2001) and dendrimers (Merdan et al., 2002). 
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PEI/DNA polyplexes are internalized by a large variety of cells via endocytosis delivering 
polymer/DNA complexes to the endolysosomal compartment. They are finally released due to 
their buffer capacity via the so-called ‘proton sponge mechanism’. The proton-sponge 
hypothesis (Behr, 1994) asserts that polymers containing a large number of unprotonated 
basic groups (typically amines) may prevent acidification of endocytic vesicles by 
sequestering protons actively transported into the compartment by the endolysosomal ATPase 
proton pump. Furthermore, because of the buffering by the polymer, the enzyme continues to 
transport protons into the vesicle, the concentration of negative counter ions and the osmotic 
pressure increase, and the vesicles ultimately rupture (Forrest and Pack, 2002). 
Despite the relatively low transfection efficiency compared to viral transfection systems, as 
well as the cytotoxicity, the polyamine PEI has gained some prominence compared to other 
non-viral gene delivery systems. The implementation of strategies for their optimization 
yielded higher transfection efficiencies and lower cytotoxicity. Different polyethylenimine 
forms like branched (BPEI) and linear (LPEI) morphological isomers (Zou et al., 2000; 
Wightman et al., 2001; Wiseman et al., 2003; Breunig et al., 2005) as well as per-N-
methylated PEIs (Breunig et al., 2004) were synthesized and appropriate transfection 
conditions were determined.  
The efficacy of PEI-derived non-viral vectors and their cytotoxic effects depend on various 
parameters: 1) material characteristics such as the molecular weight, the degree of branching, 
the cationic charge density and buffer capacity (Fischer et al., 1999; von Harpe et al., 2000; 
Kunath et al., 2003); 2) the polyplex properties, such as the DNA content, particle size, the 
N/P ratio (quotient of the nitrogen atoms of PEI to DNA phosphates) and with it the zeta 
potential dramatically influences the transfection efficacy and the cytotoxicity; 3) 
experimental conditions e. g. the polyplex concentration, the presence or absence of serum 
during transfection, the incubation time and the transfection model chosen for the gene 
delivery experiment (Lungwitz et al., 2005). In order to gain more insight into LPEI-mediated 
gene transfer and to explore conceptual aspects for further optimization various steps during 
the transfection process were investigated and the results suggest that the endocytosis seems 
not to be a decisive parameter that determines the efficacy of a polymer in the transfection 
process (Breunig et al., 2007). But the intracellular release of the nucleic acid from the non-
viral carrier system may be a relevant criterion for the high transfection efficiency of certain 
polymers. Therefore, fluorescence resonance energy transfer (FRET) in combination with 
confocal laser scanning microscopy or flow cytometry was evaluated as a tool to determine 
the intracellular disintegration of LPEI/DNA-polyplexes (Breunig et al., 2006). 
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In vivo the specific delivery of highly charged particles to the desired cells fails, due to the 
non-specific interaction with blood components and extracellular matrix as well as non-
targeted cells and tissues (Lungwitz et al., 2005). To suppress non-specific interactions, the 
cationic surface charge has been shielded by the covalent or non-covalent attachement of a 
hydrophilic polymer layer, using polyethylenglycol (PEG), pluronic® (Nguyen et al., 2000; 
Ochietti et al., 2002), polyacrylic acid (Trubetskoy et al., 2003), poly-N-(2-
hydroxypropyl)methacrylamide derived copolymers (Oupicky et al., 2002; Carlisle et al., 
2004), dextran (Tseng and Jong, 2003) or dextran sulfate (Tiyaboonchai et al., 2003), as well 
as plasma proteins like transferrin (Kircheis et al., 1999; Kircheis et al., 2001) or human 
serum albumin (Rhaese et al., 2003). 
Moreover, polyplexes between siRNA and polyethyleneimine derivatives are promising 
nonviral carriers for siRNA. The polyplex stability is of critical importance for efficient 
siRNA delivery to the cytoplasm. First studies on the evaluation of the efficacy of different 
polyethylenimine structures for siRNA delivery and the determination of the biophysical and 
structural characteristics of PEIs for siRNA delivery were successful. SiRNA delivery was 
observed within a very narrow window of conditions, and only with the 25,000 branched PEI 
at an N:P ratio of 6:1 and 8:1 and with very high siRNA concentrations (200 nM) (Grayson et 
al., 2006). Mao et al. investigated the effect of PEGylation at a constant ratio (~50 %) on the 
biophysical properties of the polyplexes (Mao et al., 2006). It was shown that both the chain 
length and graft density of PEG strongly influence siRNA condensation and stability and 
hence affect the knockdown efficiency of PEI-PEG/siRNA polyplexes. 
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2.1.3 Problems of transfection in vivo 
 
In order to study the function of genes associated with human disease, in particular with 
oncogenesis, it has been shown that gene silencing by siRNA is a very successful and 
promising tool (Cheng et al., 2003). This technology permits not only target validation but 
may, at least in theory, provide oncogene-specific siRNAs for the development of cancer-
specific therapeutic approaches (Heidenreich, 2004). Finding the oncogene-specific siRNA is 
not the major challenge. For in vivo application, the greatest difficulty still is the efficient 
delivery of siRNA or plasmid DNA, respectively, into the targeted cells. 
The advantage of viral delivery systems is their extremely high transfection efficiency in a 
variety of human tissues, but due to the toxicity of the viruses and the potential of generating 
a strong immune response this transfection method is not acceptable in vivo (Patil et al., 
2005a). 
Non-viral delivery systems can circumvent some of the problems associated with viral vectors 
and are emerging as favorable alternatives to viral vectors. The greatest advantages of non-
viral gene vectors are lack of immune response and ease of formulation and assembly 
(Merdan et al., 2002). But, besides the toxicity, the major disadvantage of non-viral 
transfection reagents and the reason for the failure of their successful application in vivo is the 
very low transfection efficiency. In order to solve this problem numerous efforts on the 
improvement of transfection methods and on the development of efficient non-viral 
transfection reagents have been made, but failed so far. Thus, there is still a great need to find 
a non-viral, efficient and non-toxic transfection reagent which can be applied repeatedly in 
vivo. 
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2.1.4 The TmHU protein 
 
2.1.4.1 The HU protein family 
HU proteins belong to a group of small basic proteins abundant in all prokaryotes capable of 
interacting with DNA and inducing DNA condensation. They are termed as histone-like or 
HU proteins because their biochemical properties are similar to eukaryotic histones (Drlica 
and Rouviere-Yaniv, 1987; Bonnefoy and Rouviere-Yaniv, 1991; Oberto and Rouviere-
Yaniv, 1996). The term HU is derived from the DNA-binding and DNA-condensing protein 
Heat Unstable Nucleotide Protein from E. coli. The HU proteins are highly homologous to 
each other and consist of about 90 amino acid residues with a monomeric molecular mass of 
9-10 kDa. The amino acid sequence is highly conserved (Drlica and Rouviere-Yaniv, 1987) 
resulting in the analogous supra-secondary structures of the HU proteins. In solution, they 
form either homodimers or heterodimers (Bonnefoy and Rouviere-Yaniv, 1991; Oberto and 
Rouviere-Yaniv, 1996). HU proteins are essentially involved in the formation of supra-
molecular nucleo-protein-complexes and play an important role in different DNA 
metabolizing processes, such as replication, transcription and transposition (Hwang and 
Kornberg, 1992; Lavoie and Chaconas, 1994). They are able to repair DNA (Murphy and 
Zimmerman, 1994; Kamashev and Rouviere-Yaniv, 2000) and to increase the “melting 
temperature” (Tm) of DNA (Esser et al., 1999). By interaction with the genome the HU 
proteins can influence gene expression, the growth and the vitality of microorganisms. 
HU proteins bind DNA mainly in a non-sequence-specific manner (Boubrik et al., 1991) with 
relatively low affinity to linear DNA, whereas kinked DNA forms tight complexes (Shimizu 
et al., 1995). On the one hand HU proteins bend double-stranded DNA, thereby condensing it 
into compact higher-ordered nucleosome-like structures (Murphy and Zimmerman, 1994), 
and, on the other hand, HU proteins promote DNA flexibility (Paull et al., 1993). More 
information on the mechanism of DNA binding was obtained with the determination of the 
HU protein structure from the thermophilic bacterium Bacillus stearothermophilus, BstHU, 
by X-ray crystallography (White et al., 1989) and NMR spectroscopy (Vis et al., 1995). 
BstHU is a homodimer, which consists of an α-helical part involved in dimerization, and of a 
β-sheet region responsible for DNA binding. Two long β-hairpin arms extending from the 
protein core are suggested to bind tightly into the minor groove of DNA (Haerd et al., 1989; 
Goshima et al., 1992).  
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2.1.4.2 TmHU, the histone-like protein from Thermotoga maritima 
Due to their enormous stability, especially against thermal denaturation, proteins from 
hyperthermophilic organisms are of major interest for the biotechnological industry (Jaenicke 
et al., 1996). Normally, they are recombinantly expressed without difficulty (Jaenicke and 
Böhm, 1998; Christodoulou and Vorgias, 2002), and due to their high thermo-stability the 
first step in the purification of the proteins from crude cell lysate is performed by cheap and 
effective heat precipitation. Moreover, the handling, storage and cooling during and after the 
purification of thermo-stabile proteins is unproblematic. 
TmHU is the HU protein from the marine hyperthermophilic eubacterium Thermotoga 
maritima. The native protein represents a stable homodimer. The monomer consists of 90 
amino acids with highly conserved regions in the sequence compared to other HU proteins. 
Esser et al. demonstrated by CD spectroscopical studies with secondary structure analysis and 
comparative modeling that the dimeric TmHU has a tertiary structure similar to homologous 
HU proteins (Esser et al., 1999). The model 3D structure of TmHU is shown in Figure 2.3. 
 
a b  
 
Figure 2.3: Model structure of TmHU. (a) Schematic representation of the dimer; the model 
is based on the NMR structure of the HU protein from B. stearothermophilus. The positions 
of additional positively charged residues in TmHU compared to BstHU are indicated by red 
circles, demonstrating their clustering at the bottom and at the DNA-binding interface of the 
protein. (b) Model of the DNA interaction between TmHU and a kinked 35 bp DNA fragment 
based on the coordinates of the IHF (integration host factor) structure from E. coli, which 
recognizes specific DNA sequences (Boubrik et al., 1991; Ellenberger and Landy, 1997). The 
protein interacts with the central part of the bended DNA, using minor groove contacts and 
contacts to the phosphodiester backbone, and induces a bend of more than 160 °, thereby 
reversing the direction of the DNA (Esser et al., 1999). 
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The “melting temperature” (Tm) of the protein was determined to be 96 °C, and thermal 
unfolding is almost completely reversible (Esser et al., 1999). Compared to other HU proteins 
TmHU possess a large number of basic amino acids, and therefore, a higher isoelectric point 
(pI = 10.36). Due to its positive charge TmHU is able to interact with DNA. The protein binds 
to DNA in a highly cooperative manner, with a KD of 73 nM and a Hill coefficient of 7.6 for a 
56 bp DNA fragment. TmHU is capable of increasing the “melting temperature” of a 
synthetic, double-stranded DNA by 47 °C, thus suggesting that DNA stabilization may be a 
major function of this protein in hyperthermophiles (Esser et al., 1999).  
 
2.1.4.3 TmHU as gene transfer reagent 
After recombinant expression in E. coli, purification and physicochemical characterization of 
the extremely hyperthermophilic DNA-binding TmHU protein (Esser et al., 1999), a 
biotechnologically feasible and economical approach for gene delivery using the TmHU 
protein as an efficient gene transfer reagent was carried out (Esser et al., 2000).  
Esser et al. established a protocol for TmHU-mediated transient transfection in vitro, 
transfecting the E. coli lacZ gene into NIH 3T3 cells. The protocol was optimized for several 
critical parameters, such as the TmHU:DNA ratio and the conditions of pre-incubation. The 
optimal TmHU:DNA ratio was 12.5:1 (wt/wt), corresponding to a 5- to 6-fold net positive 
charge excess at physiological pH. Upon heating the reaction mixture (95 °C for 40 min) and 
adding calcium to a final concentration of 2 mM, a dense, compact precipitate formed, 
accompanied by a 100-fold increase in transfection efficiency and a higher reproducibility. In 
the absence of calcium, the observed aggregates were larger, had a lower density, and floated 
in the medium. The optimized system routinely yielded about 1 · 104 X-gal positive cells/mg 
DNA, the number of transfected cells being roughly proportional to the amount of reaction 
mixture used. A control experiment without TmHU yielded only 3 X-gal positive cells/mg 
DNA, demonstrating that the transfection was not due to DNA–calcium phosphate co-
precipitation. The DEAE-dextran method (Stratagene, La Jolla, CA) and lipofection using the 
cationic lipid Tfx-50 (Promega) yielded about 3 · 102 and 3.3 · 103 X-gal positive cells/mg 
DNA, respectively. Transfecting several cell lines with TmHU, compared with DEAE-
dextran mediated transfection efficiencies were increased (33 fold (NIH 3T3), 120-fold 
(U251), and 6-fold (A431)). 293T cells could not be transfected with DEAE-dextran (the cells 
detached) but were very efficiently transfected with TmHU. 
Addition of endosomolytical agents (e.g., chloroquine) under several conditions did not 
improve transfection by TmHU but in fact was often detrimental. Esser et al. neither observed 
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a decrease in transfection efficiency when cells grew confluently nor inhibition of transfection 
by serum. All transient transfections with TmHU were therefore performed with confluent 
cultures in the presence of serum. 
Since these features point towards the feasibility of an in vivo application, Esser et al. tested 
this potential, injecting TmHU–DNA complexes into the thigh muscles of female BALB/c 
mice. The transient expression of the luciferase reporter gene increased by an average of 8-
fold compared to the injection of naked DNA. However, the conditions for efficient 
transfection in vivo differed considerably from those determined in vitro, with precipitate 
formation seemingly decreasing efficiency, probably because of impaired diffusion. The 
optimal TmHU:DNA ratio for in vivo transfection was determined to be 1.2:1 (wt/wt). 
In order to evaluate toxicity, Esser et al. monitored the number of viable 293T cells after 24 h 
incubation with various concentrations of either TmHU or the cationic lipid Lipofectin® 
(GIBCO BRL). Whereas incubation with even low amounts of Lipofectin® (0.05 mg/ml) 
caused considerable cell death, an effect of TmHU was observed only at very high 
concentrations (1 mg/ml TmHU). Considering that only 1.2 mg TmHU were used to transfect 
1 mg DNA in vivo, but usually a 3- to 4-fold mass excess of Lipofectin over DNA was used, 
the authors concluded that TmHU is at least two orders of magnitude less toxic. 
The protocol optimized for transient transfection was also successfully applied to stably 
transfect NIH 3T3 cells with the neomycin resistance gene in vitro. TmHU-mediated gene 
transfer in presence or absence of calcium yielded colonies of stable transfectants after 
selection with G418. The yields were comparable to those of the standard calcium phosphate 
precipitation method. 
It was further investigated, whether the prior formation of TmHU–DNA complexes could 
enhance the efficiency of lipofection. Different experiments were set up using 1 mg of 
plasmid DNA and varying amounts of TmHU and of the cationic lipid Tfx-50. The optimal 
condition for lipofection in the absence of TmHU was a charge ratio of 2:1, resulting in 3.3 · 
103 X-gal positive cells/mg DNA. Pre-incubation with TmHU increased the transfection 
efficiency significantly, yielding up to 1.6 · 104 X-gal positive cells/mg DNA (3:1 charge 
ratio, 6.25 mg TmHU). This yield was significantly higher than the sum of yields obtained 
using either TmHU or cationic lipid alone, indicating a synergistic effect. Unlike the 
optimized protocol for TmHU-mediated transfection, heating the TmHU–DNA mixture 
before adding it to the cationic lipid decreased the transfection efficiency to about 30%. 
Taken together, TmHU can mediate transfection of eukaryotic cells with high efficiency 
because it is a polycation, like many transfection reagents. It binds DNA nonspecifically and 
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protects it efficiently from DNase digestion. At a high TmHU:DNA ratio, the surplus positive 
charges facilitate binding of the TmHU–DNA complex to the negatively charged cell 
membrane. Furthermore, considering that some cationic amphiphilic peptides are known to 
cause endosomal disruption (Wyman et al., 1997), a fraction of TmHU molecules or partially 
denatured molecules may destabilize the endosomal membrane, inducing uptake into the 
cytosol. The presence of calcium might further enhance endosomolysis, as has been 
postulated earlier (Zaitsev et al., 1997). TmHU is an efficient carrier of heterologous DNA 
into various eukaryotic cells and an enhancer of another transfection method (lipofection). 
Moreover, large amounts of the protein can be produced easily and efficiently to provide 
sufficient material for large-scale in vitro or in vivo transfections. 
In preliminary toxicity studies, TmHU proved to be significantly less toxic than Lipofectin, 
and no adverse effects have been observed in the in vivo experiments. One important point is 
the potential immunogenicity of TmHU; the bacterial origin of the protein might elicit an 
immune response that could be detrimental for repeated injections. Relevant studies will have 
to be performed to investigate these potential hazards. In addition, the formation of large 
aggregates that is inherent to this technique may not always be favorable and may sometimes 
even pose a potential danger in vivo (e.g., in intravenous applications). 
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2.2 Objective 
 
Synthetic small interfering RNA (siRNA) has been shown to be a selective and potent 
inhibitor of gene expression in mammalian cells (Elbashir et al., 2001a). Since the specific 
down-regulation of oncogene expression is predicted to be an efficient procedure for the 
selective killing of tumor cells, siRNAs are considered as promising agents for cancer 
treatment (Dorsett and Tuschl, 2004). However, efficient transfection of the cancer cells is a 
prerequisite for this new concept, and reliable in vitro and in vivo models are indispensable 
for the proof of principle. Moreover, the in vivo application of siRNA is very critical and 
difficult. Non-toxic and safe transfection reagents suitable for in vivo application are not 
available, so far. Possibly, the discovery of the non-toxic TmHU protein as DNA transfection 
reagent may provide a new alternative for siRNA transfection in vivo. It has already been 
shown that HU proteins can bind to RNA. The bacterial histone-like protein EcoHu from 
Escherichia coli specifically recognizes similar structures not only in DNA but also in 
double-stranded RNA and in hybrids of DNA and RNA (Balandina et al., 2002). Another 
example for the interaction of HU proteins with RNA is HBsu from Bacillus subtilis, which 
binds the Alu domain of small cytoplasmatic RNA (Nakamura et al., 1999).  
 
The objective of this work was to explore the suitability of TmHU as siRNA transfection 
reagent in vitro and in vivo in order to obtain new therapy options in the treatment of tumors. 
For the development of appropriate assays three human glioblastoma cell lines had to be 
stably transfected with the gene encoding the enhanced green fluorescent protein (EGFP) and 
the gene encoding the red fluorescent protein (DsRed2), respectively. After the selection of 
the transfectants with the antibiotic G418, the fluorescent cells were enriched by cell sorting 
with the flow cytometer. The chemosensitivity of the wild type and the transfected cell lines 
had to be investigated to assure the similarity of the cell lines and the comparability of the test 
results. 
For the in vitro assay the extent of EGFP or DsRed2 expression had to be quantified with 
respect to total cell number using a Tecan GENiosPro fluorescence plate reader. A crucial 
procedure was the validation of this method with different transfection reagents, specific and 
nonspecific siRNA. The application of the siRNA-transfection reagent complexes should be 
carried out by subcutaneous implantation of micro-osmotic pumps to achieve a continuous 
release of the transfection mixture. 
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Furthermore, this project was intended to comprise the development of a practicable method 
for in vivo studies on siRNA effects. Therefore, solid subcutaneous tumors had to be 
established after subcutaneous injection of EGFP and DsRed2 expressing glioblastoma cells 
into nude mice. The quantitation of the fluorescence intensity should be accomplished in 
histological sections by conventional fluorescence microscopy and confocal laser scanning 
microscopy. This morphometric procedure is based on serial sections, very complex and 
extremely time-consuming. Moreover, the animals have to be killed and therefore only an end 
point measurement is possible. Due to this difficulty it was also planned to quantify the 
fluorescence intensity of the tumors by an in vivo imaging system, an innovative, non-
invasive method. 
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2.3 Materials and methods 
 
2.3.1 Chemicals and drugs  
Water was purified by a Milli-Q system (Millipore, Eschborn, Germany). If not mentioned 
otherwise chemicals were of analytical grade and were obtained from Merck (Darmstadt, 
Germany). The following selection antibiotics were used: ampicillin sodium (Amp, 50 μg/μl, 
Sigma, Deisenhofen, Germany), kanamycin sulfate (Kan, 50 μg/μl, Sigma) and geneticin 
disulfate (G418, neomycin, 400 μg/μl, PAA Laboratories, Cölbe, Germany). All antibiotics 
were kept as aliquoted stock solutions in millipore water at -20 °C. Phosphate buffered saline 
(PBS) was made of 8.0 g/l NaCl, 1.0 g/l Na2HPO4·2H2O, 0.2 g/l KCl, 0.2 g/l KH2PO4 and 
0.15 g/l NaH2PO4·H2O and adjusted to pH 7.4 with NaOH or HCl. DAPI (4',6'-diamidino-2-
phenylindole, Sigma) was a gift from the Institute of Pathology (University of Regensburg) 
and was kept as stock solutions with a concentration of 2 mg/ml in DMSO. SYTO 60 
(Molecular Probes, Eugene, USA) kept as 5 mM stock solution in DMSO and was aliquoted 
in sterile PBS to 50 µM. The DNA (300 mg/l) solution was made of deoxyribonucleic acid 
sodium salt from calf thymus (Sigma) diluted in CS buffer (sodium citrate 0.01 M, NaCl 0.15 
M, pH 7.0). 
 
2.3.2 Amplification and purification of plasmid DNA 
 
2.3.2.1 The pEGFP-N1, pcDNA3EGFP and pDsRed2-C1 vectors 
The glycerol stock culture of the pEGFP-N1 vector (BD biosciences Clontech, Heidelberg, 
Germany) was kindly provided by Prof. Göpferich (Instiute of Pharmacy) from the University 
of Regensburg (Figure 2.4). The pcDNA3EGFP vector was generated by the isolation of the 
EGFP encoding fragment from the pEGFP-N1 vector and the subsequent insertion into the 
HindIII/NotI cassette of the pcDNA3 vector (Ziemek, 2006). The purified plasmid DNA of 
pDsRed2-C1 (BD biosciences Clontech) was a gift from ACGT ProGenomics (Halle a. d. 
Saale, Germany) (Figure 2.5). 
 TmHU as siRNA transfection reagent 39 
 
Figure 2.4: Vector maps of pEGFP-N1 and pcDNA3. 
 
 
Figure 2.5: Vector map of pDsRed2-C1. 
 
2.3.2.2 Plasmid DNA maxi-preparation and determination of DNA concentration 
The plasmid DNA was isolated from E. coli (strain K12-XL-blue). For the plasmid DNA 
maxi-preparation of pEGFP-N1 and pcDNA3EGFP 110 ml of LB medium, supplemented 
with the appropriate selection antibiotic (Kan 30 μg/ml, Amp 100 μg/ml), were inoculated 
with a sample from the glycerol stock culture (800 μl of bacterial suspension, 200 μl 85 % 
glycerol), which was stored at -80 °C. The culture was grown overnight at 37 °C (shaker, 300 
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rpm). Next day, the DNA was isolated using the Qiagen Plasmid Purification Kit (Qiagen, 
Hilden, Germany) with the Qiagen-tip 500 column according to the manufacturer instructions. 
A 1:50 dilution of a Maxi-Prep DNA was prepared, and the DNA concentration was 
determined photometrically according to the following equation: 
c (µg/ml) = 70 A260 – 40 A280. 
The identification of the plasmid DNA was carried out by the determination of the molecular 
weight with agarose gel electrophoresis. 
 
2.3.2.3 Restriction enzyme digest 
For the restriction analysis of plasmid DNA the enzymes HindIII (10 U/μl,Roche Diagnostics, 
Mannheim, Germany) and NotI (10 U/μl, MBI Fermentas, St. Leon-Rot. Germany) were 
used. Normally, 1 μl of the enzyme stock solution was mixed with 2 μl of the 10x NEBuffer 3 
(New England BioLabs, Frankfurt am Main, Germany) including 10% of BSA solution (10 
mg/ml, Serva, Heidelberg, Germany). After addition of 0.5 μg of DNA the samples were 
diluted to a final volume of 25 μl with millipore water. The reaction was carried out for 60 
min at 37 °C in an Eppendorf reaction vessel, and enzymes were heat-inactivated for 15 min 
at 65 °C. The samples were cooled to room temperature and for agarose gel electrophoresis 5 
µl of 6x gel loading buffer (Peqlab, Erlangen, Germany) were added to each sample. 
 
2.3.2.4 Agarose gel electrophoresis 
5x TBE buffer contained 445 mM tris-base (USB, Cleveland, USA), 445 mM boric acid and 
10 mM EDTA (Titriplex III). The 5x TBE buffer stock was diluted by 1:5 with Millipore 
water to obtain 1x TBE for preparation of agarose gels. 0.5 g of agarose (peqGOLD 
Universal-Agarose; Peqlab, Erlangen, Germany) were dissolved in 50 ml of 1x TBE buffer 
under heating on a magnetic stirrer, then 2 μl of ethidium bromide solution (10 mg/ml H2O, 
Janssen Chimica, Beerse, Belgium) were added. The mixture was allowed to cool for an 
appropriate period of time and poured into the gel chamber. The solidified gel was covered 
with 1x TBE buffer up to the denoted fill line. 
Prior to electrophoresis, TBE buffer was filled into the gadget and 25 µl of each sample were 
pipetted per pocket. As reference, the peqGOLD DNA (Peqlab) ladder mix was prepared 
according to the manufacturers instructions. 
Electrophoresis was performed for 60 – 90 minutes at 90 V until tracking dye had migrated 
2/3 of the gel length. After electrophoresis, the gels were inspected in a gel analysis and 
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documentation system (Gel-Doc 2000, Bio-Rad Laboratories, München, Germany) with UV 
excitation of 254 nm. The acquired data were analyzed with the Quantity One software (Bio-
Rad). 
 
2.3.3 Cell culture 
 
The human U-87 MG (HTB 14), the U-118 MG (HTB 15) and the U-373 MG (HTB-17) 
glioblastoma/astrocytoma cells (Beckman et al., 1971) were obtained from the American 
Type Culture Collection (ATCC). Cell banking and quality control were performed according 
to the "seed stock concept" (Hay, 1988). Wild type and stably transfected U-87 MG and U- 
373 MG cells were grown in Eagle´s minimum essential medium (EMEM, Sigma) containing 
L-glutamine, 2.2 g/l NaHCO3, 110 mg/l sodium pyruvate, and 5 % fetal calf serum (FCS, 
Biochrom, Berlin, Germany), whereas the U-118 MG cells were maintained in Dulbecco´s 
minimum essential medium (DMEM, Sigma), which was also supplemented with 5 % FCS. 
The transfected cells were cultured in the appropriate culture medium containing 400 µg/ml 
of G418. All cells were cultured in a water-saturated atmosphere of 95% air and 5% carbon 
dioxide at 37 °C in 75-cm² culture flasks (Nunc, Wiesbaden, Germany) and were serially 
passaged following trypsinization using trypsin (0.05 %)/EDTA (0.02 %) (Roche Diagnostics, 
Mannheim, Germany). Culture media without phenol red were used to prevent interferences 
with the fluorescence measurements.  
 
2.3.4 Stable transfection of human glioblastoma cell lines 
 
U-87 MG and U-118 MG wild type cells were transfected with pEGFP-N1 in passage 182 
and 532, respectively, whereas the U-373 MG cell line was transfected with pcDNA3EGFP in 
passage 226. The transfection of the U-87 MG, U-118 MG and U-373 MG cells with 
pDsRed2-C1 was carried out in passages 221, 560 and 277, respectively. One day before 
transfection, wild-type cells were seeded into 6-well plates (Greiner, Frickenhausen, 
Germany) in the appropriate culture medium. The cell density was adjusted to 50-70% 
confluency on the day of transfection. The cells were transfected with the respective plasmid 
DNA, using the FuGene® 6 transfection reagent (Roche, Mannheim, Germany). For each well 
1 μg of plasmid DNA was used. The DNA/FuGene®-complex was prepared prior to 
transfection, according to the manufacturers instructions. Briefly, DNA and transfection 
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reagent were pre-incubated in serum-free medium for 15 min at RT. This mixture was added 
dropwise to the cells, and after 12 h of incubation in the incubator the medium was replaced 
with fresh culture medium. 48 hours after transfection, the culture medium was exchanged by 
medium containing 400 μg/ml of the selection antibiotic G418 (Geneticin, PAA 
Laboratories). After the first passage cells were maintained in 25-cm² culture flasks (Nunc, 
Wiesbaden, Germany). The cells were analyzed by fluorescence microscopy and flow 
cytometry. 
 
2.3.4.1 Fluorescence microscopy 
Living cells were analyzed under a LEICA DM IRB inverse microscope equipped with a PL 
FLUOTAR 10x/0.30 Ph1 objective and a FITC fluorescence filter. Images were made with a 
Nikon Coolpix 4500 digital camera. 
 
2.3.4.2 Flow cytometry and cell sorting 
The sorting of the fluorescent cells was performed with a FACSCaliburTM flow cytometer 
(BD Biosciences, Heidelberg, Germany) in the single cell modus according to the 
manufacturer´s instructions. 
 
2.3.5 Chemosensitivity assay 
 
The assays were performed according to Bernhardt et al. (Bernhardt et al., 1992). In brief: 
tumor cell suspensions (100 μl/well) were seeded into 96-well flat-bottomed microtitration 
plates (Greiner, Frickenhausen, Germany) at a density of ca. 15 cells/microscopic field 
(magnification 320x). After 2 days the culture medium was removed by suction and replaced 
by fresh medium (200 μl/well) containing varying drug concentrations or vehicle, 
respectively. On every plate 16 wells served as controls and 16 wells were used per drug 
concentration. After various times of incubation the cells were fixed with glutardialdehyde 
(Merck, Darmstadt, Germany) and stored at 4 °C. At the end of the experiment all plates were 
stained with crystal violet (Serva, Heidelberg, Germany) simultaneously. Absorbance was 
measured at 578 nm using a Biotek 309 Autoreader (Tecnomara, Fernwald, Germany). 
Growth curves were created using SigmaPlot analysis software (Systat Software GmbH, 
Erkrath, Germany). 
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2.3.6 Fluorescence detection 
 
The detection of the fluorescence spectra was performed with an SLM-AMINCO Bowman 
Series 2 Luminescence Spectrometer (AMINCO-Bowman, Urbana, USA). 
The fluorescence based assays were performed with the microplate reader GENios Pro (Tecan 
Deutschland GmbH, Crailsheim, Germany). The following filter sets were used for the 
detection of the blue, green and the red fluorescence, respectively: BP 485 ± 20 nm/ BP 535 ± 
25 nm and BP 612 ± 10 nm/ BP 670 ± 25 nm. 
 
2.3.7 Transfection of double-stranded siRNA 
 
2.3.7.1 Nonsilencing siRNA and specific EGFP-siRNA 
The chemically synthesized double stranded negative control siRNA with the non-silencing 
target sequence 5´-AAT TCT CCG AAC GTG TCA CGT-3´ was purchased from Qiagen 
(Hilden, Germany). The specific double-stranded EGFP-siRNA (MWG Biotech, Ebersberg, 
Germany) with the antisense sequence 3´-UUC GUC GUG UCG AAG AAG UUC-5´ 
targeting the EGFP coding region 237-258 relative to the first nt of the start codon 5´-AAG 
CAG CAC GAC UUC UUC AAG-3´ was a gift from Dr. Böhm (ACGT ProGenomics AG, 
Halle (Saale), Germany). 
 
2.3.7.2 Procedure 
One day before transfection 5,000 cells per well were seeded in a 96-well plate (Greiner). 20 
pmol siRNA per well were incubated with 0.3 µl of Lipofectamine 2000, 100 pmol TmHU 
protein, 25 µl CaCl2 solution (8 mM) and 100 pmol of TmHU protein plus 25 µl CaCl2 
solution (8 mM), respectively. Culture medium without serum was added to a final volume of 
200 µl per well, to adjust a final CaCl2 concentration of 1 mM. Cells were washed with PBS, 
and the mixture of siRNA and transfection reagent was added. 4 hours after incubation the 
medium was removed and culture medium containing 5% FCS was added. 72 hours after 
transfection total cell number was determined at λex = 612 and λem = 670 nm after staining of 
the living cells with the nucleic acid stain SYTO 60 (Molecular Probes), whereas EGFP 
expression was measured simultaneously at λex = 485 and λem = 535 nm.  
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2.3.8 In vivo experiments 
For the characterization of the in vivo growth of the human glioblastomas NMRI(nu/nu) nude 
mice obtained from the nude mouse laboratory of the department were used. The mice were 
allowed to take autoclaved water and food, a combined breed and maintenance diet especially 
for nude mice (Ssniff, Soest, Germany), ad libitum. The animals were housed under specified 
pathogen-free conditions at a 12 h light/dark cycle at a temperature of 25 °C and a relative 
humidity of 70 %. At an age of 6 weeks the mice were used for the studies. For subcutaneous 
injection suspensions of the respective cells were prepared in vitro. Cells were detached from 
the culture flask with trypsin/ EDTA and FCS-free medium and washed twice with FCS-free 
medium. To adjust the appropriate cell number (4 · 106 cells/100 µl) cells were resuspended in 
FCS free medium. Under aseptic conditions 100 µl of the cell suspensions were injected 
under the thoracic dermis. To maintain the subcutaneous tumors in the mice a solid tumor was 
excised when the tumor growth reached an area of about 150 mm². For serial transplantation 
solid tumors were cut into pieces of 2 mm3 in sterile PBS and transplanted for several 
passages.  
Tumor growth kinetics was recorded by measuring tumor diameters with an electronic caliper 
weekly. Tumor areas were calculated as the product of two perpendicular diameters, of which 
one represents the largest diameter of the tumor. As measure for a potential detraction of the 
animals by the tumor growth the weight of the animals was measured once a week. Tracking 
of the tumors was performed by labeling the mice with earmarks or tattoos. 
 
2.3.9 Histology 
 
2.3.9.1 Preparation of paraffin sections 
The production of the paraffin sections was performed with modifications according to the 
procedure described by Walter et al. (Walter et al., 2000). 
After dissection, tumors were fixed in 4 % buffered paraformaldehyde (Fluka, St. Gallen, 
Switzerland), pH 7.4, for at least 6 h at room temperature. Then the specimens were washed 
three times with PBS for 10 min followed by dehydration in an ascending ethanol series at 
room temperature. Ethanol was removed and xylene was added for 3 x 2 h at room 
temperature. Xylene was replaced with the paraffin Paraplast X-tra® (Sherwood Medical, 
Roth GmbH, Karlsruhe, Germany) and left for 4 x 4 h at 50-54 °C. The final embedding step 
was performed with Paraplast® at 55 °C. The blocks were stored at room temperature over 
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night and kept in the fridge until sectioning. 6 µm-thick sections were cut and mounted on 
glass slides pretreated with poly-L-lysine (Sigma). Sections were deparaffinized in xylene, 
rehydrated in a descending series of ethanol and mounted in VECTASHIELD® Hard+SetTM 
Mounting Medium containing DAPI. 
 
Table 2.1: Embedding procedure with times, embedding solvents and temperature. 
Time Solvent Temperature 
1 h   70% ethanol RT 
1 h   96% ethanol RT 
1 h   96% ethanol RT 
1 h   96% ethanol RT 
1 h 100% ethanol RT 
2 h Xylene RT 
2 h Xylene RT 
2 h Xylene RT 
4 h Paraplast X-tra 50 - 54 °C 
4 h Paraplast X-tra 50 - 54 °C 
4 h Paraplast X-tra 50 - 54 °C 
4 h Paraplast X-tra 50 - 54 °C 
Embedding Paraplast 55 °C 
 
2.3.9.2 Conventional fluorescence microscopy and confocal laser scanning microscopy 
Sections were evaluated using conventional fluorescence microscopy and with a confocal 
laser scanning microscope. The nuclei were stained with DAPI and examined with excitation-
filter BP360/51 and emission-filter BP460/10. EGFP expression was detected by laser 
scanning (Ar-Laser 488 nm, BP-filter 505-525 nm). Autofluorescence of the wild type tumors 
was detected with the same settings. The relative fluorescence intensity was quantified by the 
software tool “histo” of the Zeiss LSM Image Browser. 
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2.3.10 In vivo imaging 
 
The subcutaneous human U-373 MG EGFP tumors were investigated three months after the 
injection of the cell suspension. A 3:1 (v/v) mixture of Ketamin 10 % (WDT, Garbsen, 
Germany) and Xylazin 2 % (cp pharma, Burgdorf, Germany) was prepared and 0.01 – 0.015 
ml per 10 g body weight were injected intraperitoneally. After the narcotization, the mice 
were placed on the thermostated sample stage in the darkbox. The excitation of the green 
fluorescence in the solid tumor was performed with the excitation filter HQ 470/40. The 
fluorescence emission was detected by the CCD camera with the emission filter HQ 545/90. 
The computer based Hamamatsu Imaging System DSCN consisting of a darkbox and an air 
cooled 16 bit CCD camera ORCA II-BT-512 (Typ: C4742-MG-26LA) was used for the in 
vivo imaging studies. The composition of this in vivo imaging system is shown schematically 
in Figure 2.6. 
 
Figure 2.6: Schematic illustration of the essential components for in vivo fluorescence 
imaging. 1: flexible and heatable sample stage; 2: fluorescence imaging lenses with high 
numerical aperture; 3: light source connected to a ring light via a fiber cable and with 
excitation filter; 4: emission filter; 5: fluorescence filter sets. 
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2.3.11 Micro-osmotic pumps 
 
2.3.11.1 Preparation of micro-osmotic pumps 
Osmotic pumps (ALZET®, Charles River, Sulzfeld, Germany) were used to ensure a 
continuous and controlled release of the substances. For the application in nude mice the 
smallest size of osmotic pumps with a volume of 88 ± 3 µl (model 1003D) was chosen. The 
flow rate was 1.06 µl/h (± 0.05 µl/h) and the entire delivery period was 72 h. 
The required length of the polyethylene infusion catheter PE 60 (ALZET®) was calculated 
with the following parameters: the volume that should be released was around 100 µl and the 
inner diameter of the PE catheter was 0.75 mm. With the formula for cylinders the length was 
determined to be 226 mm (≈ 23 cm). 
The 23 cm long catheters were deformed spirally to wrap them around the pumps as tightly as 
possible. Therefore, the catheters were wound around a 1-ml syringe, dipped into boiling 
water for 1 min and subsequently cooled in ice water. Afterwards, the catheters were 
sterilized in a 10% H2O2 solution. 
ALZET pumps have a start-up gradient during which the pumps soak up fluid and come to 
temperature. This start up period was accomplished by “priming” the pumps in vitro prior to 
implantation in vivo. The empty pumps, together with the appropriate flow moderator, were 
weighed separately. Afterwards, the pumps were filled without air bubbles using a 1-ml 
syringe and a 27G canula according to the manufacturer´s instructions. The filling volume 
was controlled by weighing the pumps. Then, the catheters were filled with a 0.01% Evans 
Blue solution and attached to the flow moderator. After inserting the flow moderator into the 
pump, the pumps were weighed again. For the in vivo experiment the pre-filled pumps were 
placed in sterile 0.9% saline at 37 °C over night. 
 
2.3.11.2 Performance of the in vitro delivery study 
After filling, the pumps were placed in one well of a 6-well-plate (Greiner®) each containing 
5 ml of PBS. The end of the catheter was put in a second well filled with 2.0 ml of PBS 
(Figure 2.41). After equilibration („priming“) over night the first samples were taken from the 
wells, where the end of the catheters were put in. 1000 µl were removed and measured 
photometrically at 600 nm. Subsequently, the 1000 µl in the cuvette were transferred back to 
the corresponding well quantitatively. 
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2.3.11.3 Subcutaneous application of micro-osmotic pumps in nude mice 
The subcutaneous implantation of the prepared pumps into four nude mice was performed 
under anesthesia with a mixture of Ketamin and Xylazin. The end of the catheters was placed 
nearby the implanted tumors to assure a direct delivery on the tumor. The pumps were 
implanted in dorsal position, two pumps pointing towards the cranium (Figure 2.44a) and two 
pumps pointing towards the tail (Figure 2.44b). 
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2.4 Results 
 
2.4.1 EGFP and DsRed2 expressing human glioblastoma cells  
 
2.4.1.1 Stable transfection 
In order to investigate siRNA effects on EGFP expression levels in vitro and in vivo three 
human glioblastoma variants were stably transfected with the gene encoding the enhanced 
green fluorescent protein (EGFP) and the gene encoding the red fluorescent protein (DsRed2), 
respectively. The generated cells, expressing the green fluorescent protein were named U-87 
MG EGFP, U-118 MG EGFP and U-373 MG EGFP. They are shown in Figure 2.7. 
 
Figure 2.7: Conventional fluorescence microscopic images of EGFP expressing human 
glioblastoma cell lines U-87 MG EGFP (a, b), U-118 MG EGFP (c, d) and U-373 MG EGFP 
(e, f); on the left site cells in transmission mode. 
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The DsRed2 expressing transfectants were designated U-87 MG DsRed2, U-118 MG DsRed2 
and U-373 MG DsRed2. A confocal laser scanning image of a U-373 MG DsRed2 cell is 
shown in Figure 2.8. 
 
Figure 2.8: Confocal laser scanning image of a U-373 MG DsRed2 cell (HeNe Laser 543 nm, 
LP-filter 560 nm) 
 
2.4.1.2 Cell sorting by flow cytometry 
After the transfection of the cell lines and the selection with the antibiotic G418 only a small 
fraction of around 30% of the cells expressed EGFP. To obtain cell populations with a 
predominant EGFP expression, the fluorescent cells were collected with the FACSCaliburTM 
flow cytometer. As an example the results of the U-87 MG EGFP cell line are shown in 
Figure 2.9 and Figure 2.10. 
After cell sorting, 80% of the cells stably expressed EGFP. After numerous passages the ratio 
of fluorescent cells did not markedly decrease. Moreover, additional cell sorting did not 
increase the fraction of EGFP expressing cells. 
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Figure 2.9: U-87 MG EGFP (passage 188) cell population before sorting with the 
FACSCaliburTM flow cytometer. a) The histogram displays the number of cells with the 
corresponding fluorescence intensity. b) The DotPlot shows the living cells with a distinct 
size and the corresponding fluorescence intensity. Cells with a relative fluorescence intensity 
higher than 30 (~ 32%) were defined as EGFP expressing cells (marked in red) and were 
collected. 
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Figure 2.10: U-87 MG EGFP (passage 190) cell population after sorting with the 
FACSCaliburTM flow cytometer. a) The histogram displays the number of cells with the 
corresponding fluorescence intensity. b) The DotPlot shows the living cells with a distinct 
size and the corresponding fluorescence intensity. Cells with a relative fluorescence intensity 
higher than 30 were defined as EGFP expressing cells (marked in red) and were collected. 
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2.4.1.3 Chemosensitivity of the transfectants 
Aiming at the exploitation of siRNA effects for the down-regulation of oncogenes in tumor 
cells it is very important to assure that the behavior of the transfectants is similar to the wild 
type cells. Therefore, the growth of the wild type cells was compared with that of the EGFP 
transfected cells in culture medium with and without the selection antibiotic G418. The results 
are shown in Figure 2.11, Figure 2.12 and Figure 2.13. 
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Figure 2.11: Comparison of the cell growth of U-87 MG cells (filled circle) and U-87 MG 
EGFP cells incubated without (open square) and with 400 µg/ml G418 (open triangle), 
respectively. 
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Figure 2.12: Comparison of the cell growth of U-373 MG cells (filled circle) and U-373 MG 
EGFP cells incubated without (open square) and with 400 µg/ml G418 (open triangle), 
respectively. 
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Figure 2.13: Comparison of the cell growth of U-373 MG cells (filled circle) and U-373 MG 
EGFP cells incubated without (open square) and with 400 µg/ml G418 (open triangle), 
respectively. 
 
The transfection of human glioblastoma variants with the gene encoding EGFP did not 
significantly influence the growth kinetics of the cells. No difference between the cells 
maintained in culture medium with or without the selection antibiotic G418 was observed. 
Furthermore, the chemosensitivity of all wild type and transfected cells against the cytostatic 
doxorubicin was comparable. The results are shown for the U-373 MG cells as an example in 
Figure 2.14. 
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Figure 2.14: Incubation of a) U-373 MG wild type cells and the corresponding transfected 
cells b) U-373 MG EGFP and c) U-373 MG DsRed2 cells with various concentrations of 
doxorubicin: 2.5 nM (filled circle), 5.0 nM (filled square), 7.5 nM (filled triangle), 10 nM 
(filled diamond), 15 nM (filled inverted triangle) and vehicle EtOH 70% (open star). 
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2.4.2 Fluorescence assay by means of a microplate reader for the quantitation of 
siRNA effects in vitro 
 
Most of the commercially available siRNA transfection reagents, for example Lipofectamine® 
2000 are cytotoxic. Therefore, it is possible that large fractions of the incubated cells die 
during the experiment. In order to exclude incorrect results caused by this effect, in this assay 
the extent of EGFP or DsRed2 expression was quantified with respect to total cell number. 
 
2.4.2.1 Establishment of an assay for the quantification of EGFP expression 
Varying numbers of wild type cells and EGFP expressing cells were seeded in 96-well plates. 
The next day, the cells were stained with the nucleic acid stain SYTO 60 at a concentration of 
500 nM and incubated for two hours at 37 °C in an atmosphere of 5% CO2 (Figure 2.15). 
Afterwards, the cells were washed twice with sterile PBS, and culture medium without phenol 
red was added. 
a                                    b                          c
 
Figure 2.15: LSM images of living U-87 MG cells expressing EGFP stained with the nucleic 
acid stain SYTO 60. a: SYTO 60 (HeNe-Laser 633 nm, LP-filter 650 nm), b: EGFP (Ar-Laser 
488 nm, BP-filter 505-525 nm), c: Overlay 
 
The extent of EGFP expression was quantified with respect to total cell number using a Tecan 
GENiosPro fluorescence plate reader. For the investigations on EGFP expressing cells the cell 
number was determined by staining the cells with the red fluorescent nucleic acid stain SYTO 
60 (Molecular Probes). Total cell number was determined at λex = 612 and λem = 670 nm 
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(compare Figure 2.16), whereas EGFP expression was measured simultaneously at λex = 485 
and λem = 535 nm (compare Figure 2.17). 
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Figure 2.16: Fluorescence excitation and emission spectra of the nucleic acid stain SYTO 60 
(5 µM) bound to DNA (300 mg/l) with excitation and emission maxima at 650 nm and 681 
nm, respectively; excitation spectra: λem = 675 nm and emission spectra: λex = 599 nm; 
excitation and emission slits: 5 nm. 
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Figure 2.17: Fluorescence excitation and emission spectra of the enhanced green fluorescent 
protein EGFP (from the National Cancer Institute NCI, modified, 
http://home.ncifcrf.gov/ccr/flowcore/spectra/GFPspec.htm). 
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Measuring the green fluorescence of a dilution series of EGFP expressing cells revealed a 
linear increase in fluorescence intensity with increasing cell numbers. Wild type cells always 
yielded the same fluorescence intensity independent of the cell number (Figure 2.18). 
Therefore, the green fluorescence of the EGFP expressing cells can be corrected by 
subtraction of the constant auto-fluorescence (Figure 2.19), determined for the wild type cells. 
Detection of the red fluorescence due to nucleic acid stain SYTO 60 showed a linear 
dependency of the intensity from the cell number (Figure 2.20). 
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Figure 2.18: Comparison of the green fluorescence (λex = 485 nm, λem = 535 nm) of U-87 
MG wild type cells (filled circle) and EGFP expressing U-87 MG EGFP cells (open circle) as 
a function of the cell number. 
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Figure 2.19: Green fluorescence (λex = 485 nm, λem = 535 nm) of the EGFP expressing U-87 
MG EGFP cells (open circle) corrected for the auto-fluorescence of the wild type U-87 MG 
cells as a function of cell number. 
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Figure 2.20: Red fluorescence (λex = 612 nm, λem = 670 nm) of wild type U-87 MG cells 
(filled circle) and EGFP expressing U-87 MG EGFP cells (open circle) due to the nucleic acid 
stain SYTO 60 as a function of cell number. 
 
 TmHU as siRNA transfection reagent 59 
The fraction of EGFP expressing cells (FEGFP) was calculated according to the following 
equations: 
[ ] 100
emT  const.
emT  % F
670
corrected535,
EGFP ⋅⎟⎟⎠
⎞⎜⎝
⎛
⋅=  (eq. 2.1), 
with emT670 representing the emission of the test population at 670 nm after nucleic acid 
staining with SYTO 60. The emission of the test population at 535 nm without the 
autofluorescence of the wild type cells (emT535, corrected) was evaluated according to 
equation 3.2: 
 type wild535,535corrected 535, emC - emT emT =  (eq. 2.2) 
A constant (const.) indicating the value of the green fluorescence compared to the red 
fluorescence was determined. This constant was defined by means of the control in all tests 
according to equation 3.3. 
670
corrected 535,
emC
emC const. =  (eq. 2.3) 
The abbreviation for the emission at 670 nm of the control after nucleic acid staining with 
SYTO 60 is emC670. 
The fluorescence emission at 535 nm of the control without the autofluorescence of the wild 
type cells (emC535, corrected) was determined according to equation 3.4: 
 type wild535,535corrected 535, emC - emC emC =  (eq. 2.4) 
with emC535 and emC535, wild type representing the emission at 535 nm of the EGFP expressing 
cells and of the wild type cells, respectively. 
 
2.4.2.2 Establishment of an assay for DsRed2 expressing cells 
Different quantities of wild type cells and DsRed2 expressing cells were seeded in 96-well 
plates. The next day, the cells were stained with the nucleic acid stain DAPI at a concentration 
of 1 µM and incubated two hours at 37 °C and 5% CO2 (Figure 2.21). Afterwards, the cells 
were washed twice with sterile PBS buffer and culture medium without phenol red added. 
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Figure 2.21: Conventional fluorescence microscopic image of the DsRed2 expressing human 
U-373 MG DsRed2 glioblastoma cells stained with the nucleic acid stain DAPI. The 
excitation and emission wavelength were λex = 340 nm, λem = 460 nm for DAPI and λex = 560 
nm, λem = 600 nm for DsRed2. 
 
In case of DsRed2 expression the cell number was quantified by staining the nuclei with the 
blue fluorescent stain DAPI. Total cell number was determined at λex = 340 nm and λem = 485 
nm (compare Figure 2.22), whereas DsRed2 expression was measured simultaneously at λex = 
535 nm and λem = 612 nm. The red fluorescent protein DsRed2 shows excitation and emission 
maxima at 560 nm and 570 nm (spectra not shown). 
 
Figure 2.22: Fluorescence excitation and emission spectra of DAPI with excitation and 
emission maxima at 359 nm and 461 nm, respectively (from the Institute for stem cell 
research, ISCR, University of Edinburgh, UK). 
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Measuring the red fluorescence of a dilution series of DsRed2 expressing cells revealed a 
linear increase in fluorescence intensity with increasing cell numbers (Figure 2.23). Due to 
the low signal to noise ratio of the red fluorescence compared to the green fluorescence, the 
autofluorescence of the wild type cells was disregarded. Detection of the blue fluorescence 
due to nucleic acid stain DAPI showed a linear dependency of the intensity from the cell 
number (Figure 2.24). 
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Figure 2.23: Red fluorescence (λex = 535 nm, λem = 612 nm) of the DsRed2 expressing U-87 
MG DsRed2 cells (filled circle) as a function of cell number. 
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Figure 2.24: Blue fluorescence (λex = 340 nm, λem = 485 nm) of U-87 MG DsRed2 cells 
(open circle) due to the nucleic acid stain DAPI as a function of cell number. 
 
The fraction of DsRed2 expressing cells (FDsRed2) was calculated according to the following 
equations: 
[ ] 100
emT  const.
emT  % F
485
612
DsRed2 ⋅⎟⎟⎠
⎞⎜⎝
⎛
⋅=  (eq. 2.5), 
with emT485 representing the emission of the test population at 485 nm after nucleic acid 
staining with DAPI. The emission of the test population at 612 nm is defined by the 
abbreviation emT612.  
 
A constant (const.) indicating the value of the red fluorescence compared to the blue 
fluorescence was determined. This constant was defined by means of the control in all tests 
according to equation 3.6. 
485
612
emC
emC const. =  (eq. 2.6)  
with emC612 representing the emission at 612 nm of the DsRed2 expressing cells. The 
abbreviation for the emission at 485 nm of the control after nucleic acid staining with DAPI is 
emC485. 
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2.4.3 Cytotoxicity of the TmHU protein 
 
As a prerequisite for its application as reagent for in vivo transfection the potential 
cytotoxicity of TmHU was determined against the three human glioblastoma cell variants U-
87 MG, U-118 MG and U-373 MG. As an example the results are shown in Figure 2.25 for 
the U-87 MG cell line. As expected the TmHU protein exhibited no cytotoxic effect even at 
very high concentrations. 
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Figure 2.25: Proliferation of U-87 MG cells incubated with different concentrations of the 
TmHU protein: 0.5 µM (filled circle), 1.25 µM (filled square), 2.5 µM (filled triangle), 3.75 
µM (filled diamond), 5 µM (filled inverted triangle) and PBS as vehicle (open star). 
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2.4.4 siRNA transfection with TmHU 
 
The method was validated with EGFP specific and nonspecific siRNAs and different 
transfection reagents: Lipofectamine® 2000 as positive control, TmHU protein, CaCl2 and 
TmHU protein in combination with CaCl2. The results of three independent assays are 
summarized in Figure 2.26.  
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Figure 2.26: Fraction of EGFP expressing U-87 MG EGFP cells 72 hours after the addition 
of the substances. Culture medium (black bar) and EGFP-siRNA (red bar) served as controls. 
The nonsilencing nonspecific siRNA was incubated together with Lipofectamine® 2000 
(green bar), with TmHU (blue bar), with CaCl2 (cyan bar) and with TmHU plus CaCl2 (brown 
bar). The silencing EGFP-siRNA was incubated together with Lipofectamine® 2000 (yellow 
bar), with TmHU (pink bar), with CaCl2 (gray bar) and with TmHU plus CaCl2 (dark green 
bar). 
 
Only Lipofectamine® 2000 together with the specific EGFP-siRNA showed a down-
regulating effect on the EGFP expression. Numerous variations in the performance of the 
assay concerning the concentration ratios of transfection reagent and siRNA and the 
incubation time of the transfection mixture did not improve the effects. 
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2.4.5 In vivo growth characteristics, selection and expansion of subcutaneous 
tumors 
 
As tumor model for the in vivo investigations of siRNA effects, subcutaneous tumors of 
EGFP and DsRed2 expressing cells were established. It was shown that the tumors retain their 
ability to stably express the fluorescent proteins without selection pressure by the antibiotic 
G418. After several passages the fluorescence intensity was retained in most of the tumors. 
Only a few tumors lost their fluorescence. 
Tumor growth kinetics is displayed by tumor area over time graphs. The changes of the body 
weight are not presented, because no significant loss of weight was observed. 
The in vivo morphology of the tumors was routinely observed by the Masson-Goldner 
staining of paraffin sections. All tumors were very rich in cells, and the cells were held 
together as bundles by the connective tissue. The nuclei were pleomorphic and in part 
possessed multiple prominent nucleoli. The malignancy of these tumors is indicated by 
numerous mitoses and an invasive growth into the surrounding tissue. No differences in the 
histological appearance of the transfected and the wild type tumors were observed. 
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2.4.5.1 Subcutaneous U-87 MG EGFP tumors 
The formation of a tumor after the injection of the U-87 MG EGFP cell suspension took a 
long period of around three months (Figure 2.27). However, after the transplantation of tumor 
pieces the tumors grew faster. Within six weeks they were disposed for the next 
transplantation (Figure 2.28). 
time [d]
0 20 40 60 80 100
tu
m
or
 a
re
a 
[m
m
2 ]
0
50
100
150
200
250
300
 
Figure 2.27: Growth of subcutaneous U-87 MG EGFP tumors (passage 0) after the injection 
of the cell suspension (passage 254 in cell culture). 
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Figure 2.28: Growth of subcutaneous U-87 MG EGFP tumors (passage 1) after the 
transplantation of the tumor pieces from mouse 359. 
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2.4.5.2 Subcutaneous U-118 MG EGFP tumors 
The formation of a tumor after the injection of the U-118 MG EGFP cell suspension and 
within the first two passages took a long period of around 3.5 months (Figure 2.29 and Figure 
2.30). In passage 0 only one of 6 possible tumors emerged. However, after the transplantation 
over three passages the tumors grew faster and more evenly. Within five weeks they were 
disposed for the next transplantation (Figure 2.31 and Figure 2.32). 
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Figure 2.29: Growth of subcutaneous U-118 MG EGFP tumors (passage 0) after the injection 
of the cell suspension (passage 605 in cell culture). The tumor from mouse 375 was 
transplanted. 
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Figure 2.30: Growth of subcutaneous U-118 MG EGFP tumors (passage 2). 
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Figure 2.31: Growth of subcutaneous U-118 MG EGFP tumors (passage 3) after the 
transplantation of the tumor pieces from mouse 367. 
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Figure 2.32: Growth of subcutaneous U-118 MG EGFP tumors (passage 4) after the 
transplantation of the tumor pieces from mouse 501. 
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2.4.5.3 Subcutaneous U-373 MG EGFP tumors 
After the injection of the U-373 MG EGFP cell suspension the tumor formation took a 
relatively short period of around five weeks (Figure 2.33). However, there was one tumor 
which lost its fluorescence (mouse 347). After the transplantation of the solid tumor pieces 
the growth rate was approximately identical to the tumors of passage 0 (Figure 2.34). 
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Figure 2.33: Growth of subcutaneous U-373 MG EGFP tumors (passage 0) after the injection 
of the cell suspension (passage 312 in cell culture). 
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Figure 2.34: Growth of subcutaneous U-373 MG EGFP tumors (passage 1) after the 
transplantation of the tumor pieces from mouse 345. 
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2.4.5.4 Subcutaneous DsRed2 expressing glioblastoma 
The establishment of subcutaneous DsRed2 expressing tumors was also successful (data not 
shown). The formation of a tumor after the subcutaneous injection of the cell suspension 
required a period of around two to four months depending on the cell line. It was comparable 
to the EGFP expressing tumors. After the transplantation of small pieces of the solid tumors 
they grew faster and more evenly. Within five to eight weeks they were disposed for the next 
transplantation. 
 
2.4.6 Quantitation of EGFP in paraffin sections of subcutaneous tumors 
 
Solid tumors were established after subcutaneous injection of EGFP expressing cells into 
nude mice and quantitation of EGFP was accomplished in histological sections by 
conventional fluorescence microscopy and confocal laser scanning microscopy.  
 
 
 
a                                     b
c                                     d
 
Figure 2.35: a: Fluorescence microscopic image of a U-87 MG s.c. tumor after DAPI 
staining; b: LSM image of paraffin embedded s.c. U-87 MG tumor with relative fluorescence 
intensity of 14 (i.e. auto-fluorescence); c: Fluorescence microscopic image of an U- 87 MG 
EGFP s.c. tumor after DAPI staining; d: LSM image of paraffin embedded U-87 MG EGFP 
s.c. tumor with relative fluorescence intensity of 66. 
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Figure 2.36: Comparison of the relative fluorescence intensity of the s.c. tumor U-87 MG 
EGFP with the auto-fluorescence of the wild type tumor U-87 MG. 
 
2.4.7 In vivo imaging of subcutaneous U-373 MG EGFP tumors in nude mice 
 
In vivo imaging is a very innovative and favored approach for the detection and quantitation 
of fluorescent tissues in vivo. This method is non-invasive and the animals can be examined 
several times during the experiment. In order to gain reliable results in the quantitation of the 
fluorescence intensity the fluorescent tissues were imaged in three different positions. 
 
 
a                                           b
 
Figure 2.37: Lateral view of a subcutaneous human U-373 MG EGFP glioblastoma. a: 
transmission light; b: green fluorescence. The fluorescence image shows the vascularization 
of the tumor.  
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a                                           b
 
Figure 2.38: Dorsal view of a subcutaneous human U-373 MG EGFP glioblastoma. a: 
transmission light; b: green fluorescence. 
 
 
a                                           b
 
Figure 2.39: Ventral view of a subcutaneous human U-373 MG EGFP glioblastoma a: 
transmission light; b: green fluorescence. 
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The quantification of the fluorescence intensity was carried out by the software of the in vivo 
imaging system with the color palette indicating the fluorescence intensity. 
  
a                                     b                         c
 
Figure 2.40: Quantification of the fluorescence intensity by a color palette; a: lateral view; b: 
dorsal view; c: ventral view. The color palette indicates the fluorescence intensity. The auto-
fluorescence is displayed in gray scale. The quantification of the fluorescence intensity is 
carried out by the software of the in vivo imaging system. 
 
2.4.8 Investigations on micro-osmotic pumps 
 
The application of the siRNA-transfection reagent complexes should be carried out by 
subcutaneous implantation of micro-osmotic pumps to achieve a continuous release of the 
transfection mixture. For this purpose preliminary in vitro and in vivo studies were 
accomplished with Evans Blue, a non-toxic dye. The continuous release of the solution was 
monitored, and the practicability of subcutaneous implanted pumps with an attached catheter 
was evaluated. 
 
2.4.8.1 Verification of the delivery in vitro 
The pumps were filled with 0.9% saline and immerged in PBS. The attached catheters were 
filled with 0.01% Evans Blue solution. Nearly the complete Evans Blue solution was released 
after 70 h at 37 °C (Figure 2.41). 
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Figure 2.41: Experimental setup of the in vitro experiments with osmotic pumps. a) The 
pumps directly after the insertion in PBS; b) 70 hours after the insertion of the pumps. 
 
By removing a sample from the reservoir and measuring the absorbance of the blue solution 
at 600 nm the delivery of the pumps was determined. The steady release and slight variations 
between the three pumps were demonstrated (Figure 2.42). 
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Figure 2.42: Progression of the Evans Blue release from osmotic pumps with attached 
catheters over 70 hours. 
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2.4.8.2 Verification of the delivery in vivo 
For the implantation of the osmotic pumps 4 nude mice with subcutaneous tumors of 
comparable size, as shown in Figure 2.43, were selected. 
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Figure 2.43: Growth of subcutaneous U-118 MG EGFP tumors before the implantation of 
osmotic pumps. The changes of the body weight of the nude mice are presented as insert. 
 
The pumps were implanted in dorsal position either pointing towards the cranium (Figure 
2.44a) or towards the tail (Figure 2.44b). 
 
Figure 2.44: Subcutaneous U-118 MG 
EGFP tumor (black arrow) and placement 
of the implanted osmotic pumps in situ. 
The pumps were inserted in such a way 
that the Evans Blue solution was released 
directly on the tumor (red arrow).
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Before the dissection of osmotic pumps after three days, a distinct blue coloration surrounding 
the tumor was recognizable (Figure 2.45). 
 
Figure 2.45: Subcutaneous implanted osmotic pump with an attached catheter three days after 
the application. The outlet of the catheter nearby the tumor is marked with a blue arrow. 
 
After the transection of the skin the position of the osmotic pump and its catheter could be 
inspected. The positioning of the osmotic pump was not changed and the outlet of the catheter 
was still placed directly at the well vascularized tumor (Figure 2.46). 
 
 
Figure 2.46: Position of an osmotic pump (red arrow) with the outlet of its catheter (blue 
arrow) close to a subcutaneous U-118 MG EGFP tumor (black arrow). 
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In order to control the complete release of the Evans Blue solution the osmotic pumps were 
dissected (Figure 2.47). The ends of the catheters still contained Evans Blue solution, because 
the catheters were able to take up a volume of 100 µl, but the used pumps had only an average 
volume of 88 µl. 
 
Figure 2.47: The removed osmotic pumps three days after implantation. 
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2.5 Summary 
 
For the proof of principle of siRNA effects in vitro and in vivo in order to treat brain tumors, 
the three human glioblastoma cell lines U-87 MG, U-118 MG and U-373 MG were stably 
transfected with the EGFP and DsRed2 reporter gene, respectively. A large fraction of 
fluorescent cells is a prerequisite for the quantitative detection of variances in EGFP 
expression. Hence, the transfectants were selected with the antibiotic G418 and the ratio of 
fluorescent cells was increased up to 80% by cell sorting with the flow cytometer. 
Furthermore, in order to assure the similarity of the wild type and the transfected cells we 
analyzed the growth kinetics. Neither the EGFP expression nor the selection antibiotic G418 
affected the cell growth. Moreover, the chemosensitivity of the cell lines against different 
concentrations of doxorubicin was comparable. 
 
A suitable and convenient in vitro method was established for the quick detection of siRNA 
effects by using a fluorescence plate reader. Due to the cytotoxicity of cationic lipid or 
polymer based siRNA transfection reagents resulting in varying cell densities of the test 
population and consequently in incorrect results, the extent of EGFP or DsRed2 expression 
was quantified with respect to total cell number. Furthermore, the TmHU did not show any 
cytotoxic effect up to a very high concentration of 5 µM. 
 
The validation of this method was performed with specific EGFP-siRNA and nonspecific 
siRNA. The cationic lipid based siRNA transfection reagent Lipofectamine® 2000, the TmHU 
protein and 1 mM CaCl2 alone and in combination were compared. Although the TmHU 
protein showed very promising effects in the transfection of plasmid DNA (Esser et al., 2000), 
neither the TmHU protein nor the combination of the TmHU with CaCl2 together with the 
specific EGFP-siRNA showed a down-regulating effect on the EGFP expression. Also 
numerous variations in the performance of the assay concerning the concentration ratios of 
transfection reagent and siRNA and the incubation time of the transfection mixture did not 
improve the effects. Claudia Immisch from ACGT ProGenomics AG (Halle, Germany) tested 
further conditions and could show that the combination of TmHU with the endosomolytic 
chloroquine was efficient (Immisch, 2006). But chloroquine is inappropriate for in vivo 
studies. Thus, the TmHU protein does not fulfill the requirements of a transfection reagent for 
siRNAs. 
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In order to develop a method to study siRNA effects in vivo, solid subcutaneous tumors were 
established after subcutaneous injection of EGFP and DsRed2 expressing glioblastoma cells, 
respectively, into nude mice. The formation of a tumor after the subcutaneous injection of the 
cell suspension required a long period of around two to four months depending on the cell 
line. However, after the transplantation of small pieces of the solid tumors they grew faster 
and more evenly. Within five to eight weeks they could be disposed for the next 
transplantation. 
 
Paraffin embedding with the low melting Paraplast X-tra of the subcutaneous tumors enabled 
the quantitation of the fluorescence intensity in histological sections by conventional 
fluorescence microscopy and confocal laser scanning microscopy. These fundamental 
techniques for the determination of siRNA activity provide the basis for the detailed 
investigation on the effects of siRNA transfection reagents in vitro and in vivo. However, this 
morphometric procedure is based on serial sections, very complex and extremely time-
consuming. Moreover, the animals were killed and therefore only an end point measurement 
was possible. Due to this difficulty an in vivo imaging system for the quantitation of the 
fluorescence intensity of the tumors was tested. In order to perform the intended preclinical 
studies on RNA interference it was shown that in vivo imaging offers the appropriate method 
with reliable results in the quantitation of the fluorescence intensity, particularly with regard 
to the possibility to take multiple images during the experiment. 
 
Micro-osmotic pumps with an attached catheter will allow a continuous release of the siRNA 
transfection mixture in vivo. This was verified with preliminary in vitro and in vivo tests by 
loading the osmotic pumps with a solution of the non-toxic dye Evans Blue. The continuous 
release of the solution was monitored and the practicability of subcutaneous implantation of 
the pumps was assured. The position of the implanted osmotic pumps with their catheters did 
not change and the outlet of the catheter was still placed directly at tumor. Moreover, the 
required volume of the Evans Blue solution was delivered within the targeted period of time. 
 
The established in vivo methods could not be used for the intended investigations on the 
TmHU protein because numerous in vitro experiments with TmHU did not show any effect 
on siRNA transfection. Nevertheless, these methods are useful and recommendable for the 
investigation of more promising siRNA transfection reagents for in vivo use. 
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3.1 Introduction 
 
3.1.1 The mitotic spindle as a target in cancer chemotherapy 
 
Mitosis is an ordered series of fundamentally mechanical events in which identical copies of 
the genome are moved to two discrete locations within the dividing cell (Figure 3.1). The 
chromosome segregation during mitosis occurs on a bipolar spindle that consists of dynamic 
structures, the microtubules, and of associated proteins, contributing to the assembly and 
functionality of the whole spindle complex. For decades the mitotic spindle was identified as 
an important target in cancer chemotherapy because of its crucial role in cell division. 
 
Mitotic events
I
II
III
IV
Checkpoint
Prometaphase
PrometaphaseProphase
Interphase
Telophase/cytokinesis Metaphase
Anaphase
 
Figure 3.1: Mitosis is a series of ordered mechanical events (I-IV): (I) microtubule capture 
and spindle pole separation; (II) chromosome alignment; (III) anaphase chromosome 
movement; (IV) telophase and cytokinesis. A parallel network of kinase-dependent signaling 
cascades monitors these mechanical events and regulates transition from one stage to another 
(Wood et al., 2001). 
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3.1.1.1 The role of microtubules in the mitotic spindle 
 
The hollow cylindrical structure of microtubules is made up of 13 parallel protofilaments, 
which are composed of alternating α- and β-tubulin units aligned along the longitudinal axis 
of the microtubule. Microtubules are polar polymers with distinct plus (+) and minus (-) ends. 
The structural polarity is created by the regular, parallel orientation of their subunits. The 
process of polymerization uses the energy provided by GTP hydrolysis and shows different 
dynamics at both ends of the microtubules. The plus (+) end is able to grow rapidly and is 
kinetically more dynamic than the minus (-) end, which tends to lose subunits if not 
stabilized. Although both ends grow and shorten alternately by polymerization and 
depolymerization, net growing occurs at the plus end and net shortening at the minus end 
(Walker et al., 1988). 
Figure 3.2 illustrates the role of microtubules in mitosis. During mitosis, all microtubules are 
associated at their minus ends with the microtubule organizing centers, the centrosomes, from 
which they are nucleated (Bailly and Bornens, 1992). Three major classes of microtubules are 
found in the mitotic spindle, serving different functions. During the prometaphase the 
duplicated chromosomes attach to some microtubules, the kinetochore microtubules, through 
their kinetochore. In the following metaphase the kinetochore microtubules attach the sister 
chromatids to opposite poles of the mitotic spindle, and the chromosomes are aligned at the 
equator of the spindle. The daughter chromosomes start to get separated polewards at the 
early anaphase by a shortening of the kinetochore microtubules and by a contributing effect of 
motor proteins. This process leads to the synchronic separation of the sister chromatids to 
form two daughter chromosomes. In the later anaphase the spindle poles move apart from 
each other by the action of motor proteins, which connect and couple the polar or overlapping 
microtubules at the equator of the mitotic spindle. Furthermore, astral microtubules radiate in 
all directions from the centrosomes and stabilize the position of the spindle in the mitotic cell 
by contributing to the separation of the poles. 
Destabilization of microtubules, e.g. by microtubule-interfering agents, leads to free 
kinetochore sites, which activate the mitotic spindle assembly checkpoint. Consequently, the 
transition to the anaphase is blocked by inhibition of the anaphase-promoting complex. On the 
other hand, microtubule-stabilizing agents block the formation of spindle fibers even before 
mitosis is started. When cells are already in mitosis, these agents stabilize the spindle, finally 
preventing cytokinesis and cell cycle progression. 
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Figure 3.2: Schematic drawing of the mitotic spindle (Mollinedo and Gajate, 2003). 
Microtubules are organized by the spindle poles or centrosomes, containing a pair of centriols 
each, with the microtubule plus ends projecting away from the centrosomes. Three classes of 
microtubules are distinguished in the mitotic spindle serving different functions during 
mitosis. Kinetochore microtubules bind to the kinetochores and play a key role in attaching 
the chromosomes to the spindle and in mediating chromosome movement. Polar or overlap 
microtubules interdigitate at the equator of the spindle, provide the symmetrical and bipolar 
shape of the spindle, and mediate spindle separation in anaphase. Astral microtubules radiate 
away in all directions from the centrosomes and contribute to position the spindle in the cell 
and to the forces that separate the poles. The roles of the types of microtubules differ due to 
the binding of different protein complexes that control their respective properties and 
dynamics. Chromosome movement is mediated by both microtubule dynamics and by the 
action of motor proteins. Anaphase ensues only when all the kinetochores of each pair of 
sister chromatids are bound to microtubules (upper chromosome), and a tension is exerted on 
kinetochores by pulling them through the kinetochore microtubules to opposite directions 
(middle chromosome). A free kinetochore (lower right chromatid) activates the mitotic 
spindle assembly checkpoint, which inhibits the anaphase-promoting complex, leading to a 
blockage in cyclin B1 proteolysis, and thereby to an increased cyclin B1 level and cell cycle 
arrest at the M phase. Survivin, located in microtubules and kinetochores, seems to play a key 
role in preserving microtubule integrity and in inhibiting apoptosis during normal cell cycle, 
and may circumvent checkpoint mechanisms of growth arrest. Only microtubule-bound 
survivin associates with cdc2 and prevents apoptosis during normal mitosis through a cyclin 
B1/cdc2-mediated phosphorylation (lower left chromatid). BUB: budding uninhibited by 
benzimidazole; MAD: mitosis arrest deficient. 
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3.1.1.2 Microtubule interfering agents 
 
Microtubules are a valuable target for cancer chemotherapy due to their crucial role in vital 
cellular functions for tumor cells, including mitosis, motility and cell-cell contacts. A large 
number of chemically diverse compounds are capable to bind tubulin or microtubules leading 
to the disruption of the mitotic spindle and the inhibition of cell proliferation. 
The alkaloid colchicine from Colchicum autumnale L. is one of the first compounds identified 
as “mitotic spindle poisons” (Levan, 1938). However, colchicine is not in use as a cytostatic 
drug due to its small therapeutic index, defined as the ratio of maximum tolerated 
dose/minimum effective dose. Two decades later, alkaloids from Vinca rosea L. were 
described as agents arresting cells in mitosis with aberrant mitotic spindles (Palmer et al., 
1960). Subsequently, vincristine and vinblastine were introduced into clinical practice in the 
1960s. They are still in use as important chemotherapeutic drugs in combinative treatment 
regimen, e.g. for the curative therapy of testicular cancer, Hodgkin disease, and acute 
lymphatic leukemia, or for the palliative therapy of solid tumors. In 1986, paclitaxel, isolated 
from Taxus brevioflia L., entered into clinical trials. Paclitaxel has proven to be one of the 
most broadly effective anticancer agents. Due to its effectiveness against a broad spectrum of 
tumors and its therapeutic success, the interest in microtubules as a pharmacological target 
structure increased dramatically and led to extensive efforts put in the development of further, 
more potent and better tolerated inhibitors of microtubule function (Attard et al., 2006). 
Naturally derived compounds, such as epothilones, which are secondary metabolites from 
myxobacteria (Altmann et al., 2000), and coral-derived eleutherobin derivatives (Hamel et al., 
1999; McDaid et al., 1999) were evaluated in preclinical investigations. Also many new 
taxanes, paclitaxel prodrugs, and new formulations of classical microtubule-interfering agents 
have been in clinical development (Wood et al., 2001). 
The microtubule function is maintained in a dynamic state of polymerization and 
depolymerization (Mitchison, 1984; Desai, 1997). The vinca alkaloids and colchicine promote 
destabilization of microtubules, leading to depolymerization, whereas paclitaxel and other 
taxanes stabilize microtubules by blocking depolymerization (Schiff, 1979; Schiff, 1980). 
Both attacks to the equilibrium between polymerization and depolymerization lead to the 
disruption of this dynamic process and thus to a breakdown of the integrative function of 
polymeric tubulin. In this way it can be explained that both types of microtubule interfering 
agents share the common principle of suppressing microtubule dynamics and thereby 
microtubule functions, although these compounds have opposite effects on microtubules, 
(Jordan, 1998).  
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Figure 3.3: Chemical structures of compounds leading to microtubule depolymerization. 
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Figure 3.4: Inhibitors of microtubule depolymerization. The cellular target of paclitaxel, 
docetaxel, RPR 109881A, IDN 5109 and epothilone A is the β-tubulin in the microtubule 
polymer. The exact binding site for eleutherobin is not known yet (Mollinedo and Gajate, 
2003). 
 Inhibtiors of kinesin Eg5 97 
Figure 3.3 and Figure 3.4 show the chemical structures of microtubule-interfering agents, 
inhibiting microtubule polymerization and depolymerization, respectively. Moreover, 
microtubule interfering agents can be classified into three major categories based on their 
respective tubulin binding domains, which include the “colchicine” domain, the “vinca 
alkaloid” domain, and the “paclitaxel” domain (Mollinedo and Gajate, 2003). 
Because microtubules are also involved in a large number of other cellular functions, 
including chemotaxis, membrane and cellular scaffolding, intracellular transport, secretory 
processes and transmission of receptor signaling, microtubule interfering agents may affect 
malignant and nonmalignant cells in interphase, in addition to the mitotic phases of the cell 
cycle. This lack of selectivity towards tumor cells leads to a number of toxic side effects, 
variable and unpredictable pharmacology and dose-limiting toxicities. Severe peripheral 
neuropathy occurs in as many as 30 % of patients treated with taxanes (Lee and Swain, 2006). 
A major problem in the clinical use of tubulin-binding agents is the development of resistance 
in the tumor tissue. The vinca alkaloids and the taxanes are both substrates of the ABCB1 
transporter (p-glycoprotein 170, MDR1) (Kohno et al., 1988; Hunter et al., 1991; Zacherl et 
al., 1994), and it has been shown that ABCB1 expression causes resistance and reduced 
sensitivity to those compounds in vitro (Izquierdo et al., 1996; Loe et al., 1996). The new 
compounds IDN 5109 (Bayer, Leverkusen, Germany) and RPR 109881A (Aventis, 
Strasbourg, France) are expected to circumvent the ABCB1 mediated multidrug resistance in 
vivo, and have shown promising effects, when applied to ABCB1 overexpressing tumor cell 
lines (Polizzi et al., 1999; Gelmon et al., 2000). 
Despite the ongoing development of novel microtubule-interfering compounds the occurrence 
of the same side effects is probable. Thus, other targets providing a similar mechanism of 
action with greater specificity were explored. In the past few years, more information about 
the components involved in mitosis and their relationship to each other and to mitotic events 
was obtained. Although the understanding of these processes is incomplete, several key 
regulators were identified. The most prominent regulatory molecules involved in the 
progression through mitosis include members of several kinase families. They play important 
roles in the proper ordering of events within mitosis. It has become clear that although tubulin 
is the most abundant protein within the mitotic spindle, many additional proteins play critical 
roles in the mechanics of mitosis. Most prominent among these are members of the kinesin 
family of microtubule motor proteins. Previous studies have demonstrated a role for the 
mitotic kinesin Eg5 in establishment of spindle bipolarity in mammalian cells (Blangy et al., 
1995).  
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3.1.2 Mitotic spindle assembly 
 
Two motile processes are involved in the assembly and disassembly of microtubules and in 
segregation of chromosomes. The first is the polymerization and depolymerization of 
microtubules (Figure 3.5) physiologically regulated by a balance of microtubule stabilizing 
and destabilizing proteins, binding along the microtubules (Andersen, 2000).  
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Figure 3.5: Structure and polarity patterns of microtubules in the metaphase spindle. 
Microtubule assembly occurs at the fast growing plus end by tubulin polymerization and 
disassembly at the minus end by depolymerization (from Sharp et al., 2000, modified). 
 
Stabilizing proteins include the large group of the so-called microtubule-associated proteins 
(MAPs) (Mandelkow, 1995). These MAPs are substrates of the cyclin-dependent kinase 1 
(CDK1), and, depending on their phosphorylation state, they control the microtubule dynamic 
properties in the transition from the G2 to the M phase of the cell cycle. During mitosis an 
increased degree of phosphorylation reduces the affinity of the MAPs to microtubules, and 
thereby their promoting effect on tubulin-polymerization (Drechsel, 1992; Masson, 1995; 
Ookata, 1995). 
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Oncoprotein 18/stathmin and katanin are destabilizing factors promoting microtubule 
depolymerization (McNally, 1993; Larsson, 1997; Ahmad et al., 1999; Andersen, 2000). The 
Xenopus kinesin central motor 1 (XKCM1), a kinesin-related protein, particularly contributes 
to microtubule depolymerization during mitotic spindle assembly (Walczak et al., 1996). 
The second motile process is the ATP-dependent sliding of microtubule-binding motor 
proteins along the walls of microtubules. These motor proteins can be subdivided into two 
superfamilies of ATP-dependent force-generating enzymes, the kinesins and the dyneins 
(Vale and Fletterick, 1997). They move continuously along the microtubules, and thereby can 
carry various membrane-enclosed organelles to their destination within the cytoplasm or 
rearrange filament networks. Moreover, they serve important functions in the mitosis phase, 
e.g. movement of cytoskeletal filaments against each other, which is an indispensable process 
too. The N-terminal kinesins play a crucial role in mitotic spindle formation and in 
chromosome separation and transport. They move towards the plus end of the microtubules 
(Mandelkow, 1999). However, another kinesin subfamily, the C-terminal motor domain type 
kinesins move towards the minus end (Noda et al., 2001; Xu et al., 2002). The dyneins are 
also minus end directed motor proteins, contributing to vesicular trafficking, and to the 
positioning of cell organelles. 
During mitosis, the chronology of the interplay between microtubule-dynamics and motor 
proteins is controlled by several regulatory molecules such as Bub and Mad kinases. Those 
are essential components of the mitotic spindle assembly check point (Sorger et al., 1997; 
Skoufias et al., 2001), which monitors that all chromosomes are bivalently attached to 
microtubules via kinetochores, before mitosis is moving from the metaphase to the anaphase 
(Li and Benezra, 1996; Rudner and Murray, 1996; Sorger et al., 1997). 
Other regulatory proteins, such as the Aurora B family kinases, play an essential role in 
chromosome segregation and subsequent cytokinesis, the cytoplasmic division of the cell in 
the end of mitosis. They are also required for the orientation, condensation and cohesion of 
chromosomes, and they are involved in microtubular dynamics (Shannon, 2002).  
 
3.1.3 Microtubule-based motor proteins 
 
Two superfamilies of microtubule-based motor proteins have been discovered, the kinesins 
and the dyneins. Beside tubulin, the kinesins are the most prominent proteins contributing to 
the proper functionality of the mitotic spindle. The general structural features of the kinesin 
motors are similar throughout the whole protein superfamily (Vale and Fletterick, 1997). The 
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force-producing motor domain is divided into two major parts: one part is the globular 
catalytic core, which is conserved throughout the superfamily. The second part, the neck 
region, with a length of around 40 amino acids, is either adjacent at the N or C terminus of the 
catalytic core. Many kinesin proteins contain a long α-helical coiled-coil domain, the “stalk”, 
which is often connected to an additional globular domain at its end. The latter domain, the 
“tail”, is thought to target the motor to a particular cargo within the cell. 
The kinesins hydrolyze ATP and travel unidirectionally along the microtubule surface. The 
N-terminal kinesins are plus end directed, and the C-terminal kinesins are minus end directed. 
In mitosis, the N-terminal kinesins produce an outward-directed force, whereas the C-terminal 
kinesins act vice versa. A further minus end directed force is exerted by the motor proteins of 
the dynein superfamily. The specific movement of the mitotic spindle is not driven by the 
exclusive action of one type of motor protein, but by the simultaneous work of multiple, 
complementary and antagonistic motors (Sharp et al., 2000). During interphase and prophase, 
the duplicated centrosomes and slightly interdigitating microtubules between the two future 
poles of the spindle are formed. This initial spindle assembly is balanced by dynein on the 
actin cortex at the cell membrane pulling the poles apart (outward-directed force), and C-
terminal kinesins in the spindle midzone pulling the poles together (inward-directed force). 
The C-terminal kinesin force is limited due to the low extent of microtubule overlap in the 
midzone. However, with the continuous growth of the interdigitating microtubules, the 
kinesin force gradually increases until a steady state between the dynein and the kinesin 
forces is reached. After the degradation of the nuclear envelope in the prometaphase, another 
steady state is achieved. The length of the astral microtubules is decreased and the position of 
the bipolar spindle is determined and maintained by the action of the C-terminal kinesins and 
the bipolar kinesins (e.g. Eg5 kinesin). The bipolar kinesins are also located in the spindle 
midzone and generate an outward-directed force. The poles move further apart due to cortical 
dynein plus bipolar kinesin activity, overwhelming the inward directed forces generated by 
the C-terminal kinesin and tipping the balance of forces in the outward direction (Figure 3.6). 
At the onset of anaphase, the elongation of the spindle results in the “metaphase spindle 
steady state structure” with tension between the spindle poles, generated by antagonistic 
“inward” and “outward” forces. After passing the metaphase-anaphase checkpoint (mitotic 
spindle assembly checkpoint) the tension is released by inactivation of the C-terminal 
kinesins. Just before the disassembly of the spindle, the final steady state is achieved in the 
telophase. 
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Figure 3.6: Schematic drawing of the prometaphase-metaphase transition. The spindle poles 
move apart from each other, due to the overweight of outward directed forces. Dynein 
mediates the interaction between astral microtubules and the actin cortex (dynactin). The 
major contribution to the outward directed forces is given by the bipolar kinesins, which 
enforce anti-parallel sliding of the interdigitating microtubules of the spindle midzone. 
Together, these two forces overcome the inward directed force, produced by C-terminal 
kinesins, also located at the spindle midzone. The short arrows indicate the moving direction 
of the motor proteins along the microtubules, which is opposite to the direction of the 
produced force. 
 
It has been suggested that the expression of certain subtypes is restricted to proliferating 
tissues, and crucial for mitosis progression due to the cell cycle-dependent degradation of 
several kinesins (Brown, 1994; Funabiki, 2000; Hill, 2000). Furthermore, these mitotic 
kinesins have been shown to play essential roles during discrete phases of mitosis (Table 3.1). 
Dysfunction of certain members of this protein family has been shown to result in mitotic 
arrest. For example, the kinesin CENP-E has been shown to be an essential component of the 
mitotic spindle assembly checkpoint in vitro (Abrieu et al., 2000). It connects the checkpoint 
complex to free kinetochores of microtubule-attached chromosomes (Schaar et al., 1997; Yao 
et al., 2000) and interacts with different kinetochore proteins (Chan et al., 1998). Playing a 
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vital role in mitosis, this and other kinesins have been considered as potential new 
pharmacological targets for the treatment of malignancies. 
 
Table 3.1: Role of various mitotic kinesins in mitosis (Wood et al., 2001). 
 
Mammalian 
kinesin(1) 
Functional role 
 
 
Experimental 
validation(2) 
Mitotic 
arrest(3) 
Eg5 Spindle pole separation Human cells + 
HSFT Microtubule anchorage at the spindle 
poles 
Human cells - 
MKLP1 Microtubule organization in metaphase 
spindle midzone 
 
Late mitotic spindle microtubule 
organization and cytokinesis 
Human cells 
 
 
Drosophila, 
Caenorhabditis 
elegans 
+ 
Kif4 
 
Metaphase chromosome alignment Xenopus egg extracts 
and embryos 
n. d. 
CENP-E Metaphase chromosome alignment Human cells + 
Kid Metaphase chromosome alignment Xenopus egg extracts n. d. 
MCAK Anaphase chromosome alignment Human cells - 
RabK6 Cytokinesis Human cells - 
(1) In cases where validation has been performed in non-mammalian systems, the 
mammalian ortholog of the validated kinesin is indicated. 
(2) Non-mammalian systems are noted only for those kinesins where a mitotic role has not 
been demonstrated in mammalian cells. 
(3) Dysfunction in kinesin causes mitotic arrest (+), dysfunction does not cause mitotic 
arrest (-); effect not determined (n. d.). 
 
3.1.4 Mitotic arrest through Eg5 kinesin inhibition 
 
Eg5 is a plus end directed motor protein and belongs to the bipolar kinesin family (Sawin et 
al., 1992). It has been shown to be tetrameric, with pairs of motor domains at opposite ends of 
the molecule (Kashina et al., 1996). Due to its tetrameric, bipolar structure, kinesin Eg5 could 
function in two ways to promote spindle formation. Firstly, Eg5 promotes the formation of a 
spindle axis by cross-linking two microtubules, which are in the same orientation and moving 
towards their plus ends. Secondly, microtubules in opposite orientations are pushed apart by 
Eg5 and are thereby sorted into an antiparallel array (Walczak et al., 1998). The inhibition of 
Eg5 kinesin causes spindle pole defects and results in “rosette” structures with unseparated 
centrosomes in the center and microtubules extending radially to surrounding chromosomes 
(Sawin et al., 1992). 
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This characteristic spindle morphology with a monoastral spindle is termed “monoaster 
spindle” (Figure 3.7). The monoaster spindle is probably caused by an imbalance between the 
outward and inward directed forces, generated by dyneins and C- and N-terminal kinesins.  
a b
 
Figure 3.7: (a) Model of spindle bipolarity. Plus end directed kinesins, such as Eg5, are 
involved in the separation of centrosomes and the establishment of a symmetric spindle axis. 
Microtubules are shown in black, chromosomes in gray and Eg5 in white as a homotetramer 
(Walczak et al., 1998). (b) The inhibition of bipolar Eg5 kinesin leads to an overweight of the 
inward-directed force of the C-terminal kinesins and thus results in the formation of 
monoastral spindles (Sawin et al., 1992; Blangy et al., 1995). 
 
After the monaster spindle has completely formed, several free kinetochores of chromosomes 
are only partially connected to microtubules. As a consequence, mitotic arrest occurs because 
the mitotic spindle assembly checkpoint cannot be satisfied and the transition from the 
metaphase to the anaphase is blocked. The inhibition of the mitotic kinesin Eg5 leaves other 
essential cellular processes, which involve non-mitotic kinesins, unaffected. Due to this major 
difference to the classical microtubule-interfering agents, specific Eg5 kinesin inhibitors are 
considered a very promising approach to the development of a new class of anticancer agents 
with minimal side effects on resting cells. 
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3.1.5 Eg5 kinesin inhibitors 
 
Sakowicz et al. screened a panel of natural compounds for selective inhibition of kinesin in 
vitro and identified the first kinesin inhibitor, adociasulfate-2, which competitively inhibits 
the interaction of the kinesin motor domain with microtubules (Sakowicz et al., 1998). 
However, this first kinesin inhibitor did not show any selectivity between the three kinesin 
subtypes. Since only the kinesin Eg5 is known to cause mitotic arrest with the formation of a 
monopolar mitotic spindle, the monoaster spindle was used as an indicator in the search for 
specific Eg5 inhibitors. Using a mitotic spindle phenotype-based screening method, Mayer et 
al. identified monastrol as the first specific kinesin Eg5 inhibitor (Mayer et al., 1999). This 
compound, a 4-aryl-3,4-dihydropyrimidine-2(1H)-thione, led to a reversible mitotic arrest by 
the formation of a monopolar spindle, and did not affect the transition from the G2 cell cycle 
phase to mitosis.. Moreover, monastrol did not inhibit the motor activity of conventional 
kinesin heavy chain, and therefore, had no effect on cellular processes involving other 
kinesins (Mayer et al., 1999; Kapoor et al., 2000). These results provide the first evidence that 
the concept of the specific Eg5 kinesin inhibition as a new approach in cancer chemotherapy 
is feasible. However, racemic monastrol and its eutomer, (S)-monastrol, were determined to 
be only moderately potent allosteric inhibitors of Eg5 (Gartner et al., 2005) with IC50 values 
of 34 μM and 14 μM, respectively, determined in the microtubule-stimulated ATPase activity 
assay (Maliga, 2002). Therefore, new monastrol analogs were synthesized (Gartner et al., 
2005; Sarli et al., 2005) in order to obtain more potent Eg5 kinesin inhibitors. Hotha et al. 
reported on the tetrahydro-β-carboline compound HR22C16, which selectively inhibited Eg5 
kinesin with an IC50 value of 800 nM (Hotha et al., 2003). A derivative of HR22C16 showed 
an IC50 value of 90 nM, which is about one order of magnitude more potent than HR22C16. 
After the screening of a series of 60 β-carboline derivatives for Eg5 inhibitory activity, the 
most potent compound showed an IC50 value of 650 nM (Sunder-Plassmann et al., 2005). 
Further lead structures are currently considered as potent and specific kinesin Eg5 inhibitors. 
Among them are terpendole E (IC50 = 23 μM) (Nakazawa, 2003), CK0106023 with a Ki value 
of 12 nM (Sakowicz, 2004), and KSP-IA, a compound derived from a dihydropyrazole lead 
structure (IC50 = 10 nM (Tao et al., 2005)). In a high-throughput screening effort, Tarby et al. 
identified a series of tetrahydroisoquinolines as inhibitors of human Eg5 including a screening 
hit with an IC50 value of 9.7 µM (ATPase assay) (Tarby et al., 2006). A medicinal chemistry 
optimization effort led to the identification of “compound 32a” as a potent Eg5 inhibitor with 
an IC50 value of 104 nM (Figure 3.8). 
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Figure 3.8: Chemical structures of various kinesin inhibitors. Adociasulfate-2, was isolated 
from a marine sponge, the genus Haliclona (also known as Adocia) (Sakowicz et al., 1998). 
The identification of the first specific Eg5 kinesin inhibitor monastrol (Mayer et al., 1999) 
initiated the development and the preclinical evaluation of further, more potent Eg5 inhibitors 
as potential new anticancer agents. Among the other lead compounds, structural resemblance 
to monastrol is only observed for the β-carbolin derivative HR22C16 (Hotha et al., 2003). 
Terpendole E inhibits Eg5 kinesin specifically (Nakazawa, 2003), but with an even lower 
potency than monastrol. Based on CK0106023 (Sakowicz, 2004), a series of new 2- 
(aminomethyl)quinazolinone derivatives has been synthesized, of which one is in clinical 
phase II evaluation. The KSP-IA is the most potent specific Eg5 kinesin inhibitor by now 
(Tao et al., 2005). A medicinal chemistry optimization effort of a high-throughput screening 
hit (compound 3) led to the identification of R-4-(3-hydroxyphenyl)-N,N-7,8-tetramethyl-3,4-
dihydroisoquinoline-2(1H)-carboxamide named compound 32a (Tarby et al., 2006). 
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3.2 Objective 
 
The inhibition of kinesin Eg5 by small molecules, such as monastrol, is currently evaluated as 
an approach to develop a novel class of antiproliferative drugs for the treatment of malignant 
tumors (Wood et al., 2001). Due to the moderate inhibitory activity of the lead compound 
monastrol, new monastrol analogs were synthesized by Giannis and coworkers at the 
University of Leipzig (Gartner et al., 2005; Sarli et al., 2005), in order to obtain more potent 
Eg5 kinesin inhibitors. Experiments by means of confocal laser scanning microscopy 
demonstrated that the antiproliferative activity of the new compounds is caused by monoaster 
formation and subsequent mitotic arrest of the treated cells (Gross, 2006). The common 
clinical side effects of classical microtubule interfering agents are ascribed to the damage of 
the microtubule cytoskeleton (Quasthoff and Hartung, 2002). Thus, Dietmar Gross showed 
that the arrangement of β-actin and tubulin, vital components of the cytoskeleton of mitotic 
and quiescent cells, were not affected by the new compounds. The effects of the monastrol 
analogs were compared to the classical tubulin depolymerising agent vinblastine. 
 
With respect to the treatment of primary and secondary CNS tumors, the objective of this 
work was to investigate the antiproliferative effect of the new monastrol analogs on human 
glioblastoma cell variants, using the crystal violet chemosensitivity assay (Bernhardt et al., 
1992). This project comprises the determination of the antiproliferative activity after the pre-
incubation of the compounds in culture medium to consider potential inactivation of the 
compounds by esterases or binding to serum proteins. The incubation of the cells for 1, 3 and 
6 hours with the Eg5 inhibitors was intended to identify the required duration of drug 
exposure. Furthermore, confluent cells should be treated with Eg5 inhibitors to compare their 
effects with those of anti-tubulin drugs like paclitaxel against resting cells. Due to the 
necessity of overcoming the blood-brain barrier in the treatment of brain tumors, we planned 
to investigate if the Eg5 inhibitors are modulators of the ABCB1 transporter (p-glycoprotein 
170) at effective antiproliferative concentrations, using the calcein-AM assay (Homolya et al., 
1993; Hollo et al., 1994; Homolya et al., 1996).  
The results have been published in part (Müller et al., 2007). 
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3.3 Materials and methods 
 
3.3.1 Kinesin Eg5 inhibitors 
 
Monastrol and the new monastrol analogs dimethylenastron, enastron, were synthesized and 
characterized as described (Gartner et al., 2005; Sarli et al., 2005). The 3,4-dihydro-4-(3´-
hydroxyphenyl)quinazoline-2(1H)-thiones, the vasastrols, VS-12, VS-17, VS-38, VS-42, VS-
48, VS-54, VS-83 as well as the 3,4-dihydrophenylquinazoline-2(1H)-thiones VS-1, VS-43 
and VS-46 were synthesized and characterized as described (Sarli et al., 2005). These 
compounds and another substance, G-72, were provided by the workgroup of Prof. Giannis 
(University of Leipzig, Germany). S-Trityl-L-cysteine (Brier et al., 2004) was purchased from 
MP BIOMEDICALS (Eschwege, Germany) (Figure 3.9). 10 mM stock solutions were 
prepared in DMSO and stored at –20 °C. 
 
3.3.2 Cell lines and culture conditions 
 
Human U-87 MG (HTB 14), U-118 MG (HTB 15), and U-373 MG (HTB 17) 
glioblastoma/astrocytoma cell lines were obtained from ATCC (Rockville, MD, USA). Cell 
banking and quality control were performed according to the ‘‘seed stock concept’’ (Hay, 
1988). U- 87 MG and U-373 MG cells were grown in Eagle’s minimum essential medium 
containing L-glutamine, 2.2 g/L NaHCO3, 110 mg/l sodium pyruvate and 5 % fetal calf serum 
(FCS), whereas the U-118 MG cells were maintained in Dulbecco’s minimal essential 
medium supplemented with 5 % FCS. Kb-V1 cells, a ABCB1 (p-gp 170) overexpressing 
subclone (Kohno et al., 1988; Hubensack, 2005) of Kb cells (ATCC CCL-17), were 
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10 % FCS and 300 
ng/ml vinblastine (SIGMA, Munich, Germany). All cell types were maintained in water 
saturated atmosphere (95 % air/5 % carbon dioxide) at 37 °C in 75-cm2 culture flasks 
(NUNC, Wiesbaden, Germany) and were serially passaged following trypsinization using 
0.05 % trypsin/0.02 % EDTA (Roche Diagnostics, Mannheim, Germany). Mycoplasma 
contamination was routinely monitored by PCR (Venor® GeM, Minerva Biolabs GmbH, 
Berlin, Germany), and only Mycoplasma free cultures were used.  
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Figure 3.9: Chemical structures of the selective Eg5 inhibitor monastrol, the new monastrol 
analogs enastron and dimethylenastron, the 3,4-dihydro-4-(3´-hydroxyphenyl)quinazoline-
(1H)-thiones VS-12, VS-17, VS-38, VS-42, VS-48, VS-54, VS-83, the 3,4-dihydrophenyl-
quinazoline-2(1H)-thiones VS-1, VS-43 and VS-46, the Eg5 inhibitor G-72 and the non-
specific kinesin inhibitor S-trityl-L-cysteine. 
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3.3.3 Chemosensitivity assay 
 
The assays were performed as described previously (Bernhardt et al., 1992). In brief, tumor 
cell suspensions (100 µl/well) were seeded into 96-well flat-bottomed microtitration plates 
(GREINER, Frickenhausen, Germany) at a density of ca. 15 cells/microscopic field 
(magnification 320-fold). After 2–3 days, the culture medium was removed by suction and 
replaced by fresh medium (200 µl/well) containing varying drug concentrations or vehicle 
(DMSO). Drugs were added as 1,000-fold concentrated feed solutions. On every plate 16 
wells served as controls and 16 wells were used per drug concentration. After various times of 
incubation the cells were fixed with glutardialdehyde (Merck, Darmstadt, Germany) and 
stored at 4 °C. At the end of the experiment, all plates were processed simultaneously 
[staining with 0.02 % aqueous crystal violet (SERVA, Heidelberg, Germany) solution (100 
µl/well)]. Excess dye was removed by rinsing the trays with water for 20 min. The stain 
bound by the cells was re-dissolved in 70 % ethanol (180 µl/well) while shaking the 
microplates for about 3 h. Absorbance at 578 nm (a parameter proportional to cell mass) was 
measured using a BIOTEK 309 Autoreader (TECNOMARA, Fernwald, Germany). Drug 
effects were expressed as corrected T/C-values for each group according to 
 
T/Ccorr = 
0
0
C- C
C - T
 · 100 [%] (eq. 3.1), 
 
where T is the mean absorbance of the treated cells, C the mean absorbance of the controls 
and C0 the mean absorbance of the cells at the time (t = 0) when drug was added. 
 
When the absorbance of treated cells T is less than that of the culture at t = 0 (C0), the extent 
of cell killing was calculated as 
cytocidal effect [%] = 
0
0
C
TC −
 · 100 (eq. 3.2). 
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3.3.4 Flow cytometric calcein-AM efflux assay 
 
In Kb-V1 cells, calcein-AM is extruded by ABCB1 (p-gp) before esterases can cleave the 
ester bonds, and calcein is not accumulated (Homolya et al., 1993). Therefore, modulators of 
the ABCB1 function can easily be recognized by flow cytometric measurement of the change 
in the calcein-AM efflux. 
Calcein-AM (Molecular Probes Eugene, OR, USA) was dissolved in DMSO (MERCK, 
Darmstadt, Germany) to achieve a final concentration of 1 mM and aliquoted into stock 
solutions that were stored at -20 °C. Elacridar, a 3rd generation ABCB1 inhibitor (kindly 
provided by GlaxoSmithKline, NC, USA) served as a positive control for the inhibition of 
calcein-AM efflux. 
Kb-V1 cells were trypsinized 3 or 4 days after the passaging and washed with PBS at 25 °C. 
To 0.75 ml cell suspension containing 1 · 106 cells in loading buffer (120 mM NaCl, 5 mM 
KCl, 2 mM MgCl2 · 6 H2O, 1.5 mM, CaCl2 · 2 H2O, 25 mM HEPES, 10 mM glucose, pH 7.4) 
0.25 ml loading suspension (loading buffer, 20 mg/ml BSA, 5 µl/ml of Pluronic® F127 
[Molecular Probes, Eugene, OR, USA, 20 % stock in DMSO)] was added. The samples were 
mixed with different concentrations of test compounds and vortexed. After 15 min, calcein-
AM solution was added to achieve a concentration of 1 µM. After incubation for 10 min at 37 
°C/5 % CO2 the supernatant was discarded after centrifugation for 7 min at 4 °C and 1,100 
rpm. The cell pellet was rinsed once with ice-cold PBS and resuspended in 0.5 ml of loading 
buffer per 1 · 106 cells. Calcein fluorescence was measured by a FACS Calibur® (Becton 
Dickinson, Heidelberg, Germany) flow cytometer in the FL1-H channel. In each measurement 
30,000 gated events were evaluated. The photomultiplier settings were as follows: E-1 for 
FSC, 270 for SSC and 300 for FL1-H. Data were analyzed by the WinMDI 2.8 software. 
 
 
 
3.3.5 Confocal laser-scanning microscopy 
 
All investigations performed by confocal laser-scanning microscopy were done by Dietmar 
Gross. For details see his doctoral thesis (Gross, 2006). 
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3.3.5.1 Treatment of the cells 
Cells were seeded into 8-well Lab-Tek Chamber Slides (NUNC, Wiesbaden, Germany). At 
75 % confluency, the culture medium was replaced with medium containing 50 µM 
monastrol, 1 µM S-trityl-L-cysteine or 10 nM vinblastine. The concentrations of the new 
monastrol analogs were selected on the basis of chemosensitivity data, obtained by the kinetic 
crystal violet assay. Cells were incubated at 37 °C for 2 h. 
 
3.3.5.2 Fixation and permeabilization of the glioblastoma cells 
After the incubation with drugs, the medium was carefully removed, and the cells were fixed 
with 4 % paraformaldehyde solution in phosphate buffered saline (PBS) for 20 min at room 
temperature. Thereafter, each well was washed three times with PBS containing 0.5 % bovine 
serum albumin (BSA, SERVA, Heidelberg, Germany). Cells were permeabilized by 
incubation with PBS containing 0.5 % BSA and 1 % Triton-X 100 (SERVA, Heidelberg, 
Germany) for 10 min at room temperature, followed by three washing steps with PBS 0.5 % 
BSA. 
 
3.3.5.3 Staining and immunofluorescence 
Chromosomes were stained with SYTOXGreen® nucleic acid staining dye (Molecular Probes, 
Eugene, OR, USA). Microtubules were stained using mouse anti-human α-tubulin primary 
antibody (Dianova, Hamburg, Germany) and Alexa Fluor®546 conjugated goat anti-mouse 
secondary antibody (Molecular Probes). All antibodies were used in a 1:200 dilution in PBS, 
containing 0.5 % BSA. β-Actin was stained with Alexa Fluor® 647 phalloidin (Molecular 
Probes). Microscopic images were acquired with a Carl Zeiss Axiovert 200M LSM510 
confocal laser scanning microscope. Multi-fluorescence image acquisition was performed in 
multitrack acquisition mode using the following parameters: SYTOXGreen®, 488 nm Argon 
laser, 505 nm longpass filter, Alexa Fluor® 546, 543 nm HeNe laser, 560–615 nm bandpass 
filter, Alexa Fluor® 647, 633 nm HeNe laser, 650 nm longpass filter. 
 
3.3.5.4 Image processing 
False colors were used for β-actin (red), tubulin (green) and DNA (blue). Images (Figure 
3.18a) were processed with the AutoDeBlur® deconvolution software. 
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3.4 Results 
 
3.4.1 Drug exposure and chemosensitivity 
 
48 h after seeding glioblastoma cells were treated with monastrol, enastron, dimethylenastron, 
vasastrol VS-12, VS-17, VS-38, VS-42, VS-48, VS-54, VS-83, with VS-1, VS-43, VS-46 and 
G-72 at various concentrations up to 10 µM. In these experiments, the drug (and vehicle) 
containing culture media were not exchanged during the whole incubation period. The results 
are exemplarily summarized for U-373 MG cells in Figure 3.10, Figure 3.11, Figure 3.12 and 
Figure 3.13. In these plots of T/Ccorr versus time of incubation t = 0 indicates the time when 
drug was added. According to eq. 4.1, any growth curve of a drug treated cell population can 
be reconstructed from the T/Ccorr values and the data from the growth curve of the 
corresponding control (Bernhardt et al., 1992). 
 
For enastron a cytotoxic effect was observed at a concentration of 5 µM (Figure 3.10b), 
whereas monastrol was less effective even at 50 µM (Figure 3.10a). A cytostatic effect (0 % 
T/Ccorr towards the end of the incubation period, i.e., 100 % inhibition of net cell 
proliferation) was observed at 1 µM of dimethylenastron (Figure 3.10c). Compared to 
monastrol, the two new compounds showed an at least one order of magnitude higher 
antiproliferative activity against the glioblastoma cells. 
 
The vasastrols VS-12, VS-38 and VS-42 showed no relevant cytotoxic effect up to a 
concentration of 10 µM (Figure 3.11a, c, d). A cytotoxic effect was observed for VS-17 
(Figure 3.11b) and VS-48 (Figure 3.12a) at a concentration of 10 µM. The vasastrols VS-54 
and VS-83 showed a strong cytostatic effect at a concentration of 10 µM and 5 µM, 
respectively. Compared to monastrol, VS-83 showed an at least one order of magnitude 
higher antiproliferative activity against the glioblastoma cells. 
 
Even at a high concentration of 10 µM, all 3,4-dihydrophenylquinazoline-2(1H)-thiones, VS-
1, VS-43 and VS-46 (Figure 3.13a, b, c), were ineffective. However, the (Z)-4-(4-
(dimethylamino)benzylidene)-2-phenyl-1H-imidazol-5(4H)-one, G-72, showed cytotoxic and 
cytostatic effects at a concentration of 1 µM and 10 µM, respectively (Figure 3.13d). 
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Figure 3.10: Proliferation kinetics of U-373 MG cells (passage 317) during permanent 
incubation with monastrol (a), the new monastrol analogs enastron (b) and dimethylenastron 
(c). Open stars vehicle (DMSO), open circles 0.25 µM, filled diamond 0.5 µM, filled inverted 
triangles 1 µM, filled circles 5 µM, filled triangles 10 µM and filled squares 50 µM. 
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Figure 3.11: Proliferation kinetics of U-373 MG cells (passage 317) during permanent 
incubation with the vasastrols VS-12 (a), VS-17 (b), VS-38 (c) and VS-42 (d). Open stars 
vehicle (DMSO), filled inverted triangles 1 µM and filled triangles 10 µM. 
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Figure 3.12: Proliferation kinetics of U-373 MG cells (passage 317) during permanent 
incubation with the vasastrols VS-48 (a), VS-54 (b) and VS-83 (c). Open stars vehicle 
(DMSO), filled inverted triangles 1 µM, open diamonds 3 µM, filled circles 5 µM and filled 
triangles 10 µM. 
116 Chapter 3  
 
a) VS-1
time of incubation [h]
0 50 100 150 200
T/
C
co
rr
. [
%
]
0
20
40
60
80
100
120
140
ab
so
rb
an
ce
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
b) VS-43
time of incubation [h]
0 50 100 150 200
T/
C
co
rr
. [
%
]
0
20
40
60
80
100
120
140
ab
so
rb
an
ce
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
c) VS-46
time of incubation [h]
0 50 100 150 200
T/
C
co
rr
. [
%
]
0
20
40
60
80
100
120
140
ab
so
rb
an
ce
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
d) G-72
time of incubation [h]
0 50 100 150 200 250
T/
C
co
rr
. [
%
]
-20
0
20
40
60
80
100
120
140
ab
so
rb
an
ce
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
 
 
Figure 3.13: Proliferation kinetics of U-373 MG cells (passage 317) during permanent 
incubation with the 3,4-dihydrophenylquinazoline-2(1H)-thiones VS-1 (a), VS-43 (b), VS-46 
(c) and the (Z)-4-(4-(dimethylamino)benzylidene)-2-phenyl-1H-imidazol-5(4H)-one G-72 (d). 
Open stars vehicle (DMSO), filled inverted triangles 1 µM and filled triangles 10 µM. 
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3.4.2 Incubation of glioblastoma cells after pre-incubation of new Eg5 
inhibitors in culture medium 
 
To consider potential inactivation of the compounds by esterases or binding to serum proteins, 
we pre-incubated monastrol (50 µM), enastron (5 µM), dimethylenastron (1 µM) and G-72 
(10 µM) in culture medium for 1, 3 (data not shown) and 6 h. Then, the cells (U-87 MG, U-
118 MG, and U-373 MG) were continuously incubated with culture medium containing the 
pre-incubated compounds. As shown for U-373 MG cells in Figure 3.14, the antiproliferative 
effects of monastrol, enastron, dimethylenastron and G-72 were retained compared to 
permanent drug exposure of the cells (Figure 3.10a, b, c and Figure 3.13d), indicating that the 
compounds were neither inactivated by hydrolysis nor by binding to serum proteins. 
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Figure 3.14: Incubation of U-373 MG cells (passage 310) after pre-incubation of 50 µM 
monastrol (a), 5 µM enastron (b), 1 µM dimethylenastron (c) and 10 µM G-72 (d) in culture 
medium. Open stars vehicle (DMSO), filled squares 1 h and filled triangles 6 h pre-
incubation period. 
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3.4.3 Effect of new Eg5 inhibitors after incubation times of 1, 3 and 6 h 
 
To explore the necessary drug residence time to reach a sufficient antiproliferative effect, the 
cells were incubated for 1, 3 (data not shown) and 6 hours with 10 µM of dimethylenastron 
and G-72 (Figure 3.15). Drug exposure for 1, 3 or 6 hours caused a significant reduction of 
the cytostatic effect compared to continuous incubation. However, this short incubation 
period of only 1 hour was sufficient to achieve a significant cytotoxic effect. 
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Figure 3.15: Drug exposure of U-373 MG cells with 10 µM of dimethylenastron (a) and G-72 
(b) for a time period of 1 and 6 h. Open stars vehicle (DMSO), filled squares 1 h and filled 
triangles 6. 
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3.4.4 Effect of new monastrol analogs on quiescent cells 
 
Confluent cells were treated with Eg5 inhibitors to compare their effects against resting cells 
with those of anti-tubulin drugs like paclitaxel. Rotenone, an ubiquinon reductase inhibitor 
blocking ATP synthesis, served as a positive control for maximum cytocidal effect. The 
results are shown in Figure 3.16. Cell death (see eq. 4.2) was observed as expected for the 
rotenone treated cells. In contrast to paclitaxel, all tested Eg5 inhibitors had no effect on 
resting cells. All results described above were qualitatively and quantitatively similar for 
human U-118 MG glioblastoma/astrocytoma cells (results not shown). 
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Figure 3.16: Incubation of resting U-373 MG (a) and U-87 MG cells (b) with paclitaxel, 
rotenone, the new monastrol analogs and G-72. Open stars vehicle (DMSO), filled squares 
paclitaxel (10 nM), filled triangles rotenone (500 nM), filled circles enastron (20 µM), filled 
diamonds dimethylenastron (20 µM) and filled inverted triangles G-72 (20 µM). 
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3.4.5 Flow cytometric calcein-AM efflux assay (ABCB1 assay) 
 
We used the 3rd generation ABCB1 inhibitor elacridar (Kemper, 2003) as positive control. 
The new kinesin Eg5 inhibitors dimethylenastron and vasastrol VS-83 did not inhibit ABCB1 
activity up to a concentration of 20 µM (Figure 3.17). 
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Figure 3.17: Calcein-AM efflux from Kb-V1 cells after incubation with vehicle (dotted), 50 
nM elacridar (black) and 20 µM dimethylenastron (grey). Overlay histograms of gated Kb-V1 
cells using fluorescence 1 (BP/30 nm). Structural formula: elacridar. 
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3.4.6 Effect of the new monastrol analogs on the spindle apparatus and on the 
cytoskeleton of resting cells 
 
According to the results of the chemosensitivity tests, human U-87 MG cells were incubated 
with 5 µM enastron, 1 µM dimethylenastron and 5 µM vasastrol VS-83 for 2 h. As shown in 
Figure 3.18a, the compounds enastron and dimethylenastron produced the same characteristic 
effect on the formation of the mitotic spindle as the selective Eg5 kinesin inhibitor monastrol. 
However, the new compounds induced monoasters at lower concentrations, confirming the 
observations of monoaster formation in other cell types (Gartner et al., 2005). A different 
monoaster phenotype was observed after incubation with VS-83, similar to monoaster 
formation induced by the non-selective kinesin inhibitor S-trityl-L-cysteine (Figure 3.18a). 
 
While vinblastine treatment resulted in the disruption of the tubulin assembly in resting cells, 
the new monastrol analogs showed no effect on microtubular structures (Figure 3.18b). 
Neither was the β-actin cytoskeleton affected by the new compounds, exemplarily shown for 
dimethylenastron (Figure 3.18d). No differences to the morphology of the untreated cells 
Figure 3.18c) were observed. 
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monastrol enastron dimethylenastron VS-83
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β-actin tubulin nuclei merge
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Figure 3.18: a) Formation of monoastralic spindles in human U-87 MG cells after incubation 
with monastrol (50 µM), the new monastrol analogs enastron (1 µM), dimethylenastron (1 
µM), vasastrol VS-83 (5 µM), and S-trityl-L-cysteine (1 µM); merged images of stained 
spindle and chromosomes. b) Human U-87 MG glioblastoma cells, incubation with 10 nM 
vinblastine, 1 µM S-trityl-L-cysteine and dimethylenastron (1 µM). c) Resting U-87 MG cells 
after incubation with 1 µM dimethylenastron and d) untreated cells. In quiescent cells, the 
microtubular and the β-actin cytoskeleton are not affected by the kinesin inhibiting 
compound. 
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3.5 Discussion 
 
In the present study we demonstrated that, compared to the first selective small molecule Eg5 
kinesin inhibitor monastrol, the newly synthesized monastrol analogs enastron, 
dimethylenastron and vasastrol VS-83 exhibit higher antiproliferative activity against human 
glioblastoma cells. Enastron and vasastrol VS- 83 showed cytotoxic effects at a concentration 
of 5 µM, whereas monastrol was less effective even at 50 µM. For dimethylenastron, even 
higher antiproliferative potency was observed. The latter monastrol analogue was identified as 
the most potent compound with an approximately 100-fold higher antiproliferative efficacy 
compared to monastrol. 
The vasastrol VS-83 represents the most potent Eg5 inhibitor of the 3,4-dihydro-4-(3´-
hydroxyphenyl)quinazoline-2(1H)-thiones with higher antiproliferative activity compared to 
VS-12, VS-17, VS-38, VS-42, VS-48 and VS-54. The 3,4-dihydrophenylquinazoline-2(1H)-
thiones VS-1, VS-43 and VS-46 were ineffective up to a concentration of 10 µM, indicating 
that the 3´-hydroxyl group is essential for the Eg5 inhibitory activity. 
The antiproliferative activity of all tested monastrol derivatives and G-72 was not reduced by 
the pre-incubation in serum supplemented culture medium, indicating that the compounds 
were not inactivated by esterase cleavage or by binding to serum proteins. 
By analogy to the results of the chemosensitivity experiments, the microscopic studies 
showed that the new monastrol analogues give rise to mitotic arrest in human glioblastoma 
cells by inducing the formation of monoasters, the characteristic effect of the Eg5 kinesin 
inhibition. This effect was observed after 2 h of drug exposure. In contrast to the work of Sarli 
et al. (Sarli et al., 2005), reporting on similar effects of monastrol and VS-83, in our studies 
the incubation with VS-83 led to a different monoaster phenotype, which was also observed 
after incubation with S-trityl-L-cysteine. However, Sarli et al. (Sarli et al., 2005) applied 100 
µM monastrol and 25 µM VS-83 to synchronized simian BSC-1 cells. In addition, the BSC-1 
cells were incubated for 10 h, whereas the human U-87 MG glioblastoma cells were treated 
with monastrol (50 mM) and VS-83 (5 µM) for 2 h. 
In contrast to the antimicrotubular agent paclitaxel, none of the investigated Eg5 inhibitors 
had a cytocidal effect on resting cells. These results were supported by microscopic studies on 
the effect of the new monastrol analogs on the microtubules and the β-actin (cytoskeleton) of 
resting cells. Thus, these compounds are supposed to be less neurotoxic anticancer drugs in 
comparison to classical tubulin inhibitors. 
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Since the ABCB1 efflux pump, located at the blood–brain barrier, is suggested to be the 
major reason for multidrug resistance of brain tumors against numerous anticancer agents 
(Fellner et al., 2002), the effect of the new Eg5 kinesin inhibitors on the ABCB1 function was 
investigated using the flow cytometric calcein-AM efflux assay. While the 3rd generation p-gp 
inhibitor elacridar showed a high ABCB1 inhibition and consequently a strong calcein 
accumulation in Kb-V1 cells, no difference between the vehicle control and the tested Eg5 
inhibitors was observed. 
This demonstrates that the new compounds are neither modulators nor substrates of the 
ABCB1 transporter up to 20 µM, a concentration much higher than required for monoaster 
formation and the inhibition of cell proliferation, respectively. From a therapeutic point of 
view, ABCB1 inhibition at higher concentrations (f2 value of 113 µM), as recently described 
for monastrol (Peters, 2006), seems to be of minor relevance. 
Taken together the new monastrol analogs enastron and its derivative dimethylenastron as 
well as the vasastrol VS-83 represent an interesting class of potential anticancer drugs, 
whereas dimethylenastron (ATPase IC50 200 nM) is considered as a promising lead structure 
for the development of further new derivatives with even higher potency for the inhibition of 
the Eg5 kinesin. This is supported by the report of Tarby et al. (Tarby et al., 2006), who 
developed a potent Eg5 inhibitor, derived from the 4-phenyl-tetrahydroisoquinoline lead 
series. The compound showed an IC50 value of 104 nM in an ATPase assay and induced the 
characteristic monoastralic spindles in PtK2 cells. 
Enastron, dimethylenastron and VS-83 were ineffective against resting cells so that these 
compounds should be less neurotoxic in comparison to classical tubulin inhibitors. As the 
monastrol analogs are neither substrates nor modulators of ABCB1, these Eg5 inhibitors may 
be promising new agents for further preclinical studies aiming at the treatment of primary and 
secondary CNS tumors. 
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4.1 Introduction 
 
The chemotherapy of brain tumor often fails due to extremely low drug concentrations 
reached in the brain, although the administered cytostatics should be able to penetrate across 
the blood brain barrier (BBB) because of their physicochemical properties (Loescher and 
Potschka, 2005). This can be explained by the high affinity of these compounds to efflux 
transporters (Johnson, 2002), localized at the luminal membrane of the brain capillary 
endothelial cells (Bendayan et al., 2002). These efflux transport proteins belong to the ABC 
superfamily including ABCB1 (P-glycoprotein 170) and ABCG2 (breast cancer resistance 
protein) (Dean and Allikmets, 2001) and are also responsible for the classical multiple drug 
resistance (MDR) and atypical multiple drug resistance of cancer cells (Bosch and Croop, 
1996; Doyle and Ross, 2003; Glavinas et al., 2004). 
 
An attractive strategy to overcome the BBB is the administration of an efflux pump inhibitor 
in combination with a cytostatic (Breedveld et al., 2006). The study by Fellner et al. with the 
2nd generation ABCB1 inhibitor valspodar (SDZ PSC-833) and the anticancer drug paclitaxel, 
an ABCB1 substrate, has proven this concept (Fellner et al., 2002). This combination led to 
increased brain levels of paclitaxel in nude mice by a factor of 6-8 compared to paclitaxel 
monotherapy. Moreover, in nude mice with intracerebral human U-118 MG glioblastoma the 
co-administration of valspodar and paclitaxel reduced the tumor volume by 90 %, whereas 
paclitaxel alone was ineffective. However, due to the modulation of ABCB1 in liver, kidneys 
and bone marrow by valspodar, the paclitaxel blood level increased and paclitaxel toxicity 
became dose-limiting with valspodar. Another reason for increased plasma concentrations of 
paclitaxel is the fact that valspodar inhibits the cytochrome P450 3A4-mediated metabolism 
of paclitaxel (Fischer et al., 1998).  
 
To overcome the limitations of the 2nd generation ABCB1 modulators, 3rd generation 
inhibitors, purported to specifically and potently inhibit ABCB1 function have been 
developed (Krishna and Mayer, 2000). These agents do not affect cytochrome P450 3A4 at 
relevant concentrations (Dantzig et al., 1999; Wandel et al., 1999). One of the most promising 
3rd generation ABCB1 inhibitors is tariquidar, which is supposed to selectively modulate the 
ABCB1 transporter (Thomas and Coley, 2003). This assumption is supported by 
investigations on the effect of tariquidar on the tissue distribution of paclitaxel (Fankhänel et 
al., 2005). The co-administration of tariquidar (p.o.) and paclitaxel (i.v.) led to high 
 Tariquidar analogs as ABCB1 and ABCG2 inhibitors 135 
brain/plasma ratios of paclitaxel (ratio 1.5 – 4.5) indicating that ABCB1 inhibition by 
tariquidar did lead to a specific accumulation of paclitaxel in the brain of nude mice. In 
contrast, the co-administration of valspodar resulted in 2- to 15-fold lower brain/plasma ratios 
of paclitaxel compared to tariquidar. But, tariquidar was not able to induce the same increase 
in the concentration of paclitaxel in the brain of nude mice as that achieved by valpodar 
administration (6- to 8-fold), although tariquidar showed higher inhibitory activity in vitro. 
Despite very high tariquidar concentrations in the brain, co-application of tariquidar led only 
to an increase in paclitaxel brain concentrations by a factor of 2.5- to 6.7. As an explanation it 
can be speculated that the highly lipophilic tariquidar is trapped in the lipid compartment of 
the brain. 
 
To investigate this hypothesis more hydrophilic tariquidar analogs with improved 
pharmacokinetic properties were synthesized. The compounds were investigated for inhibition 
of ABCB1 and ABCG2. Surprisingly, minimal structural changes at the aromatic core of 
tariquidar yielded very potent and selective ABCG2 inhibitors. The use of ABCG2 inhibitors 
might also be of interest for improvement of CNS penetration of ABCG2 substrates 
(Breedveld et al., 2006). Due to the relatively recent discovery of the ABCG2 transporter in 
1998 (Allikmets et al., 1998; Doyle et al., 1998) only a few ABCG2 inhibitors have been 
reported so far (Ahmed-Belkacem et al., 2006). Fumitremorgin C (FTC), a mycotoxin from 
Aspergillus fumigatus, was reported first (Rabindran et al., 2000), but its neurotoxicity 
precluded its use in in vivo experiments. One of the most potent ABCG2 inhibitors is 
elacridar (GF120918), which is also known to be a very potent ABCB1 inhibitor (Hyafil, 
1993). But it is not known, whether for cancer treatment a dual ABCB1 and ABCG2 inhibitor 
is superior to a selective inhibitor (Breedveld et al., 2006). This probably depends on the 
affinity of the cytostatic to the ABCB1 or ABCG2 transporter. The most potent ABCG2 
inhibitor known so far is the FTC analog Ko143 with an EC90 value of 23 nM determined by 
the fluorescence based measurement of increased mitoxantrone accumulation in drug-resistant 
mouse MEF3.8/T6400 cells and in human IGROV/T8 cells (Allen et al., 2002). Its low 
cytotoxicity, with an IC50 value of 100- to 1000-fold higher than for ABCG2 inhibition, made 
it promising for in vivo studies. Ko143 was non-toxic in mice at 10-50 mg/kg oral doses, and 
it increased the bioavailability of orally administered topotecan compared to elacridar (Allen 
et al., 2002). 
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However, in order to use the ABCG2 inhibitors for the treatment of tumors, compounds with 
specific cytotoxicity might be advantageous with regard to the concept that every type of 
cancer contains cancer stem cells. This cancer stem cell model considers malignant tumors as 
abnormal organs initiated by cancer stem cells. The cancer stem cells might play a decisive 
role in tumor initiation and progression because they have the ability to self-renew and to give 
rise to new tissues (Reya et al., 2001). Furthermore, they tend to be more resistant to 
chemotherapeutics than other cell types from the same tissue due to the expression of the 
ABCG2 transporter. 
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4.2 Objective 
 
The efflux of cytostatics due to (over)expression of ABC transporters such as ABCB1 (P-
glycoprotein 170) and ABCG2 (breast cancer resistance protein, BCRP) is a major limitation 
in cancer chemotherapy (Johnson, 2002). Inhibition of the transporters is an effective 
approach to the treatment of glioblastoma by overcoming the blood brain barrier as proven by 
the study of Fellner et al. with a combination of valspodar and paclitaxel (Fellner et al., 2002). 
Using the more potent ABCB1 inhibitor tariquidar, a higher brain/plasma ratio of paclitaxel 
was detected in mice (Fankhänel et al., 2005). However, despite of high tariquidar 
concentrations in the brain, paclitaxel brain levels did not increase compared to the valspodar 
group (Fankhänel et al., 2005). As an explanation it can be speculate that the highly lipophilic 
tariquidar is trapped in the lipid compartment of the brain. To investigate this hypothesis we 
started a project to develop more hydrophilic tariquidar analogs with improved 
pharmacokinetic properties. The new tariquidar analogs were synthesized and characterized 
by Michael Egger and Xuqin Li from the workgroup of Prof. König at the Institute for 
Organic Chemistry, University of Regensburg. 
 
The objective of this work was to investigate the new tariquidar analogs for inhibition of 
ABCB1 and ABCG2 in order to determine the potency and the selectivity. Therefore, the IC50 
values of the compounds were determined in two different flow cytometric fluorescence-
based assays. The inhibitory activity at the ABCB1 transporter was examined with the 
calcein-AM efflux assay and at the ABCG2 transporter with the mitoxantrone efflux assay, 
respectively. An alternative for the determination of the inhibitory activity is to investigate the 
potential of the compounds to overcome the multidrug resistance of ABCB1 or ABCG2 
expressing cells. Therefore, ABCB1 positive Kb-V1 cells and ABCG2 positive MCF-7/Topo 
cells, respectively, were treated with different concentrations of tariquidar analogs alone and 
in combination with non-toxic topotecan concentrations. 
With respect to the treatment of brain tumors the antiproliferative effect of the new tariquidar 
analogs was investigated on human glioblastoma U-373 MG cells, using the crystal violet 
chemosensitivity assay. Furthermore, confluent U-373 MG cells should be treated with 
tariquidar analogs to compare their effects with those of anti-tubulin drugs like paclitaxel 
against resting cells. 
The results have been published in part (Egger et al., 2007) 
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4.3 Materials and methods 
 
4.3.1 Drugs and chemicals 
 
Tariquidar (free base) was synthesized according to Dodic et al. (1995), Roe et al. (1999) and 
Sharp et al. (1998) with slight modifications (Hubensack, 2005). Calcein-AM, purchased 
from Biotrend (Köln, Germany), was dissolved in DMSO (Merck, Darmstadt, Germany) to 
achieve a final concentration of 1 mM. The aliquoted stock solutions were stored at -20 °C. 
Mitoxantrone stocks were obtained by diluting Novantron® (Wyeth Pharma, Münster, 
Germany) in 70 % ethanol to a concentration of 2 mM. The 1 mM stock solutions of 
vinblastine (Vinblastine sulfate, Sigma, Munich, Germany) and paclitaxel (Sigma) were made 
in 70 % ethanol. All stocks were stored at –20 °C. Topotecan stocks were obtained by diluting 
Hycamtin® (GlaxoSmithKline, München, Germany) in 70 % ethanol to a concentration of 0.1 
mM and stored at 4 °C. 
 
4.3.2 Tariquidar analogs 
 
All tariquidar analogs were synthesized, characterized and provided by the workgroup of 
Prof. König (University of Regensburg, Germany). 10 mM stock solutions were prepared in 
DMSO and stored at –20 °C. According to the substitution pattern the tariquidar analogs can 
be subdivided in three series of compounds. The general structure of the tariquidar analogs 
with residues R1, R2, R3 and R4 and the corresponding compounds are listed in Table 4.1, 
Table 4.2 and Table 4.3. 
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Table 4.1: Structures of tariquidar, tariquidar analogs and intermediates with variations in 
residue R3 and R4. 
N
H
O
N
O
O
CH3
CH3
R3 R1
R4
R2  
Compound 
(lab code) 
R1 R2 R3 R4 
tariquidar O
N
HN
 
H OCH3 OCH3 
1  (ME5-5) NH2 H SO2NH2 H 
2  (ME5-7) O
N
HN
 
H SO2NH2 H 
3* (ME27-1) NHBoc H H Br 
4* (ME27-2) NH2 H H Br 
5* (ME27-3) O
N
HN
 
H H Br 
6* (ME27-4) O
N
HN
 
H H H3CO(CH2)2O(CH2)2NH-
7* (ME30-1) O
N
HN
 
H H morpholino 
8* (ME33-1) 
N  
H H H5C2O(CH2)2O- O
HN
*) Synthesis of these compounds has already been published (Egger et al., 2007) 
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Table 4.2: Structures of tariquidar and tariquidar analogs with quinoline-3-carboxamido as R2 
and variations of R3 and R4. 
N
H
O
N
O
O
CH3
CH3
R3 R1
R4
R2  
Compound 
(lab code) 
R1 R2 R3 R4 
tariquidar 
N
O
HN
 
H OCH3 OCH3 
9  (ME24-5) H 
N
O
HN
 
H OCH3 
10 (ME25-3) H 
N
O
HN
 
OCH3 OCH3 
11 (ME18-3) H 
N
O
HN
 
OCH3 H 
12 (ME17-3) H 
N
O
HN
 
CH3 H 
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Table 4.3: Structures of tariquidar analogs and intermediates with a methoxycarbonyl group 
as R3. 
N
H
O
N
O
O
CH3
CH3
R3 R1
R4
R2  
 
Compound 
(lab code) 
R1 R2 R3 R4 
13 (ME1-2) H NO2 COOCH3 H 
14 (ME1-3) H NH2 COOCH3 H 
15 (ME1-4) H 
N
O
HN
 
COOCH3 H 
16 (ME22-1) H 
N
O
HN
 
COOCH3 H 
17 (ME19-2) H 
N
O
HN
 
COOCH3 H 
18 (ME11-1) H 
N
N
O
HN
 
COOCH3 H 
19 (ME12-1) H 
N
O
HN
 
COOCH3 H 
20 (ME14-1) H 
N
N
O
HN
 
COOCH3 H 
21 (ME21-1) H 
N
N
O
HN
CH3  
COOCH3 H 
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4.3.3 Cell lines and culture conditions 
 
Kb-V1 cells, an ABCB1 overexpressing subclone (Kohno et al., 1988) of HeLa derived 
human Kb cells (ATCC CCL-17), were obtained by adding increasing amounts of vinblastine 
after subculturing to achieve a final concentration of 300 ng/ml culture medium within a 
period of about 90 days. The culture medium was Dulbecco´s modified Eagle´s medium 
(Sigma, Deisenhofen, Germany) supplemented with 10 % FCS (Biochrom, Berlin, Germany) 
and 300 ng/ml vinblastine. After 3 passages the chemoresistant cells expressed sufficient 
quantities of the ABCB1 transporter. New cells were thawed after Kb-V1 cells were 
cultivated for about 15 weeks (Hubensack, 2005). 
MCF-7/Topo cells, an ABCG2 overexpressing subclone of MCF-7 breast adenocarcinoma 
cells (ATCC HTB-22), were obtained by adding increasing volumes of a topotecan solution 
within a period of about 40 days to achieve a final concentration of 500 ng/ml culture 
medium. After three passages in Eagle´s minimum essential medium (Sigma, Deisenhofen, 
Germany) supplemented with 5 % FCS and 500 ng/ml topotecan, the treated cells expressed 
sufficient quantities of ABCG2 (Hubensack, 2005). All cell types were maintained in a water 
saturated atmosphere (95 % air/5 % carbondioxide) at 37 °C in 75-cm² culture flasks (NUNC, 
Wiesbaden, Germany) and were serially passaged following trypsinization using 0.05 % 
trypsin/0.02 % EDTA (Roche Diagnostics, Mannheim, Germany). Mycoplasma 
contamination was routinely monitored by PCR (Venor® GeM, Minerva Biolabs GmbH, 
Berlin), and only Mycoplasma free cultures were used. 
 
4.3.4 Flow cytometric calcein-AM efflux assay 
 
In Kb-V1 cells calcein-AM is extruded by ABCB1 before esterases can cleave the ester 
bonds, and calcein is not accumulated (Homolya et al., 1993). Therefore, p-gp modulators can 
easily be recognized by flow cytometry. Depending on the modulator concentration the 
change in the calcein-AM efflux or rather in the relative fluorescence intensity of the cells is 
measured (see Chapter 4). The assay was performed according to Müller et al (Müller et al., 
2007). 
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4.3.5 Flow cytometric mitoxantrone efflux assay 
 
The assay was performed according to the cited literature (Lee et al., 1994; de Bruin et al., 
1999; Maliepaard et al., 1999; Robey et al., 2001) with modified assay conditions. ABCG2 
expressing MCF-7/Topo cells were passaged 3 or 4 days before the assay was carried out, 
trypsinized, washed with PBS at 25 °C, and adjusted to a number of 1·106 cells per ml with 
culture medium. Mitoxantrone was added to the cell suspension to achieve a concentration of 
20 µM (10 µl of 2 mM stock solution in 70 % ethanol). Different concentrations of the test 
compound, solvent and fumitremorgin C (10 µM) were added, respectively. After a short 
vortexing step the cell suspensions were incubated for 30 min at 37 °C/5 % CO2, which is a 
sufficient incubation period for maximal mitoxantrone uptake into the cells, according to the 
literature. Subsequently, the cells were washed with ice cold PBS at 4 °C. For the 
determination of the 100 % mitoxantrone uptake the cells of the fumitremorgin C sample 
were resuspended in ice cold PBS and placed on ice in the dark until measurement to avoid 
mitoxantrone efflux. All other samples were resuspended in culture medium. After an 
incubation period of 1 h at 37 °C/5 % CO2 an equilibrium of mitoxantrone had developed 
between the cytoplasm of the cells and the surrounding medium. After the medium was 
removed by centrifugation, the cell pellet was rinsed once with ice cold PBS, resuspended in 
0.5 ml of PBS per 1·106 cells. A FACS Calibur™ (Becton Dickinson, Heidelberg, Germany) 
was used to analyze the fluorescence intensity of the cells. A minimum of 20,000 events was 
collected per sample and the events were gated according to forward scatter and sideward 
scatter to exclude clumps and debris. The photomultiplier settings were as follows: E-1 for 
FSC, 200 for SSC, 450 for FL1-H and 700 for FL4-H. FL4-H histograms were analyzed by 
the WinMDI 2.8 software. 
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4.3.6 Chemosensitivity assay 
 
The assays were performed as described previously (Bernhardt et al., 1992). In brief: tumor 
cell suspensions (100 µl/well) were seeded into 96-well flat bottomed microtitration plates 
(Greiner, Frickenhausen, Germany) at a density of ca. 15 cells/microscopic field 
(magnification 320-fold). After 2-3 days the culture medium was removed by suction and 
replaced by fresh medium (200 µl/well) containing varying drug concentrations or vehicle. 
Drugs were added as 1000-fold concentrated feed solutions. On every plate 16 wells served as 
controls and 16 wells were used per drug concentration. After various times of incubation the 
cells were fixed with glutardialdehyde (Merck, Darmstadt, Germany) and stored in a 
refrigerator. At the end of the experiment all plates were processed simultaneously (staining 
with 0.02 % aqueous crystal violet (SERVA, Heidelberg, Germany) solution (100 µl/well)). 
Excess dye was removed by rinsing the trays with water for 20 min. The stain bound by the 
cells was redissolved in 70 % ethanol (180 µl/well) while shaking the microplates for about 3 
hours. Absorbance (a parameter proportional to cell mass) was measured at 578 nm using a 
BIOTEK 309 Autoreader (TECNOMARA, Fernwald, Germany).  
Drug effects were expressed as corrected T/C-values for each group according to 
 
T/Ccorr = 
0
0
C- C
C - T
 · 100 [%]   (eq. 4.1), 
 
where T is the mean absorbance of the treated cells, C the mean absorbance of the controls 
and C0 the mean absorbance of the cells at the time (t = 0) when drug was added. 
 
When the absorbance of treated cells T is less than that of the culture at t = 0 (C0), the extent 
of cell killing was calculated as 
cytocidal effect [%] = 
0
0
C
TC −
 · 100  (eq. 4.2). 
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4.3.7 Cell cycle analysis 
 
Cell cycle analysis was performed with the new tariquidar analogs at a concentration of 10 
µM. In order to obtain a sufficient number of cells the incubation was carried out in 75 cm2 
culture flaks (NUNC, Wiesbaden, Germany) with 20 ml of culture medium. For each 
concentration of the test compounds U-373 MG cells were seeded in one culture flask, 
respectively, and grown to 70-80 % confluence. 20 µl of the stock solutions were added to the 
culture medium to achieve the final concentration of the test compounds and afterwards the 
cells were incubated for 24 h in a water saturated atmosphere (95 % air/5 % carbondioxide) at 
37 °C. The culture medium was removed, the cells were trypsinized, washed with PBS and 
adjusted to number of 1·106 cells per ml with PBS. 5 ml of this cell suspension (5 · 106 cells) 
was pipetted in a 12 ml Falcon® tube (BD Biosciences, Heidelberg, Germany) and centrifuged 
at 1200 rpm for 10 min. The supernatant was discarded, the cell pellet was resuspended with 1 
ml of PBS and the cells were separated by pipetting. 
The fixation of the cells was assured by adding 9 ml ice cold 70 % ethanol and incubated at 4 
°C for 1 h. After centrifugation the supernatant was discarded, cells were separated by 
pipetting with 1 ml of PBS and finally 9 ml of PBS were added. The cell suspension was 
centrifuged again, the supernatant was discarded, the cell pellet was resuspended with 0.5 ml 
of PBS and 0.5 ml of DNA extraction buffer (192 ml of 0.2 M Na2HPO4 and 8 ml of 0.1 M 
citric acid, pH 7.8) were added. After an incubation period of 5 min at room temperature the 
cell suspension was centrifuged, the supernatant was discarded and 1 ml DNA staining 
solution (20 mg/l propidium iodide (SIGMA) and 200 mg/l RNase (SIGMA) in PBS) was 
added. All samples were incubated as exactly as possible for 30 min in the dark (Jaroszeski et 
al., 1998). A FACS Calibur™ (Becton Dickinson, Heidelberg, Germany) and CellQuest 
software was used to analyze the fluorescence intensity of the cells. A minimum of 30,000 
events was collected per sample and the events were gated according to forward scatter and 
sideward scatter to exclude clumps and debris. The photomultiplier settings were as follows: 
E-1 for FSC (log), 150 for SSC (log) and 375 for FL3-H (linear). The amplifier gain for FL3-
H, FL3-A and FL3-W were 2.00, 1.85 and 1.00, respectively. The FL3-A versus FL3-W dot 
plots and the corresponding FL3-H histograms were analyzed by the software "MultiCycle for 
Windows" (Phoenix Flow Systems, San Diego, CA, USA) at the Institute of Pathology 
(University of Regensburg)  
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4.4 Results 
 
The Kb-V1 and the MCF-7/Topo cell variants, respectively, were used to investigate the 
inhibitory activity and selectivity of new tariquidar analogs at the ABCB1 and ABCG2 
transporter. The tariquidar analogs were examined in two different test series. Firstly, the 
inhibitory activity and selectivity was investigated with the flow cytometric calcein-AM 
efflux assay and mitoxantone efflux assay, respectively. Secondly, the ability of the 
modulators to potentiate the cytotoxicity of the cytostatic topotecan was evaluated in the 
chemosensitivity assay. 
Furthermore, the antiproliferative effect of the compounds on human glioblastoma U-373 MG 
cells was determined in the chemosensitivity assay during permanent incubation. In order to 
proof whether the cytotoxic effect of the compounds is caused by specific interference during 
cell cycle, quiescent U-373 MG cells were incubated with the tariquidar analogs.  
 
4.4.1 Inhibitory activity and selectivity 
 
The ABCB1 inhibitory activity (IC50 values) of the new tariquidar analogs was determined in 
the calcein-AM efflux assay. In order to obtain information about the selectivity of the 
modulators the inhibitory activity at the ABCG2 transporter was tested in the mitoxantrone 
assay. The test compounds were used at different concentrations with respect to the 
construction of concentration response curves. A sample incubated without test compounds 
(with DMSO as vehicle) served as negative control and represented 0 % inhibition. The value 
for 100 % inhibition was determined with tariquidar (1 µM) in case of the calcein-AM efflux 
assay and with fumitremorgin C (10 µM) in case of the mitoxantrone efflux assay. The 
geometric means were calculated from the fluorescence intensity histograms, related to the 
controls and plotted against the test compound concentration. Addition of increasing 
modulator concentrations led to sigmoidal concentration response curves. The IC50 values 
were calculated using Hill equation. The results of the calcein-AM efflux assay (a) and of the 
mitoxantrone efflux assay (b) of the tariquidar analogs are shown in Figure 4.1, Figure 4.2, 
Figure 4.3 and Figure 4.4. 
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Figure 4.1: a) ABCB1 inhibition and b) ABCG2 inhibition by tariquidar and new tariquidar 
analogs in dependence of their concentrations. Compound 3 (open inverted triangle), 4 (filled 
triangle), 5 (open circle), 6 (open square), 7 (open triangle) and 8 (open diamond). The 
inhibitory activity of the compounds 3 and 4 has not been tested so far. 
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Figure 4.2: a) ABCB1 inhibition and b) ABCG2 inhibition by tariquidar and new tariquidar 
analogs in dependence of their concentrations. Tariquidar (open stare), compound 9 (filled 
circle), 10 (filled diamond), 11 (filled inverted triangle) and 12 (filled square). 
 
 Tariquidar analogs as ABCB1 and ABCG2 inhibitors 149 
 
Figure 4.3: a) ABCB1 inhibition and b) ABCG2 inhibition by tariquidar and new tariquidar 
analogs in dependence of their concentrations. Compound 13 (open circle), 14 (open square), 
15 (filled star), 16 (filled circle), 17 (filled square) and 18 (filled triangle). 
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Figure 4.4: a) ABCB1 inhibition and b) ABCG2 inhibition by tariquidar and new tariquidar 
analogs in dependence of their concentrations. Compound 19 (filled diamond), 20 (filled 
inverted triangle) and 21 (filled square). 
 
The results of the concentration-response curves of the tariquidar analogs are summarized as 
IC50 values, efficacies and Hill coefficients in Table 4.4. 
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Table 4.4: Inhibitory activity (IC50 values), efficacy and Hill coefficients of tariquidar and 
tariquidar analogs at the ABCB1 and ABCG2 transporter, respectively. 
 
Compd. IC50 [nM] 
ABCB1 
efficacy 
[%] 
Hill 
coeff. 
n IC50 [nM] 
ABCG2 
efficacy 
[%] 
Hill 
coeff. 
n 
tariquidar 223 ± 8 102 2.6 5 1,176 ± 123 52 0.9 1 
1 no effect − − 2 no effect − − 2 
2 no effect − − 2 no effect − − 2 
3 4,720 ± 169 63 2.1 1 n. d.   
4 11,700 ± 1,510 94 1.8 1 n. d.   
5* 145 ± 12 98 1.9 3 711 ± 62 49 0.9 2 
6* 1,575 ± 98 105 2.3 3 7,375 ± 1,000 99 1.0 1 
7* 593 ± 21 109 2.9 3 1,320 ± 83 85 1.3 1 
8* 181 ±6 116 2.7 3 920 ± 64 70 1.2 1 
9 15,840 ± 2,500 13 2.1 2 9,333 ± 1,970 104 0.7 1 
10 17,950 ± 4,200 98 2.2 2 988 ± 64 47 0.9 1 
11 7,175 ± 190 30 3.7 1 393 ± 59 66 0.7 1 
12 15,100 ± 1,550 20 1.9 1 1,990 ± 355 52 0.9 1 
13 9,600 ± 85 95 3.1 3 5,564 ± 323 23 1.2 1 
14 12,570 ± 502 70 2.9 3 13,300 ± 4,300 114 1.2 1 
15 9,450 ± 417 64 2.1 3 100 ± 8 100 0.7 2 
16 38,570 ± 8,840 59 1.0 1 55 ± 4 54 1.0 3 
17 ~ 30,000 ~ 10 0.5 1 290 ± 110 30 0.5 1 
18 34,660 ± 183 50 1.3 2 154 ± 15 114 0.8 1 
19 19,300 ± 5,180 73 0.9 1 6,310 ± 1,106 111 1.2 1 
20 29,100 ± 8,430 41 0.8 1 2,270 ± 760 57 0.5 1 
21 84,170 ± 26,690 50 0.9 1 709 ± 63 50 0.7 1 
*) ABCB1 inhibitory activity has already been published (Egger et al., 2007) 
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4.4.2 Effect of tariquidar analogs on the chemosensitivity of Kb-V1 cells 
against topotecan 
 
Over the whole incubation period of up to 150 h Kb-V1 cells were exposed to the cytostatic 
drug topotecan, which is a known ABCB1 substrate. Topotecan was used at a low 
concentration of 50 nM that did not affect the growth of Kb-V1 cells. Additionally, the cells 
were incubated with combinations of topotecan and 4 different concentrations of the 
tariquidar analogs. The ability of the tariquidar analogs to reverse resistance of the Kb-V1 
cells to topotecan is shown in Figure 4.5, Figure 4.6, Figure 4.7, Figure 4.8 and Figure 4.9. To 
consider that this effect results from ABCB1 inhibition, the effect of the tariquidar analogs 
alone on Kb-V1 cells was tested as well. 
 
Figure 4.5: a) Effect of compound 5 on proliferating Kb-V1 cells (passage 46) during 
permanent incubation. b) Effect of compound 5 in combination with 50 nM topotecan. 
Vehicle (open star), 50 nM topotecan (filled circle) and compound 5 at different 
concentrations: 50 nM (filled square), 100 nM (filled triangle), 500 nM (filled diamond) and 1 
µM (filled inverted triangle). 
 
The resistance of Kb-V1 cells to topotecan was completely reversed by the addition of 
compound 5 (Figure 4.5) and 7 (Figure 4.6), respectively, at a concentration of 50 nM, 
whereas these tariquidar analogs alone had no cytotoxic effect. Compound 13 (Figure 4.7) 
showed a weak cytotoxic effect at a concentration of 10 µM. But the same effect could be 
observed by the addition of compound 13 at a concentration of 1 µM to topotecan and the 
completely reversed resistance was determined at a concentration of 10 µM. 
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Figure 4.6: a) Effect of compound 7 on proliferating Kb-V1 cells (passage 46) during 
permanent incubation. b) Effect of compound 7 in combination with 50 nM topotecan. 
Vehicle (open star), 50 nM topotecan (filled circle) and compound 7 at different 
concentrations: 50 nM (filled square), 100 nM (filled triangle), 500 nM (filled diamond) and 1 
µM (filled inverted triangle). 
 
 
Figure 4.7: a) Effect of compound 13 on proliferating Kb-V1 cells (passage 29) during 
permanent incubation. b) Effect of compound 13 in combination with 50 nM topotecan. 
Vehicle (open star), 50 nM topotecan (filled circle) and compound 13 at different 
concentrations: 0.5 µM (filled square), 1 µM (filled triangle), 3 µM (filled diamond) and 10 
µM (filled inverted triangle). 
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Figure 4.8: a) Effect of compound 14 on proliferating Kb-V1 cells (passage 38) during 
permanent incubation. b) Effect of compound 14 in combination with 50 nM topotecan. 
Vehicle (open star), 50 nM topotecan (filled circle) and compound 14 at different 
concentrations: 0.5 µM (filled square), 1 µM (filled triangle), 3 µM (filled diamond) and 10 
µM (filled inverted triangle). 
 
 
Figure 4.9: a) Effect of compound 15 on proliferating Kb-V1 cells (passage 38) during 
permanent incubation. b) Effect of compound 15 in combination with 50 nM topotecan. 
Vehicle (open star), 50 nM topotecan (filled circle) and compound 15 at different 
concentrations: 0.5 µM (filled square), 1 µM (filled triangle), 3 µM (filled diamond) and 10 
µM (filled inverted triangle). 
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Compound 14 (Figure 4.8) showed a cytotoxic effect at a concentration of 10 µM. The 
combination of topotecan with 14 at this concentration resulted in a strong cytostatic effect. 
However, concentrations above 1 µM are very high and not relevant for in vivo applications. 
The combination of topotecan with compound 15 (Figure 4.9) at a concentration of 3 µM 
resulted in a cytocidal effect indicating the reversion of the topotecan resistance. But at this 
concentration compound 15 alone had a cytostatic effect, and incubation with 10 µM of 
compound 15 led to a cytocidal effect. 
 
4.4.3 Effect of tariquidar analogs on the chemosensitivity of MCF-7/Topo cells 
against topotecan 
 
Over the whole incubation period of up to 170 h MCF-7/Topo cells were exposed to the 
cytostatic drug topotecan which is a not only a known ABCB1 but also an ABCG2 substrate. 
Topotecan was used at a low concentration of 100 nM that did not affect the growth of MCF-
7/Topo cells. Additionally, the cells were incubated with combinations of topotecan and 4 
different concentrations of the tariquidar analogs. The ability of the tariquidar analogs to 
reverse resistance of the MCF-7/Topo cells to topotecan is shown in Figure 4.10, Figure 4.11, 
Figure 4.12, Figure 4.13, Figure 4.14, Figure 4.15 and Figure 4.16. To consider that this effect 
results from ABCG2 inhibition, the effect of the tariquidar analogs alone on MCF-7/Topo 
cells was tested. 
 
The resistance of MCF-7/Topo cells to topotecan was completely reversed by the addition of 
compound 11 (Figure 4.10) at a concentration of 100 nM, whereas these tariquidar analog 
alone had no cytotoxic effect at this concentration. Only at a concentration of 500 nM this 
analog showed a cytostatic effect. 
Compound 12 (Figure 4.11) alone had no cytotoxic effect on MCF-7/Topo cells at all. But the 
combination of 12 at a concentration of 500 nM with topotecan caused a cytostatic effect. 
Compound 13 (Figure 4.12) and 14 (Figure 4.13) exhibited very similar antiproliferative 
effects. The incubation of MCF-7/Topo cells with 30 µM of the tariquidar analogs alone and 
in combination with topotecan resulted both in a cytocidal effect. However, at a concentration 
of 10 µM a difference became obvious: the tariquidar analog alone had only a cytotoxic effect 
whereas the combination with topotecan led to a cytostatic effect. 
156 Chapter 4  
 
Figure 4.10: a) Effect of compound 11 on proliferating MCF-7/Topo cells (passage 94) 
during permanent incubation. b) Effect of compound 11 in combination with 100 nM 
topotecan. Vehicle (open star), 100 nM topotecan (filled circle) and compound 11 at different 
concentrations: 1 nM (filled square), 10 nM (filled triangle), 100 nM (filled diamond) and 500 
nM (filled inverted triangle). 
 
Figure 4.11: a) Effect of compound 12 on proliferating MCF-7/Topo cells (passage 94) 
during permanent incubation. b) Effect of compound 12 in combination with 100 nM 
topotecan. Vehicle (open star), 100 nM topotecan (filled circle) and compound 12 at different 
concentrations: 1 nM (filled square), 10 nM (filled triangle), 100 nM (filled diamond) and 500 
nM (filled inverted triangle). 
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Figure 4.12: a) Effect of compound 13 on proliferating MCF-7/Topo cells (passage 90) 
during permanent incubation. b) Effect of compound 13 in combination with 100 nM 
topotecan. Vehicle (open star), 100 nM topotecan (filled circle) and compound 13 at different 
concentrations: 1 µM (filled square), 3 µM (filled triangle), 10 µM (filled diamond) and 30 
µM (filled inverted triangle). 
 
Figure 4.13: a) Effect of compound 14 on proliferating MCF-7/Topo cells (passage 90) 
during permanent incubation. b) Effect of compound 14 in combination with 100 nM 
topotecan. Vehicle (open star), 100 nM topotecan (filled circle) and compound 14 at different 
concentrations: 1 µM (filled square), 3 µM (filled triangle), 10 µM (filled diamond) and 30 
µM (filled inverted triangle). 
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Figure 4.14: a) Effect of compound 15 on proliferating MCF-7/Topo cells (passage 49) 
during permanent incubation. b) Effect of compound 15 in combination with 100 nM 
topotecan. Vehicle (open star), 100 nM topotecan (filled circle) and compound 15 at different 
concentrations: 1 nM (filled square), 10 nM (filled triangle), 100 nM (filled diamond) and 500 
nM (filled inverted triangle). 
 
Figure 4.15: a) Effect of compound 16 on proliferating MCF-7/Topo cells (passage 110) 
during permanent incubation. b) Effect of compound 16 in combination with 100 nM 
topotecan. Vehicle (open star), 100 nM topotecan (filled circle) and compound 16 at different 
concentrations: 10 nM (filled triangle), 100 nM (filled diamond) and 500 nM (filled inverted 
triangle). 
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Figure 4.16: a) Effect of compound 18 on proliferating MCF-7/Topo cells (passage 110) 
during permanent incubation. b) Effect of compound 18 in combination with 100 nM 
topotecan. Vehicle (open star), 100 nM topotecan (filled circle) and compound 18 at different 
concentrations: 1 nM (filled square), 10 nM (filled triangle), 100 nM (filled diamond) and 500 
nM (filled inverted triangle). 
 
Compound 15 (Figure 4.14) alone had such a pronounced cytostatic effect on MCF-7/Topo 
cells at a concentration of 100 nM that only a slight enhancement of the effect caused by the 
combination with topotecan was detectable. At a concentration of 500 nM no difference 
between the treatment of the cells with 15 alone and in combination with topotecan was 
measured at all. 
Incubation of MCF-7/Topo cells with compound 16 (Figure 4.15) alone resulted in weak 
cytotoxic effects at concentrations of 100 nM and 500 nM. However, the same concentrations 
of 16 resulted in cytostatic effects when the compound was combined with topotecan 
indicating that the topotecan resistance of the cells was completely reversed. 
Strong cytostatic effects were observed incubating MCF-7/Topo cells with compound 18 
(Figure 4.16) at concentrations of 10 nM, 100 nM and 500 nM. However, the combination of 
topotecan and compound 18 at a very low concentration of 1 nM resulted in a complete 
reversion of the multidrug resistance of the cells and a cytostatic effect. The use of higher 
concentrations of 18 also yielded a cytostatic effect, thus providing no benefit. 
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4.4.4 Effect of tariquidar analogs on proliferating U-373 MG cells 
 
Incubating Kb-V1 or MCF-7/Topo cells, respectively, with the new tariquidar derivatives 
alone, some of the compounds showed cytotoxic, cytostatic or cytocidal effects. In order to 
proof whether these effects resulted from the inhibition of the ABC transporters or not, the 
chemosensitivity of ABCB1 and ABCG2 negative human glioblastoma U-373 MG cells was 
investigated (Figure 4.17 to Figure 4.21). Antiproliferative effects of the tariquidar derivatives 
on U-373 MG cells would point out that the cytotoxicity of the compound is independent of 
their inhibitory activity at the ABCB1 or ABCG2 transporter, respectively. 
 
Figure 4.17: Effect of compound 11 (a) and compound 12 (b) on proliferating U-373 MG 
cells (passage 362) during permanent incubation; vehicle (open star), 0.1 µM (filled circle), 
0.5 µM (filled square), 1 µM (filled triangle), 3 µM (filled diamond) and 10 µM (filled 
inverted triangle). 
 
On proliferating U-373 MG cells compound 11 showed a cytostatic effect at a concentration 
of 10 µM indicating that the cytotoxic effect on proliferating MCF-7/Topo was independent 
of ABCG2 inhibition. Compound 12 had a very weak cytotoxic effect on MCF-7/Topo cells 
and also the effect on U-373 MG cells was very weak even at very high concentrations of 3 
and 10 µM. On Kb-V1 and MCF-7/Topo cells compounds 13 and 14 exerted nearly the same 
cytotoxic effect at 10 µM and cytostatic effect at 30 µM, respectively. On U-373 MG cells 
both compounds had a strong cytostatic effect at a concentration of 10 µM. 
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Figure 4.18: Effect of compound 13 (a) and compound 14 (b) on proliferating U-373 MG 
cells (passage 359) during permanent incubation; vehicle (open star), 0.1 µM (filled circle), 
0.5 µM (filled square), 1 µM (filled triangle), 3 µM (filled diamond) and 10 µM (filled 
inverted triangle). 
 
 
Figure 4.19: Effect of compound 15 (a) and compound 16 (b) on proliferating U-373 MG 
cells (passage 359 and 362, respectively) during permanent incubation; vehicle (open star), 
0.1 µM (filled circle), 0.5 µM (filled square), 1 µM (filled triangle), 3 µM (filled diamond) 
and 10 µM (filled inverted triangle). 
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Figure 4.20: Effect of compound 18 (a) and compound 20 (b) on proliferating U-373 MG 
cells (passage 362) during permanent incubation; vehicle (open star), 0.1 µM (filled circle), 
0.5 µM (filled square), 1 µM (filled triangle), 3 µM (filled diamond) and 10 µM (filled 
inverted triangle). 
 
 
Figure 4.21: Effect of compound 21 on proliferating U-373 MG cells (passage 363) during 
permanent incubation; vehicle (open star), 0.01 µM (filled circle), 0.05 µM (filled square), 
0.1 µM (filled triangle), 1 µM (filled diamond) and 10 µM (filled inverted triangle). 
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On Kb-V1 and on MCF-7/Topo cells compound 15 had a cytostatic effect at a concentration 
of 3 µM and 100 nM, respectively. On proliferating U-373 MG cells compound 15 showed a 
cytotoxic effect at a concentration of 100 nM and a cytostatic effect at 500 nM indicating that 
its cytotoxicity is independent of the ABCB1 or ABCG2 inhibition. The incubation of U-373 
MG cells with compound 16 led to a cytostatic effect at a concentration of 3 µM and to a 
cytocidal effect at 10 µM. On proliferating U-373 MG cells compound 18 had a cytostatic 
effect at a concentration of 10 µM indicating that the cytotoxic effect on proliferating MCF-
7/Topo cells was independent of the inhibitory activity at the ABCG2 transporter. Compound 
20 exerted a cytotoxic effect on proliferating U-373 MG cells at a concentration of 1 µM, a 
cytostatic effect at 3 µM and a cytocidal effect at 10 µM. The strongest cytototoxicity 
exhibited compound 21 with a cytostatic effect a very low concentration of 50 nM and a 
cytostatic effect at 100 nM. 
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4.4.5 Effect of tariquidar analogs on quiescent U-373 MG cells 
 
It was shown that some of the new tariquidar analogs exhibited cytotoxic effects on 
proliferating Kb-V1, on MCF-7/Topo and on U-373 MG cells. In order to compare their 
effects with those of tubulin inhibitors like paclitaxel against resting cells, confluent cells 
were treated with the tariquidar analogs at a very high concentration of 10 µM. Rotenone, an 
ubiquinon reductase inhibitor, blocking ATP synthesis, served as a positive control for 
maximum cytocidal effect. The results are shown in Figure 4.22 and Figure 4.23. 
 
Figure 4.22: Incubation of resting U-373 MG cells with rotenone (500 nM), paclitaxel (10 
nM) and new tariquidar analogs (20 µM); vehicle (open star), rotenone (filled hexagon). a) 
Paclitaxel (open diamond) and series 1 with compound 3 (open inverted triangle), 4 (filled 
triangle), 5 (open circle), 6 (open square), 7 (open triangle) and b) series 2 with compound 9 
(filled circle), 10 (filled diamond), 11 (filled inverted triangle) and 12 (filled square). 
 
After 48 h, the positive control rotenone had a very strong cytocidal effect as expected. 
Compound 6 produced nearly the same effect as rotenone. The cytostatic paclitaxel exerted a 
very weak cytocidal effect after 3 days and compound 3 showed this effect after 6 days. The 
tariquidar analogs 4, 5, 7 of series 1 and 9, 10, 11, 12 of series 2 had no effect on resting cells. 
 Tariquidar analogs as ABCB1 and ABCG2 inhibitors 165 
 
Figure 4.23: Incubation of resting U-373 MG cells with rotenone (500 nM) and new 
tariquidar analogs (20 µM); vehicle (open star), rotenone (filled hexagon). a) Series 3 with 
compound 13 (open circle), 14 (open square), 15 (filled star), 16 (filled circle), 18 (filled 
triangle) and b) series 4 with compound 19 (filled diamond), 20 (filled inverted triangle) and 
21 (filled square). 
 
The tariquidar analogs 13, 14, 15, 16, 20 and 21 had no effect on resting cells. Compounds 18 
and 19 produced a cytocidal effect after 6 and 3 days, respectively. The results demonstrate 
that the cytotoxic effect of the tariquidar analogs on proliferating cells resulted from a specific 
interference of the compounds during the cell cycle. Only compound 6 showed a very strong 
cytocidal effect caused by an unspecific effect on the cells indicating that this tariquidar 
analog is not suitable for in vivo studies. 
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4.4.6 Cell cycle analysis of tariquidar analogs 
 
In order to gain information about the mechanism of cytotoxicity cell cycle analyses were 
performed with the new tariquidar analogs. As positive control for the cell cycle arrest during 
mitosis (G2/M phase) the microtubule interfering agent vinblastine was used (Figure 4.24c). 
Topotecan, an inhibitor of the DNA topoisomerase I leading to cell arrest during DNA 
synthesis (S phase), served as the second positive control (Figure 4.24d). 
 
Figure 4.24: Cell cycle analysis of U-373 MG cells. a) FL3-Area versus FL3-Width dot plot 
of the DMSO control showing a singlet gate R1, which excludes aggregates. b) Cells gated in 
region R1 displayed in the FL3-H histogram representing the DNA distribution of untreated 
cells. c) FL3-H Histogram representing the DNA content of U-373 MG cells incubated with 
vinblastine (50 nM) and d) with topotecan (100 nM). 
 
The fractions of U-373 MG cells in the G1/G0 phase, in the S phase and in the G2/M phase 
after the incubation with the cytostatic drugs and the tariquidar analogs, respectively, were 
calculated and are summarized in Table 4.5. Compared to the cells incubated with the solvent 
DMSO, the treatment of the cells with vinblastine resulted in a very strong increase in the 
percentage of M/G2 phase cells and a decrease in the portion of cells in G1/G0 phase. 
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Table 4.5: Effect of DMSO, vinblastine, topotecan and the tariquidar analogs on the portion 
of U-373 MG cells in G1/G0 phase, S phase and G2/M phase. 
Compound Concentration [µM] G1/G0 phase [%] S phase [%] G2/M phase [%] 
DMSO  72.3 13.2 14.5 
vinblastine 0.01 24.0 12.6 63.4 
vinblastine 0.05 10.4 16.0 73.6 
topotecan 0.1 12.2 70.8 17.0 
3 10 72.2 13.0 14.8 
4 10 72.1 11.8 16.1 
5 10 74.6 9.9 15.5 
6 10 53.6 23.0 23.4 
7 10 70.4 10.1 19.5 
8 10 75,5 11.0 13.5 
9 10 70.2 11.2 18.6 
10 10 71.9 9.9 18.2 
11 10 75.1 11.4 12.9 
12 10 70.6 10.5 18.9 
13 10 62.8 11.3 26.0 
14 10 69.3 9.1 21.5 
15 3 73.4 12.7 13.8 
16 10 70.3 13.1 16.6 
17 10 67.5 11.5 21.0 
18 10 67.1 12.8 20.1 
19 10 58.9 28.6 12.5 
20 10 69.8 12.6 17.6 
21 10 65.9 17.7 16.4 
 
As expected, topotecan led to an increased ratio of cells arrested during S phase. Compound 
6, 13 and 19 led to a slightly increased portion of the cells in S phase or G2/M phase, 
respectively. But these results are not definitely and allow no statement about the mechanism 
of the cytotoxic effect of the compounds. Moreover, the cell cycle analysis of all other 
tariquidar analogs showed about the same percental distribution of the cells like the control 
sample indicating that the toxicity of the compounds is caused by an effect on the cell cycle 
during the G1/G0 phase. 
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4.5 Discussion 
 
Aiming at tariquidar analogs with improved solubility and pharmacokinetics more hydrophilic 
analogs were synthesized. The new compounds were investigated for their inhibitory activity 
and their selectivity on ABCB1 overexpressing Kb-V1 cells (Müller et al., 2007) and ABCG2 
overexpressing MCF-7/Topo cells. The IC50 values of the compounds were determined with 
the calcein-AM efflux assay at the ABCB1 transporter and with the mitoxantrone efflux assay 
at the ABCG2 transporter, respectively. The ABCB1 inhibitory activity was retained in the 
series of tariquidar analogs bearing more hydrophilic substituents and having the 
quinolinecarboxamide moiety in the same position as in tariquidar (compounds 5, 6, 7 and 8 
of series 1). Compared to tariquidar with an IC50 value of 223 nM, the compounds 5 and 8 
were even more potent with IC50 values of 181 nM and 145 nM, respectively. These results 
demonstrate that structural changes in the chosen position are indeed tolerated without 
considerable decrease in activity. Regarding the clog P values of the compounds 5, 6, 7 and 8 
with 7.1, 4.3, 5.1 and 6.0, respectively, a correlation between the lipophilicity of the 
compounds and the inhibitory activity was observed (Egger et al., 2007). In the same order, as 
clog P rises, the activity against ABCB1 increases. In the literature it is still a matter of debate 
whether high lipophilicity is an important criterion (amongst others) for the inhibition of ABC 
transporters (Wiese and Pajeva, 2001). The results obtained from this small series are in 
accordance with this hypothesis, assuming that the newly introduced side chains only affect 
physicochemical parameters. As the lipophilicity of the compounds ranges from clog P values 
of 7 to 4, this series of new ABCB1 modulators is well suited to test in vivo if the more 
lipophilic analogs accumulate to a higher extent in the lipid compartment of the brain or not. 
These compounds are also ABCG2 inhibitors but with a clear selectivity to the ABCB1 
transporter. 
Further tariquidar analogs with the carboxamide residue shifted to the neighbor position were 
synthesized. Surprisingly, this structural modification resulted in ABCG2-selective inhibitors. 
For three derivatives, compound 16, 15 and 18, IC50 values of 55, 100, and 154 nM were 
determined. With the mitoxantrone efflux assay an IC50 value of 225 nM for Ko143, the most 
potent ABCG2 inhibitor reported so far (Allen et al., 2002), was measured. Hence, the new 
tariquidar analogs 16, 15 and 18 are more potent than Ko143. Moreover, compound 16 had 
only a very weak effect on ABCB1, thus representing the most potent and a very selective 
ABCG2 inhibitor. 
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Furthermore, the comparison of the Hill coefficients at the ABCB1 and ABCG2 transporters 
is informative. The Hill coefficients at the ABCG2 transporter range from 0.5 to 1.3 pointing 
out that the ABCG2 transporter comprises only one binding site. However, the investigations 
on the tariquidar analogs at the ABCB1 transporter resulted in very variable Hill coefficients 
between 0.5 and 3.7, indicating that the ABCB1 transporter includes up to four binding sites 
with positive cooperativeness. 
The potential of the compounds to overcome the multidrug resistance mediated by ABC 
transporters was observed in the kinetic chemosensitivity assay. Therefore, ABCB1 positive 
Kb-V1 cells and ABCG2 positive MCF-7/Topo cells, respectively, were incubated with 
different concentrations of the tariquidar analogs alone and in combination with non-toxic 
topotecan concentrations. All tested tariquidar analogs were able to overcome the topotecan 
resistance of the cells, and concentrations far below the IC50 value of the respective 
compounds led to cytostatic effects. In addition, the incubation of Kb-V1 or MCF-7/Topo 
cells, respectively, with the tariquidar analogs alone resulted in some cases in cytotoxic, 
cytostatic or cytocidal effects. The investigation of these compounds on ABCB1 and ABCG2 
negative human glioblastoma U-373 MG cells revealed that the toxicity of the compounds is 
independent of their inhibitory activity at the ABC transporters. Furthermore, confluent U-
373 MG cells were treated with the cytotoxic tariquidar analogs in order to proof if the 
antiproliferative effect is caused by a specific interference during the cell cycle or not. Only 
compound 6 induced a very strong cytocidal effect caused by an unspecific interference with 
the cells. All other tariquidar analogs had no relevant cytocidal effect on quiescent cells and 
are therefore suitable for in vivo investigations. 
 
In summary, potent and more hydrophilic ABCB1 inhibitors derived from tariquidar were 
obtained. These new P-glycoprotein inhibitors are promising candidates for future preclinical 
investigations to compare their accumulation in the brain of nude mice with that of the parent 
compound and to study the antitumor activity-enhancing effect in combination with cytostatic 
drugs. Furthermore, very potent and selective ABCG2 inhibitors were identified which should 
be useful pharmacological tools for in vitro and in vivo investigations. With respect to the 
treatment of brain tumors and regarding the tumor stem cell concept, the ABCG2 inhibitors 
with cytotoxic effects are possibly very effective cytostatic drugs. 
 
 
 
170 Chapter 4  
References 
 
Ahmed-Belkacem, A., Pozza, A., Macalou, S., Pérez-Victoria, J. M., Boumendjel, A. and Di 
Pietro, A. (2006) Inhibitors of cancer cell multidrug resistance mediated by breast 
cancer resistance protein (BCRP/ABCG2). Anticancer Drugs 17(3):239-243. 
Allen, J. D., van Loevezijn, A., Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., 
Schellens, J. H. M., Koomen, G.-J. and Schinkel, A. H. (2002) Potent and Specific 
Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and 
in Mouse Intestine by a Novel Analogue of Fumitremorgin C. Mol. Cancer Ther. 
1(6):417-425. 
Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V. and Dean, M. (1998) A 
Human Placenta-specific ATP-Binding Cassette Gene (ABCP) on Chromosome 4q22 
That Is Involved in Multidrug Resistance. Cancer Res. 58(23):5337-5339. 
Bendayan, R., Lee, G. and Bendayan, M. (2002) Functional expression and localization of P-
glycoprotein at the blood brain barrier. Microsc. Res. Tech. 57(5):365-380. 
Bernhardt, G., Reile, H., Birnböck, H., Spruss, T. and Schönenberger, H. (1992) Standardized 
kinetic microassay to quantify differential chemosensitivity on the basis of 
proliferative activity. J. Cancer Res. Clin. Oncol. 118(1):35-41. 
Bosch, I. and Croop, J. (1996) P-glycoprotein multidrug resistance and cancer. Biochim. 
Biophys. Acta 1288(2):F37-F54. 
Breedveld, P., Beijnen, J. H. and Schellens, J. H. M. (2006) Use of P-glycoprotein and BCRP 
inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. 
Trends Pharmacol. Sci. 27(1):17-24. 
Dantzig, A. H., Shepard, R. L., Law, K. L., Tabas, L., Pratt, S., Gillespie, J. S., Binkley, S. N., 
Kuhfeld, M. T., Starling, J. J. and Wrighton, S. A. (1999) Selectivity of the Multidrug 
Resistance Modulator, LY335979, for P-Glycoprotein and Effect on Cytochrome P-
450 Activities. J. Pharmacol. Exp. Ther. 290(2):854-862. 
de Bruin, M., Miyake, K., Litman, T., Robey, R. and Bates, S. E. (1999) Reversal of 
resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. 
Cancer Lett. 146(2):117-126. 
Dean, M. and Allikmets, R. (2001) Complete Characterization of the Human ABC Gene 
Family. J. Bioenerg. Biomembr. 33(6):475-479. 
Doyle, L. and Ross, D. (2003) Multidrug resistance mediated by the breast cancer resistance 
protein BCRP (ABCG2). Oncogene 22(47):7340-7358. 
 Tariquidar analogs as ABCB1 and ABCG2 inhibitors 171 
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K. and Ross, D. D. 
(1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. 
Proc. Natl. Acad. Sci. U. S. A. 95(26):15665–15670. 
Egger, M., Li, X., Müller, C., Bernhardt, G., Buschauer, A. and König, B. (2007) Tariquidar 
Analogues: Synthesis by CuI-Catalysed N/O-Aryl Coupling and Inhibitory Activity 
against the ABCB1 transporter. Eur. J. Org. Chem. DOI: 10.1002/ejoc.200700142 
Fankhänel, M., Fellner, S., Spruss, T., Bernhardt, G. and Buschauer, A. (2005) Report of the 
European High Grade Glioma Group Meeting, February 25-26, Regensburg, Germany 
- The p-gp modulators elacridar and tariquidar enhance the paclitaxel concentration in 
the brain of nude mice. Turk J Cancer 35(1):41. 
Fellner, S., Bauer, B., Miller, D. S., Schaffrik, M., Fankhänel, M., Spruss, T., Bernhardt, G., 
Gräff, C., Färber, L., Gschaidmeier, H., Buschauer, A. and Fricker, G. (2002) 
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. 
Clin. Invest. 110(9):1309-1318. 
Fischer, V., Rodriguez-Gascon, A., Heitz, F., Tynes, R., Hauck, C., Cohen, D. and Vickers, 
A. E. M. (1998) The Multidrug Resistance Modulator Valspodar (PSC 833) Is 
Metabolized by Human Cytochrome P450 3A. Implications for Drug-Drug 
Interactions and Pharmacological Activity of the Main Metabolite. Drug Metab. 
Dispos. 26(8):802-811. 
Glavinas, H., Krajcsi, P., Cserepes, J. and Sarkadi, B. (2004) The role of ABC transporters in 
drug resistance, metabolism, and toxicity. Curr. Drug Deliv. 1(1):27-42. 
Homolya, L., Hollo, Z., Germann, U., Pastan, I., Gottesman, M. and Sarkadi, B. (1993) 
Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. 
Biol. Chem. 268(29):21493-21496. 
Hyafil, F., Vergely, C., Du Vignaud, P., Grand-Perret, T. (1993) In vitro and in vivo reversal 
of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer 
Res. 53(19):4595-4602. 
Jaroszeski, M., Gilbert, R. and Heller, R. (1998) Flow cytometric detection and quantitation 
of cell-cell electrofusion products. Methods Mol. Biol. 91(1):149-156. 
Johnson, W. W. (2002) P-glycoprotein-mediated efflux as a major factor in the variance of 
absorption and distribution of drugs: modulation of chemotherapy resistance. Methods 
Find. Exp. Clin. Pharmacol. 24(8):501-514. 
Kohno, K., Kikuchi, J., Sato, S., Takano, H., Saburi, Y., Asoh, K. and Kuwano, M. (1988) 
Vincristine-resistant human cancer KB cell line and increased expression of 
multidrug-resistance gene. Jpn. J. Cancer Res. 79(11):1238-1246. 
172 Chapter 4  
Krishna, R. and Mayer, L. D. (2000) Multidrug resistance (MDR) in cancer: Mechanisms, 
reversal using modulators of MDR and the role of MDR modulators in influencing the 
pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11(4):265-283. 
Lee, J., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. and Bates, S. 
(1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National 
Cancer Institute drug screen. Mol. Pharmacol. 46(4):627-638. 
Loescher, W. and Potschka, H. (2005) Drug resistance in brain diseases and the role of drug 
efflux transporters. Nature Rev. Neurosc. 6(8):591-602. 
Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C. A. 
M., Ruevekamp-Helmers, M. C., Floot, B. G. J. and Schellens, J. H. M. (1999) 
Overexpression of the BCRP/MXR/ABCP Gene in a Topotecan-selected Ovarian 
Tumor Cell Line. Cancer Res. 59(18):4559-4563. 
Müller, C., Gross, D., Sarli, V., Gartner, M., Giannis, A., Bernhardt, G. and Buschauer, A. 
(2007) Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues 
against human glioblastoma cells. Cancer Chemother. Pharmacol. 59(2):157-164. 
Rabindran, S. K., Ross, D. D., Doyle, L. A., Yang, W. and Greenberger, L. M. (2000) 
Fumitremorgin C Reverses Multidrug Resistance in Cells Transfected with the Breast 
Cancer Resistance Protein. Cancer Res. 60(1):47-50. 
Reya, T., Morrison, S. J., Clarke, M. F. and Weissman, I. L. (2001) Stem cells, cancer, and 
cancer stem cells. 414(6859):105-111. 
Robey, R. W., Honjo, Y., van de Laar, A., Miyake, K., Regis, J. T., Litman, T. and Bates, S. 
E. (2001) A functional assay for detection of the mitoxantrone resistance protein, 
MXR (ABCG2). Biochimica et Biophysica Acta (BBA) - Biomembranes 
1512(2):171-182. 
Thomas, H. and Coley, H. M. (2003) Overcoming multidrug resistance in cancer: an update 
on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10(2):159-165. 
Wandel, C., Kim, R. B., Kajiji, S., Guengerich, F. P., Wilkinson, G. R. and Wood, A. J. 
(1999) P-Glycoprotein and Cytochrome P-450 3A Inhibition: Dissociation of 
Inhibitory Potencies. Cancer Res. 59(16):3944-3948. 
Wiese, M. and Pajeva, I. K. (2001) Structure-Activity Relationships of Multidrug Resistance 
Reversers. Curr. Med. Chem. 8(6):685-713. 
 
  173 
 
 
 
 
 
 
Chapter 5 
 
Summary 
 
5 Summary 
 
 
 
 
 
 
 
 
174 Chapter 5  
No effective chemotherapy for the treatment of malignant brain tumors, especially 
glioblastoma, exists so far. Despite the progress in surgical techniques and advances in the 
irradiation treatment, the concomitant chemotherapy is essential for the prevention of relapse 
and of major importance for patient outcome. The introduction of temozolomide combined 
with radiation in clinical practice led to slightly improved long-term survival, but malignant 
gliomas remain resistant to cancer chemotherapy. Thus, new strategies for the treatment of 
brain tumors are still needed. Objectives of this work were the evaluation of the TmHU 
protein as siRNA transfection reagent (Chapter 2), investigations on new kinesin Eg5 
inhibitors, which specifically inhibit cell division during mitosis (Chapter 3), and the 
exploration of new tariquidar analogs as ABCB1 and ABCG2 inhibitors (Chapter 4). 
Due to the selective down-regulation of oncogene expression by small interfering RNA, 
siRNAs are considered as promising anticancer agents allowing the selective killing of tumor 
cells. The suitability of the non-toxic TmHU protein as siRNA transfection reagent was 
explored in vitro and in vivo in order to investigate the down-regulation of gene expression in 
human glioblastoma cells. The efficient transfection of the cancer cells is a prerequisite for 
this new concept, and, therefore, reliable in vitro and in vivo models were developed for the 
proof of principle. A suitable and convenient in vitro method was established for the quick 
detection of siRNA effects on the EGFP or DsRed2 expression, respectively, with respect to 
total cell number by using a fluorescence plate reader. In order to study siRNA effects in vivo 
subcutaneous tumor models were established in nude mice and two fluorescence detection 
methods were evaluated. The fluorescence intensity was quantified by confocal laser scanning 
microscopy of paraffin embedded tumor sections and by in vivo imaging. In preliminary tests 
with micro-osmotic pumps the continuous release of a suspension and the practicability of 
subcutaneous implantation were assured. Unfortunately, the established in vivo methods 
could not be used for the intended investigations on TmHU because this protein was not 
suitable for siRNA transfection. Nevertheless, these methods are recommendable for the 
investigation of promising in vivo transfection reagents. 
The inhibition of kinesin Eg5 by small molecules such as monastrol is currently evaluated as 
an approach to develop a novel class of antiproliferative drugs for the treatment of malignant 
tumors. Therefore, the effects of new monastrol analogs on the proliferation of human U-87 
MG, U-118 MG, and U-373 MG glioblastoma cells were investigated. Compared to 
monastrol, the new cell cycle specific compounds showed an at least one order of magnitude 
higher antiproliferative activity. The compounds were neither inactivated by hydrolysis nor by 
binding to serum proteins. Due to the necessity of overcoming the blood–brain barrier (BBB) 
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in the treatment of brain tumors, it was investigated if the new monastrol analogues are 
modulators or substrates of the ABCB1 transporter by a flow cytometric calcein-AM efflux 
assay. The tested compounds showed no modulating effects on the ABCB1 function. With 
respect to the treatment of primary and secondary CNS tumors, the results suggest that the 
new monastrol analogs represent an interesting class of potential anticancer drugs, predicted 
to be less neurotoxic in comparison to classical tubulin inhibitors. 
The efflux of cytostatics due to expression of ABC transporters such as ABCB1 and ABCG2 
at the BBB leads to extremely low drug concentrations in the brain and is therefore a major 
limitation in cancer chemotherapy. A strategy to overcome the BBB is the administration of 
an efflux inhibitor in combination with a cytostatic. The 3rd generation inhibitor tariquidar led 
to better brain/plasma ratios of paclitaxel but could not increase the paclitaxel brain levels 
compared to co-administration of the 2nd generation inhibitor valspodar. The very high 
tariquidar brain levels indicate that the very lipophilic tariquidar is trapped in the lipid 
compartment of the brain. Aiming at tariquidar analogs with improved solubility and 
pharmacokinetics, more hydrophilic analogs were synthesized. The compounds were 
investigated on ABCB1 overexpressing Kb-V1 and ABCG2 overexpressing MCF-7/Topo 
cells for inhibitory activity and for cytotoxicity, alone and in combination with cytostatics. 
Surprisingly, slight structural modifications resulted in ABCG2 selective inhibitors. Three 
analogs have IC50 values of 55, 100, and 154 nM, comparable with the most potent reported 
ABCG2 inhibitor Ko143. Some ABCG2 inhibitors showed specific toxicity which could be 
advantageous regarding the treatment of brain tumors. These very potent and selective 
ABCG2 inhibitors should be useful pharmacological tools for in vitro and in vivo 
investigations. 
